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Zusammenfassung 
Integrierte multi-Omics Analyse der Leberkarzinogenese im SRF-VP16iHep 
Mausmodell 
SRF-VP16iHep	 Mäuse	 zeigen	 Aktivität	 das	 SRF-VP16	 Protein,	 einem	 konstitutiven	
Transkriptionsfaktor	 und	 Aktivator	 von	 CArG-box-regulierten	 Zielgenen,	 im	
hepatozellulären	 Mosaikmuster.	 Die	 dadurch	 ausgelöste	 Hyperproliferation	 von	
Hepatozyten	 führt	 zur	 Ausbildung	 von	 prä-malignen	 Knoten	 (“nodules”),	 aus	 denen	
sich	Hepatozelluläre	Karzinome	(murine	HCCs,	mHCCs)	entwickeln	(Ohrnberger*	and	
Thavamani*	 et	 al.,	 2015).	 Die	 vorliegenden	 Arbeit	 konzentriert	 sich	 auf	 die	
Charakterisierung	 der	HCC	Tumorgewebe,	 sowie	 die	 bei	 deren	 Entstehung	 durchlau-
fenen	 Progressionstadien,	 indem	 verschiedene	 genomweite	 Omic	 Analyseplattformen	
zum	Einsatz	 gebracht	werden.	Dabei	war	 es	Ziel	 dieser	Arbeit,	 essentielle	molekulare	
und	zelluläre	Ereignisse	bei	der	HCC	Tumorentstehung	zu	identifizieren.			
Die	 eingesetzten	 Omic	 Analyseplattformen	 waren	 Transkriptomic	 (RNAseq),	
Proteomik/Phospho-Proteomik,	 und	 Exom-Sequenzierung.	 Genomische	 Sanger-
Sequenzierung	 von	 Kandidaten-Loci	 zeigte	 die	 Anwesenheit	 von	 Ctnnb1	 und	 Trp53	
Mutationen	 in	zwei	verschiedenen	Untergruppen	der	mHCCs.	Die	Transkriptom-	und	
Proteomprofile	von	Ctnnb1-Wildtyp	und	Ctnnb1-mutierten	mHCCs	zeigten	signifikante	
Unterschiede.	Vergleichende	Clusteranalyse	der	Transkriptionsprofile	der	SRF-VP16iHep-
Proben	 mit	 humanen	 HCC	 Tumorproben	 zeigte	 signifikante	 Überlappung	 der	 SRF-
VP16iHep	HCCs	mit	der	G1/G2	Untergruppe	humaner	HCCs.	Dabei	wurden	gemeinsame	
Gensignaturen	identifiziert,	z.	B.	bezüglich	der	erhöhten	Expression	von	„oncofetal	liver	
genes“.	 Eine	 vollständige	 Exom-Sequenzierung	 (WES)	 von	 prä-malignen	 Knoten	 und	
mHCCs	 der	 SRF-VP16iHep	 Mäuse	 zeigte	 die	 inhärente	 Heterogenität	 der	 mHCCs.	 Die	
durchgeführte	 multi-Omics	 Analyse	 gibt	 Hinweise	 auf	 erfolgte	 metabolische	 Repro-
grammierung	 in	mHCC	Geweben,	 speziell	 auf	 die	 Aktivierung	 der	 aeroben	Glycolyse	
und	des	mitochondrialen	1C-Metabolismus.	
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Abstract 
Integrated multi-omic analysis of HCC formation in the SRF-VP16iHep 
mouse model. 
	
SRF-VP16iHep	 mice	 activate	 the	 constitutive	 transcription	 factor	 SRF-VP16	 in	 a	
hepatocyte-specific	mosaic	fashion	and	consequently,	develop	hepatocellular	carcinoma	
(mHCC)	 (Ohrnberger*	 and	 Thavamani*,	 et	 al.,	 2015).	 Using	 the	 SRF-VP16iHep	 mouse	
model,	 this	 thesis	 focuses	 on	 the	 characterization	 of	 mHCC	 formation	 from	 pre-
malignant	liver	nodules.	The	objective	of	the	current	study	was	to	identify	carcinogenic	
driver	 events	 responsible	 for	malignant	 transformation	 and	 tumor	 formation	 in	 SRF-
VP16iHep	 livers.	 To	 this	 end,	 an	 integrated	 multi-omics	 analysis	 approach	 was	
undertaken,	 which	 involved	 the	 investigation	 of	 the	 genome	 (exome),	 transcriptome	
and	proteome	at	 the	premalignant	 and	advanced	 stages	of	HCC	development.	 Sanger	
sequencing	 of	 genomic	 candidate	 loci	 revealed	 the	 presence	 of	 Ctnnb1	 and	 Trp53	
mutations	 in	 two	 different	 subsets	 of	 mHCCs,	 respectively.	 Transcriptome	 and	
proteome	 profiles	 of	 Ctnnb1	mutant	 and	Ctnnb1	wildtype	mHCCs	 showed	 significant	
differences	 between	 the	 two	 subsets.	 SRF-VP16iHep	 tumor	 transcriptomes	 showed	
striking	 similarities	 to	 that	 of	 a	 distinct	 subset	 of	 human	HCCs.	 This	 identified	 SRF-
VP16iHep	to	resemble	the	G1/G2	subtype	of	human	HCCs,	as	was	 indicated	by	common	
gene	 expression	 signatures,	 for	 example	 activated	 oncofetal	 genes.	 Whole	 exome	
sequencing	 (WES)	 analysis	 of	mHCCs	 and	 pre-malignant	 nodular	 tissues	 revealed	 an	
inherent	 heterogeneity	 of	 each	 mHCC,	 even	 when	 originating	 within	 one	 individual	
liver.	In	addition,	integrated	omics	analysis	of	mHCCs	from	SRF-VP16iHep	mice	indicated	
the	 occurrence	 of	 metabolic	 reprogramming,	 for	 example	 the	 activation	 of	 aerobic	
glycolysis	and	of	the	mitochondrial	1C-metabolism.	
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1	 INTRODUCTION 
1.1  Cancer 
1.1.1  Definition 
Malignant	neoplasm,	also	known	as	cancer,	 is	a	collective	 term	used	 to	denote	
hyper-proliferative	 diseases,	 in	 which	 abnormal	 cells	 divide	 uncontrollably	 and	 can	
invade	neighboring	tissues	and	thereby	spread	to	other	parts	of	 the	body	through	the	
blood	and	lymph	systems.		
1.1.2  Mortality and morbidity 
	 Cancer	is	the	second	highest	cause	of	death	worldwide,	accounting	for	more	than	
8	million	deaths	in	the	year	2012	(Figure	1-1).	That	is,	one	among	every	seven	persons	in	
the	world	dies	of	cancer-related	causes.		
	
Figure 1-1: The top 5 causes of death worldwide in 2012. The numbers of deaths 
represented are in thousands. Source: GLOBOCAN 2012 (Ferlay et al., 2015). 
	 The	International	Agency	on	Cancer	(IARC)	estimates	that	in	2012	there	were	14.1	
million	new	cancer	 cases	diagnosed	worldwide.	The	comparable	estimate	 for	 the	year	
2008	had	been	12.7	million	new	cases.	The	yearly	incidence	of	cancer	in	the	year	2030	is	
expected	to	rise	to	21.7	million	and	the	annual	deaths	to	13	million.	However	the	World	
Health	Organization	cautions	that	actual	numbers	 in	2030	might	be	drastically	 larger,	
owing	 to	 the	 people	 around	 the	world	 increasingly	 adopting	 lifestyle	 habits	 that	 can	
significantly	increase	the	risk	of	cancer	occurrence	(Ferlay	et	al.,	2015).	
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1.1.3 Recent advancements in cancer research –
‘omics’ approaches 
1.1.3.1  Human genome project 
	 The	 invention	 of	 DNA	 sequencing	 technology	 by	 Frederick	 Sanger	 spurred	
numerous	developments	 in	 the	 field	of	 genome	sequencing.	Further	 advancements	 in	
this	area	led	to	the	complete	automation	of	the	process.	This	achievement	encouraged	
scientists	to	undertake	the	sequencing	of	the	complete	human	genome.	Eventually,	 in	
the	year	 1988	there	was	a	Memorandum	of	Understanding	(MoU)	signed	between	the	
National	Institute	of	Health	(NIH)	and	the	United	States	Department	of	Energy		(DOE)	
to	 work	 together	 towards	 the	 common	 goal	 of	 unraveling	 the	 nucleotide	 sequence	
composition	of	 the	entire	human	genome.	This	 joint	 initiative,	which	 started	 in	 1990,	
was	later	known	as	the	Human	Genome	Project.		
	 In	 June	 2000,	 it	 was	 announced	 that	 the	 entire	 human	 genome	 had	 been	
sequenced	 and	 the	 first	 publication	 regarding	 the	 sequenced	 human	 genome	 was	
published	in	the	journal	Nature,	 in	February	2001.	Some	of	the	techniques	used	in	the	
process	 were	 DNA	 sequencing,	 Restriction	 Fragment-Length	 Polymorphism	 (RFLP)	
analysis,	 use	 of	 Yeast	 Artificial	 Chromosomes	 (YAC)	 or	 of	 Bacterial	 Artificial	
Chromosomes	(BAC),	Polymerase	Chain	Reaction	(PCR),	and	electrophoresis	(Lander	et	
al.,	2001).		
The	unlocking	of	 the	human	genome	sequence	 revolutionized	cancer	 research,	
effectively	 giving	 rise	 to	 the	 ‘omics’	 era.	 This	 coincided	 with	 the	 technological	
developments	enabling	the	high-throughput	analysis	of	genes,	transcripts,	proteins,	and	
metabolites	 therefore	 resulting	 in	 the	 various	 omics	 fields	 namely,	 genomics,	
trascriptomics,	 epigenomics,	 proteomics,	 and	metabolomics	 (Rochfort,	 2005).	 Omics-
based	 cancer	 research	 has	 resulted	 in	 a	 vast	 expansion	 of	 knowledge	 regarding	 the	
genomic	basis	of	cancer	and	also	helped	in	the	application	of	this	knowledge	for	better	
treatment.			
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1.1.3.2  Genomics 
	 High-throughput	determination	of	the	cancer	genome	sequences	has	resulted	in	
the	discovery	of	numerous	oncogenes	and	tumor	suppressor	genes	that	play	major	roles	
in	 the	 progression	 of	 different	 tumors.	 Mutations	 could	 be	 detected	 in	 tumor	
suppressor	 genes	 thereby	 impairing	 their	 vital	 functions	 such	 as	 cell	 cycle	 regulation	
(TP53,	CDK1,	CDK2)	or	DNA	mismatch	repair	(MMR),	and	thus	assisting	the	tumor	in	
its	 incessant	 proliferation	 (Weinert	 and	 Lydall,	 1993)	 (Hsieh	 and	 Yamane,	 2008).	
Alternatively	there	were	also	mutations	found	in	various	oncogenes,	resulting	in	a	gain	
of	function	in	these	genes.	These	included	growth	factor	receptors	(EGFR,	VEGFR)	and	
other	genes	that	promote	cellular	proliferation	and	invasion	(MYC,	RAS)	(Hanahan	and	
Weinberg,	 2000).	 These	 studies	 have	 also	 resulted	 in	 the	 development	 of	 treatment	
modalities	targeting	these	genes	in	order	to	inhibit	cancer	growth	in	a	specific	manner	
(Kandula	 et	 al.,	 2013;	 Nan	 et	 al.,	 2017).	 The	 past	 few	 decades	 have	 seen	 significant	
advances	 in	 the	 field	 of	 Next	 Generation	 Sequencing	 (NGS)	 which	 has	 enabled	 the	
sequencing	of	tumor	samples	at	a	high	resolution	that	could	be	compared	against	the	
human	genome	using	various	tools	(Gu	et	al.,	2013;	Li	and	Durbin,	2009).	Comparison	of	
the	 consensus	 sequences	 of	 reads	 which	 together	 help	 detecting	 genomic	 variations	
including	the	following.	
! Genomic	point	mutations	
! Genomic	insertions	and	deletions	
! Genomic	copy	number	variation	
! Genomic	loss	of	heterozygosity	(LOH)		
! Gene	translocation	or	gene	fusion	
! Genome	and	chromatin	modifications,	including	CpG	methylation	
and	histone	modification.	
This	 information	 can	give	 significant	 insight	 about	 the	 genomic	profiles	 of	 the	
cancer	cells	and	thereby	help	us	to	understand	the	molecular	mechanisms	involved	in	
carcinogenesis.	 	 The	 NGS	 technology	 could	 be	 used	 in	 different	 approaches,	 namely	
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whole	 genome	 sequencing	 (WGS),	 whole	 exome	 sequencing	 (WES)	 and	 whole	
transcriptomic	sequencing	(RNAseq)	analyses,	depending	on	the	part	of	the	genome	or	
transcriptome	studied.		
1.1.3.3 Whole Exome Sequencing 
A	majority	of	the	cancer	mutations	occurred	in	the	coding	region	of	the	genome,	
which	comprises	about	1%	of	the	entire	genome.	In	order	to	focus	more	on	this	region,	
various	 methods	 were	 developed	 to	 enrich	 these	 regions	 during	 the	 initial	 sample	
library	preparation	steps.	Probe	hybridization	methods	were	used	to	select	these	nucleic	
acid	fragments,	from	the	pool	of	random	sheared	DNA	fragments	(Gnirke	et	al.,	2009;	
Hodges	et	al.,	2007;	Turner	et	al.,	2009).	Given	the	constraints	of	sequencing	depth	and	
costs,	the	WES	approach	turned	out	to	be	an	effective	way	of	analyzing	cancer	genome	
alterations	(Ng	et	al.,	2010;	Ng	et	al.,	2009).	This	was	mainly	due	to	the	200	times	more	
coverage	and	about	 100	 times	more	 read	depth	 that	 could	be	achieved	with	 the	 same	
amount	 of	 sequencing	 power	 compared	 to	 that	 of	whole	 genome	 sequencing	 (WGS).	
The	 technique	 is	 still	 being	 improved,	 particularly	 regarding	 the	 more	 efficient	 and	
equal	capturing	of	exons	throughout	the	genome	(Bamshad	et	al.,	2011).			
1.1.3.4 Transcriptomics 
	 Initially,	analyses	of	the	RNA	content	of	cells	(transcriptomics)	had	been	carried	
out	 using	 the	method	known	 as	 the	 serial	 analysis	 of	 gene	 expression	 (SAGE),	which	
involved	 the	 manual	 sequencing	 of	 9	 base	 or	 13	 base	 tags	 of	 cDNAs	 (Tarasov	 et	 al.,	
2007).	But	this	technique	was	superseded	by	the	microarray	technology.	The	microarray	
technology	is	based	on	the	principle	of	hybridization	of	the	RNAs	with	complementary	
DNA	microarrays	(Bumgarner,	2013).	The	DNA	microarrays	were	designed	to	cover	the	
entire	 complement	of	RNAs	present	 in	 a	 cell	 or	 tissue	 sample,	 i.e.	 the	 transcriptome.	
Microarrays	continued	to	be	the	method	of	choice	for	transcriptome	profiling	until	the	
advancement	 of	Next-Generation	 Sequencing	 (NGS)	 technology,	which	was	 based	 on	
short-read	sequencing	of	cDNA	fragments	of	about	100	bp	in	size.	NGS	can	be	applied	
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to	 sequence	 analysis	 of	 genomes	 and	 of	RNA	populations	 (the	 latter	 is	 referred	 to	 as	
RNAseq).	However,	the	potential	of	RNAseq	was	greatly	increased	with	the			invention	
of	 high-throughput	 techniques	 for	 short-read	 sequencing	 by	 Illumina	 Inc./Solexa,	
whose	Genomic	Analyzers	enabled	reading	of	gigabase	 lengths	of	sequence	in	a	single	
run	(Davies,	2010).	RNAseq	analysis	facilitates	the	measurement	of	total	gene	expression	
levels,	 the	 detection	 of	 RNA	 splicing	 events,	 the	 identification	 of	 mutations	 at	 the	
mRNA	 level	 and	 also	 for	 the	 identification	 of	 hitherto	 unknown	 coding	 regions.	
Notably,	RNAseq	analyses	have	 revealed	previously	unknown	 translocations	 and	gene	
fusions	 associated	 with	 cancer	 (ALK-EML4,	 ERG-TMPRSS2,	 BCR-ABL)	 (Salesse	 and	
Verfaillie,	2002;	Soda	et	al.,	2007;	Tomlins	et	al.,	2005).	These	analyses	have	also	led	to	
the	development	of	treatment	possibilities	targeting	the	fusion	gene	products	(Wang	et	
al.,	2013).	Recently,	there	have	been	improvements	in	the	RNAseq	technology	to	identify	
miRNAs,	snoRNAs,	and	translated	RNAs	(RIboseq,	CLIP-seq).	These	developments	help	
greatly	in	advancing	the	field	of	cancer	research	(McGettigan,	2013).	
1.1.3.5  Proteomics 
	 Given	 the	 significant	 advancements	 in	 the	 genomics	 field,	 the	 proteomics	 also	
had	its	share	of	substantial	developments	in	the	past	few	decades.	The	term	proteome	
itself	was	coined	in	the	year	1995	by	Ian	Humphery-Smith	and	colleagues	to	denote	the	
entire	protein	content	being	expressed	from	a	genome	(Wilkins	et	al.,	1996).	In	line	with	
the	 omics	 development,	 the	 term	 proteomics	 encompasses	 the	 study	 of	 protein	
expression,	 protein-protein	 interactions	 and	 protein	 post-translational	 modifications	
(Prabakaran	et	al.,	 2012).	The	 initial	proteomic	methods	were	based	on	2-dimensional	
gel	electrophoresis	(O'Farrell,	1975)	followed	by	identification	of	the	separated	proteins	
via	mass	spectrometry	(MS).	2D-gel	electrophoresis	had	its	own	limitations	such	as	low	
coverage	 depth,	 low	 range	 of	 detection	 and	 improper	 protein	 separation	 and	 so	 on	
(Gygi	et	al.,	2000).	However,	with	a	variety	of	factors	coming	into	play	such	as	improved	
genomics	 technologies,	 improved	 mass	 spectrometry	 instruments,	 and	 also	 better	
protein	 and	 peptide	 separation	 techniques,	 a	 new	 high-throughput	 proteomic	
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technology	could	be	developed.	It	is	referred	to	as	the	shotgun	proteomics.		It	involves	a	
combination	 of	 top	 down	 and	 bottom	 up	 approaches	 for	 protein	 analysis.	 In	 this	
approach,	protein	mixtures	were	subjected	to	digestion	by	proteolytic	enzymes	such	as	
trypsin	 or	 Lys	C	 and	 the	 resulting	 peptide	mixtures	were	 analyzed	 (Tyers	 and	Mann,	
2003).	 In	 this	 technique,	 proteins	 isolated	 from	 cells	 and	 fragmented	 into	 peptides,	
which	 are	 separated	 by	 liquid	 chromatography	 (LC)	 and	 identified	 by	 coupled	 mass	
spectrometry	 (LC-MS).	 This	 includes	 the	 fractionation	 of	 selected	 peptides	 using	
tandem	 mass	 spectrometry	 (LC-MS/MS)	 (Hu	 et	 al.,	 2007).	 The	 obtained	 spectra	 are	
then	 analyzed	 for	 both	 peptide	 identification	 and	 quantification	 purposes.	 This	
quantification	 could	 be	 done	 in	 various	 ways	 such	 as	 label-free	 quantification,	 or	 by	
using	stable	isotope	labeling	(Asara	et	al.,	2008;	Zhu	et	al.,	2010).	In	recent	years	there	
have	 been	 numerous	 improvements	 in	 the	 different	 steps	 of	 the	 LC-MS/MS	method,	
which	 have	 helped	 in	 enabling	 characterization	 and	 comparison	 of	 the	 proteomic	
profiles,	 absolute	 quantification	 of	 proteins,	 as	 well	 as	 the	 determination	 of	 dynamic	
and	spatial	characteristics	of	proteins	in	the	cells.		
	 Moreover,	 there	have	been	significant	advances	 in	 the	 field	of	 identifying	post-
translational	modifications	(PTM)	as	well.	In	recent	years,	various	strategies	have	been	
developed	to	address	the	identification	of	various	PTMs.	For	example,	in	case	of	protein	
phosphorylation,	 new	 methods	 have	 been	 developed	 such	 as	 phospho-peptide	
enrichments	 using	 immobilized	metal	 ion	 chromatography	 (IMAC),	 titanium	 dioxide	
chromatography,	 phosphotyrosine	 immunoprecipitation,	 or	 a	 combination	 of	 these	
approaches	 (De	 Corte	 et	 al.,	 1999;	Macek	 et	 al.,	 2009;	 Pinkse	 et	 al.,	 2004;	 Villen	 and	
Gygi,	2008).	These	technologies	have	contributed	to	our	understanding	of	the	signaling	
pathways	 involved	 in	 cancer.	 The	 accurate	 quantification	 of	 phospho-peptides	 has	
helped	to	delineate	the	role	of	kinases	and	phosphatases	in	cancer	progression.		
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 1.1.3.6  Metabolomics 
	 Metabolomics	denotes	analysis	of	the	complete	spectrum	of	metabolites	present	
in	a	cell	or	tissue.	Dynamic	analysis	of	the	cellular	metabolome,	in	response	to	different	
treatments	 at	 different	 time-points,	 helps	 in	 the	 elucidation	 of	 the	 physiologic	
responses	 of	 cells	 to	 drug	 treatments	 or	 any	 other	 external	 modulation	 (Kaddurah-
Daouk	et	al.,	2008).	This	can	be	used	in	many	ways	in	cancer	research	since	tumor	cells	
have	to	adjust	their	physiology	to	the	specific	needs	of	a	malignant	tumor	tissue.	Animal	
studies	have	also	demonstrated	the	advantages	of	metabolomic	analyses	in	the	pursuit	
of	 toxicological	 studies	 (van	 Ravenzwaay	 et	 al.,	 2007).	Metabolic	 pathways	 in	 cancer	
frequently	relate	to	altered	requirements	of	tumor	cells	for	energy	(ATP)	and	anabolic	
building	blocks	 (nucleotides,	 amino	acids,	membrane	components,	 etc.).	Newer	 fields	
such	 as	 lipidomics	 as	well	 are	 catching	 up,	 in	 order	 to	 look	 at	 the	wide	 spectrum	 of	
chemical	components	involved	in	tumor	proliferation	(Shevchenko	and	Simons,	2010).	
Metabolomic	analyses	can	also	be	carried	out	using	mass	spectrometry-based	analytical	
tools.	 Developments	 in	 LC-MS/MS	 analyses	 have	 greatly	 improved	 the	 sensitivity,	
coverage	and	efficiency	of	metabolomic	 studies	 (Menni	 et	 al.,	 2013;	Mittelstrass	 et	 al.,	
2011).		
 1.1.3.7 Combined ‘omics’ analysis 
	 In	order	to	better	understand	the	molecular	mechanisms	underlying	the	special	
characteristics	of	cancer	cells,	various	combinatorial	approaches	can	be	employed	using	
different	 omics	 strategies.	 The	 combined	 omics	 approaches	 have	 already	 been	
successfully	 used	 to	 generate	 significant	 insights	 into	 human	 disease	 biology.	 One	
study,	for	example,	reported	the	simultaneous	analysis	of	different	omics	technologies,	
including	 transcriptomics,	 proteomics,	 genomics	 and	 metabolomics	 of	 a	 single	
individual	patient	for	a	particular	period	of	time;	the	study	showed	various	phenotypic	
insights,	which	ultimately	helped	in	revealing	various	medical	risks	of	the	patient	(Chen	
et	 al.,	 2012).	 Another	 example	 demonstrating	 advantages	 of	 such	 combined	 omics	
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approaches	in	cancer	research	investigated	ovarian	cancer.		In	this	study,	ovarian	tumor	
samples	 collected	 as	 part	 of	 The	 Cancer	 Genome	 Atlas	 (TCGA)	 program	 were	
characterized	 based	 on	 their	 genomic	 copy	 number	 variations,	 proteomic	 profile	 and	
posttranslational	 modifications.	 This	 study	 revealed	 various	 pathways	 that	 could	 be	
associated	with	patient	survival	 (Zhang	et	al.,	2016a).	 It	 is	well	known	that	 the	cancer	
cells	 can	 acquire	 resistance	 to	 certain	 drugs,	 often	 resulting	 in	 recurrent	 aggressive	
tumors.	Such	resistance	is	known	to	be	acquired	by	mutations	in	key	genes	involved	in	
regulating	 cancer	 cell	 physiology.	 In	 one	 such	 example,	mutations	 in	 the	 EGFR	 gene	
rendered	acquired	 resistance	of	 lung	cancer	cells	 against	 the	 tyrosine	kinase	 inhibitor	
Gefitinib	 (Ma	 et	 al.,	 2011).	 Combined	 omics	 approaches	 can	 effectively	 identify	 such	
survival	mechanisms	activated	by	the	cancer	cell	at	genomic,	proteomic	or	metabolomic	
levels.	This	may	 lead	 to	 strategies	of	personalized	medicine,	where	a	combined	omics	
analysis	 of	 tumor	 tissue	 from	 an	 individual	 cancer	 patient	 can	 help	 decide	 the	 best	
possible	 treatment	 modality.	 	 Such	 therapeutic	 decisions	 could	 be	 made	 in	 an	
individualistic	manner,	using	combined	multi-omics	approaches.		
	 Various	 databases	 exist,	 such	 as	 TCGA	 (The	 Cancer	 Genome	 Atlas)	 and	 ICGC	
(International	 Cancer	 Genome	 Consortium),	 which	 have	 compiled	 large-scale	 multi-
omics	 data	 sets	 of	 human	 cancer	 patients.	 	 This	 encourages	 further	 research	 on	 the	
alterations	occurring	at	different	omics	levels	in	various	cancers.		
1.1.4 Liver cancer  
Cancer	of	the	liver	is	the	sixth	most	frequently	occurring	cancer	worldwide	and	is	
the	second	highest	cause	of	cancer-related	deaths.	It	is	more	prevalent	among	men	than	
women.	 The	 geographical	 distribution	 of	 liver	 cancer	 occurrences	 among	 men	 and	
women	 for	 the	 year	 2012	 is	 shown	 in	 (Figure	 1-2a	 and	 1-2b).	 Liver	 cancer	 is	 more	
common	in	the	regions	of	sub-Saharan	Africa	and	Southeast	Asia.	This	is	likely	due	to	
the	higher	prevalence	of	Hepatitis	B	and	Hepatitis	C	virus	 infections	 in	 these	regions.	
Among	the	782,000	new	liver	cancer	incidences	diagnosed	worldwide	in	2012,	about	half	
were	registered	in	China	(Ferlay	et	al.,	2015).	
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Figure 1-2a: Global incidence map of liver cancers in males. 
Source : (Ferlay et al., 2015). 
	
	
	
Figure 1-2b: Global incidence map of liver cancers in females. 
.Source : (Ferlay et al., 2015). 
	
The	 mortality	 of	 liver	 cancer	 is	 the	 second	 highest	 among	 all	 cancers.	 Liver	
cancer	 has	 the	 worst	 mortality-to-incidence	 ratio	 among	 the	 top	 8	 common	 cancers	
around	the	world	(Figure	1-3)	(Ferlay	et	al.,	2015).		
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Figure 1-3: Mortality-to-incidence ratios of cancers of different organs. Liver 
cancer had the worst mortality-to-incidence ratio in the year of 2012. Source: 
Globocan 2012 
1.1.5 Types of liver cancer 
	 There	are	different	types	of	liver	cancer	depending	on	their	cellular	origin.		
" Hepatocellular	carcinoma	(HCC)	
	 	 More	than	70%	of	 liver	cancers	are	of	this	sub-type.	They	arise	 from	the	
hepatocytes	 of	 the	 liver.	 HCCs	 can	 be	 further	 classified	 into	 different	 sub-categories	
such	 as	 scirrhous	 HCC,	 fibrolamellar	 carcinoma,	 combined	 HCC-cholangiocarcinoma	
(HCC-CC),	 sarcomatoid	 HCC,	 lymphoepithelioma-like	 HCC,	 clear	 cell	 HCC,	 diffuse	
cirrhosis-like	HCC,	and	steatohepatitic	HCC	(Shafizadeh	and	Kakar,	2013).	
" Intrahepatic	cholangiocarcinoma	(ICC)	
	 	 These	comprise	about	10%	-	20%	of	all	liver	cancers.	They	originate	from	
the	cholangiocytes,	which	are	cells	lining	the	bile	ducts	inside	the	liver.		
" Angiosarcoma	and	hemangiosarcoma		
	 	 	This	sub-type	of	 liver	cancer	arises	from	the	endothelial	cells,	 lining	the	
blood	vessels	within	the	liver.	The	major	risk	factor	associated	with	these	cancers	is	the	
exposure	to	vinyl	chloride	and	thorium	dioxide	(Thorostrast).	It	can	also	be	caused	by	
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exposure	 to	 radium	 or	 arsenic.	 Individuals	 having	 the	 condition	 of	 hereditary	
hemochromatosis	are	known	to	be	more	prone	to	develop	this	cancer.	
" Hepatoblastoma		
	 	 This	is	a	rare	type	of	liver	cancer	affecting	mainly	children	younger	than	4	
years	 of	 age.	 The	morphology	 of	 the	 cells	 of	 this	 tumor	 closely	 resembles	 that	 of	 the	
fetal	liver	cells.		
" Secondary	liver	cancer	(Metastatic	liver	cancer)		
	 	 Secondary	 liver	 cancer	 occurs	 mainly	 from	 primary	 cancers	 of	 the	
pancreas,	colon,	stomach,	breast	and	lung.	It	is	more	predominant	in	Western	countries	
compared	to	Africa	and	Asia.		
1.2 Hepatocellular carcinoma (HCC) 
	 HCC	 is	 the	 most	 common	 form	 of	 primary	 liver	 cancer.	 It	 is	 the	 third	 most	
leading	 cause	 of	 cancer-related	 deaths	 worldwide	 (Waller	 et	 al.,	 2015).	 In	 the	United	
States	 alone,	HCC	 is	 the	 fastest	 rising	 cause	of	 cancer	mortality.	The	US	 incidence	of	
HCC	has	 increased	 three-fold	 in	 the	past	 few	decades.	 	This	may	be	attributed	 to	 the	
increasing	Hepatitis	C	virus	infections	among	the	population	as	well	as	dietary	habits.	
The	etiological	factors	associated	with	HCC	are	as	follows.		
1.2.1 Etiological factors 
1.2.1.1 Cirrhosis  
	 Cirrhosis	is	one	of	the	main	risk	factors	associated	with	HCC.	Cirrhosis	could	be	
caused	by	different	sources	such	as	Hepatitis	virus	infection	or	inflammation.	Prolonged	
inflammation	 or	 any	 other	 disease	 in	 the	 liver	 might	 affect	 proliferative	 activity	 of	
hepatocytes.,	 Hepatocytes	 are	 among	 the	 cells	 of	 the	 human	 body	 of	 highest	
proliferation	capacity,	contributing	to	the	liver’s	unique	regenerative	ability	(Delhaye	et	
al.,	 1996).	 Increased	 fibrosis	 in	 the	 liver,	 followed	by	cirrhosis,	 is	 associated	with	 liver	
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cancer	progression,	 enabling	malignant	 transformation	of	hepatocyte	 and	hence	HCC	
formation	(Caillot	et	al.,	2009).			
The	mechanisms	causing	cirrhotic	livers	to	develop	HCCs	have	been	investigated	
widely.	Two	of	 the	key	 factors	 accelerating	 this	process	 are	 telomere	dysfunction	and	
changes	in	the	liver	micro-	and	macro-environment	(El-Serag	and	Rudolph,	2007).	
	 The	telomere	size	of	the	cell	is	maintained	by	the	enzyme	telomerase,	which	also	
maintains	 the	 chromosomal	 stability	 of	 proliferating	 cells	 (Wege	 and	 Brummendorf,	
2007).	Shortening	of	telomere	lengths	as	a	consequence	of	elevated	cell	division	activity	
has	 been	 directly	 correlated	 with	 enhanced	 fibrosis	 and	 is	 often	 observed	 in	 chronic	
diseases	 of	 the	 liver	 (Wiemann	 et	 al.,	 2002).	 Telomere	 dysfunction	 is	 always	
accompanied	 by	 other	 factors	 such	 as	 p53	mutations,	 accelerating	 the	 progression	 of	
cirrhotic	livers	into	cancer	stages	(Sanyal	et	al.,	2010).	
Other	factors	involved	in	fibrosis	and	cirrhosis	include	the	activation	of	stellate	
cells,	often	observed	in	cirrhotic	livers,	which	results	in	the	production	of	cytokines	and	
growth	factors,	as	well	as	stiffening	extracellular	matrix	structures,	all	of	which	assist	in	
the	 development	 of	 liver	 tumors.	 The	 milieu	 of	 a	 cirrhotic	 liver	 may	 also	 cause	 the	
activation	 and	 transformation	 of	 liver	 stem	 cells,	 as	 suggested	 by	 RNA	 expression	
patterns	found	in	human	HCCs	that	are	typical	of	stem	cells	(Sanyal	et	al.,	2010).	Other	
molecular	 alterations	 that	might	 trigger	 the	malignant	 transformation	 from	 cirrhotic	
tissue	are	those	affecting	the	DNA	damage	checkpoints	such	as	impaired	p53	function,	
inhibition	 of	 p27	 cell	 cycle	 regulator,	 down-regulation	 of	 p16	 cell-cycle	 inhibitor,	 and	
loss	of	heterozygosity	of	the	Insulin-like	growth	factor	2-receptor	(IGF2R)	locus	(Sanyal	
et	al.,	2010).	
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1.2.1.2 Hepatitis B virus (HBV) infection  
	 HBV	 infection	 accounts	 for	 more	 than	 50%	 of	 HCC	 occurrences	 worldwide.	
About	 90%	of	HBV	 infections	 are	 acute	 infections.	 Increased	 levels	 of	HBV	DNA	has	
been	found	to	predispose	to	elevated	HCC	incidence	 in	patients	(Farazi	and	DePinho,	
2006).	HBV	is	a	partially	double-stranded	DNA	virus	belonging	to	the	Hepadnaviridae	
family.	The	HBV	genome	codes	for	the	following	components:	reverse	transcriptase	and	
DNA	polymerase	(pol),	capsid	protein	called	the	hepatitis	B	core	antigen	(HBcAg),	the	
envelope	proteins	which	are	associated	with	the	endoplasmic	reticulum	membrane,	and	
the	x	protein	(HBx).	The	integration	of	the	HBV	genome	in	the	host	cell	DNA	results	in	
a	 variety	 of	 immediate	 responses	 in	 the	 cell,	 such	 as	 regulation	 of	 cancer-related	
signaling	 pathways	 and	 activation	 of	 relevant	 genes,	 namely	 telomerase	 reverse	
transcriptase	 (TERT),	 platelet-derived-growth-factor	 receptor-β	 (PDGFR-β),	 PDGF-β	
and	 mitogen	 activated	 protein	 kinase	 1	 (MAPK1)	 (Farazi	 and	 DePinho,	 2006).	 HBV	
infection	can	also	trigger	genomic	instability	by	causing	chromosomal	rearrangements	
(Farazi	and	DePinho,	2006).	The	protein	HBx	can	alter	the	expression	of	several	growth-
control	genes	and	can	also	bind	and	inactivate	the	p53	tumor	suppressor	protein.	This	
causes	 an	 increase	 in	 cellular	 proliferation	 at	 the	 cost	 of	 efficient	 DNA-damage	
checkpoints.	 The	protein	HBx	 alone	was	 sufficient	 to	 induce	HCCs	 in	mice	 at	 a	 high	
infectivity	of	90%	(Sanyal	et	al.,	2010).			
	 There	are	multiple	ways	of	tumor	induction	upon	HBV	infection.		One	involves	
the	immune	response	of	the	host	cell,	resulting	in	T-cell	activation,	hepatocyte	necrosis	
and	 liver	 inflammation,	 which	 leads	 to	 constant	 regeneration	 and	 ultimately	 liver	
cancer	(Farazi	and	DePinho,	2006).	Another	mechanism	involves	the	interaction	of	the	
virus	 with	 the	 endoplasmic	 reticulum	 (ER),	 resulting	 in	 ER	 stress	 and	 subsequently	
oxidative	 stress,	 leading	 to	 the	 formation	 of	 free	 radical-induced	mutations	 and	 also	
stellate	cell	activation.	HBV	 infection	can	result	 in	HCCs	either	directly	or	by	causing	
pre-cancerous	 cirrhosis.	 HBV	 is	 also	 known	 to	 cause	 liver	 diseases	 other	 than	 HCCs	
(Farazi	and	DePinho,	2006).	
INTRODUCTION	
	
	16	
1.2.1.3 Hepatitis C virus (HCV) infection  
	 HCV	 infection	 accounts	 for	 about	 one-third	 of	 liver	 cancers	 worldwide.	 HCV	
infection	always	results	 in	cirrhosis	of	the	liver	before	progressing	into	cancers.	About	
60	 –	 80%	 of	 HCV	 infections	 are	 chronic	 infections.	 HCV	 is	 a	 positive-stranded	 RNA	
virus	belonging	to	the	Flaviviridae	family.	The	genome	of	the	HCV	virus	encodes	a	host	
of	non-structural	core	proteins	(NS2,	NS3,	NS4A,	NS5A	and	NS5B),	which	interact	with	
the	 ER	 of	 the	 host	 cell	 and	 produces	 the	 viral	 replicase	 and	 viral	 envelope	 proteins	
(Farazi	and	DePinho,	2006).	The	HCV	core	protein	can	also	promote	oxidative	 stress,	
resulting	 in	 activation	 of	 the	MAPK	 and	 the	 NFκB	 signaling	 pathways.	 This	 triggers	
cytokine	 production	 and	 then	 inflammation	 of	 the	 liver,	 which	 leads	 to	 tumor	
formation	 (Sanyal	 et	 al.,	 2010).	 HCV	 infection	 has	 been	 found	 to	 result	 in	 hepatic	
steatosis	 of	 the	 liver	 and	 induction	 of	 reactive	 oxygen	 species,	 subsequently	 causing	
HCC	development	(Farazi	and	DePinho,	2006)	
The	 HCV	 is	 known	 for	 its	 elaborate	 immune	 evasion	 mechanisms,	 either	 by	
preventing	T-cell	activation	by	inhibiting	dendritic	cell	functions,	or	by	interacting	with	
various	factors	such	as	Tumor	Necrosis	factor	α	(TNFα)	and	interferon-α	(IFNα).	HCV	
core	 proteins	 have	 been	 observed	 to	 directly	 interact	with	 components	 of	 the	MAPK	
signaling	 pathway	 and	 activate	 it.	 The	 core	 protein	 NS5A	 has	 been	 reported	 to	
inactivate	 p53	 function	 by	 sequestering	 it	 to	 the	 perinuclear	 membrane	 (Farazi	 and	
DePinho,	 2006).	 HCV	 infection	 has	 also	 been	 associated	 with	 fibrosis	 and	 type-2	
diabetes	 in	 patients,	 mainly	 due	 to	 the	 induction	 of	 insulin	 resistance	 (IR)	 in	 the	
patients.	Mice	containing	the	HCV	core	protein	have	been	shown	to	develop	IR	and	also	
an	 increase	 in	 levels	of	 the	pro-inflammatory	 factor	TNFα	and	IL-6,	probably	secreted	
by	 the	 Kupffer	 cells	 in	 response	 to	 oxidative	 stress	 caused	 by	 the	 HCV	 core	 protein	
(Sanyal	et	al.,	2010)	This	suggests	a	complex	mechanism	involved	in	the	HCV	induced	
carcinogenesis	of	the	liver.		
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1.2.1.4 Alcohol consumption 
	 Alcohol	 is	 one	 of	 the	most	 important	 life	 style-associated	 risk	 factors	 of	HCC.	
Similar	to	consequences	upon	HCV	infection,	chronic	alcohol	exposure	can	result	in	the	
activation	 of	 Kupffer	 cells	 and	 monocytes	 and	 subsequently	 cause	 the	 release	 of	
cytokines	 and	 chemokines	 such	 as	 TNFα,	 IL-1β	 and	 IL-6,	 which	 greatly	 affects	
hepatocyte	 survival.	 This	 sets	 up	 a	 mechanism	 of	 continuous	 destruction	 and	
regeneration	of	hepatocytes,	which	leads	to	stellate	cell	activation	and	ultimately	 liver	
cancer	 (Farazi	 and	 DePinho,	 2006).	 	 Alcohol	 exposure	 also	 leads	 to	 oxidative	 stress,	
which	can	result	in	fibrosis	of	the	liver,	by	induction	of	the	activated	stellate	cells	into	
synthesizing	more	collagen,	and	enhanced	cell	proliferation.	The	fibrotic	condition	can	
subsequently	develop	into	cirrhosis	and	ultimately	support	the	formation	of	HCC.	This	
was	 demonstrated	 in	 PDGF	 transgenic	mice	 (Campbell	 et	 al.,	 2005).	 Oxidative	 stress	
may	also	cause	hepatocyte	damage	by	inhibiting	the	STAT1-directed	activation	of	IFNγ,	
and	also	by	causing	oncogenic	mutations.	It	may	also	cause	chromosomal	instability	by	
accelerating	 the	 shortening	 of	 telomeres,	 which	 activates	 liver	 cirrhosis	 (Farazi	 and	
DePinho,	2006).	
	 Alcohol	 can	 also	 act	 synergistically	 with	 HCV	 infections	 in	 causing	 HCCs.	
Alcohol	 can	 enhance	HCV	 replication	 and	 also	 induce	 changes	 in	 the	 hyper-variable	
region	 of	 the	 viral	 genome.	 The	 mitochondrial	 and	 ER	 stress	 caused	 due	 to	 HCV	
infection	 could	 be	 further	 aggravated	 upon	 alcohol	 exposure,	 which	 further	 leads	 to	
increased	 ROS	 production	 and	 glutathione	 oxidation	 (Sanyal	 et	 al.,	 2010).	 The	
association	 of	 alcohol	 and	 HCV	 infection	 has	 the	 maximum	 effect	 on	 induction	 of	
oxidative	stress	in	the	liver,	thereby	pushing	the	organ	into	fibrosis	and	cirrhosis.		
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 1.2.1.5 Aflatoxin B1 
	 Aflatoxin	 B1	 is	 a	 fungal	 toxin	 associated	 with	 elevated	 incidences	 of	 HCC	
formation.	 Aflatoxin	 B1	 exposure	 and	 HBV	 infection	 often	 co-exist	 in	 HCC	 patients.	
Aflatoxin	 B1	 is	 known	 to	 cause	 activating	mutations	 in	 the	HRAS	 oncogene	 and	 also	
inactivating	mutations	in	the	p53	tumor	suppressor	gene	(Farazi	and	DePinho,	2006).	
 1.2.1.6 Non-alcoholic fatty liver disease (NAFLD) 
	 About	 one-fifth	 of	 the	 population	 of	 Western	 countries	 suffers	 from	 this	
condition.	 NAFLD	 is	 a	 high	 risk	 factor	 associated	 with	 HCC	 occurrence.	 NAFLD	 is	
histologically	 similar	 to	 alcoholic	 hepatitis	 although	 it	 is	 not	 caused	 due	 to	 alcohol	
exposure.	 Some	 of	 the	 variations	 observed	 in	 NAFLD	 livers	 include	 features	 such	 as	
hepatic	 steatosis,	 hepatocyte	 injury,	 and	 cytological	 ballooning.	 This	 implies	 an	
underlying	complexity	in	terms	of	pathological	conditions	existing	in	these	livers,	such	
as	 excessive	 fat,	 inflammation,	 ballooning	 degeneration	 and	 nonalcoholic	
steatohepatosis	 (NASH)	 (Sanyal	 et	 al.,	 2010).	NAFLD	has	been	closely	 associated	with	
type	2	diabetes	and	obesity.	The	three	conditions	of	NAFLD,	NASH,	and	HCC	are	likely	
to	be	co-occurring.	NAFLD	is	postulated	to	be	driven	by	insulin	resistance	(IR),	which	
increases	the	fatty	acid	uptake	of	the	liver	by	increasing	peripheral	lipolysis.	This	results	
in	 fat	 deposition	 in	 the	 liver	 coupled	 with	 simultaneous	 increase	 in	 lipogenesis	 (de	
novo)	and	reduction	of	lipoprotein	secretion	from	the	liver,	which	causes	accumulation	
of	 triglycerides	 in	 the	 liver.	 Increased	 levels	 of	 intrahepatic	 fatty	 acids	 can	 result	 in	
oxidative	stress	and	the	subsequent	production	of	ROS,	which	oxidize	the	fat	deposits	
into	 lipid	 peroxidation	 products,	 leading	 to	 oxidative	 damage	 to	 the	 mitochondrial	
genome	and	impairment	of	the	respiratory	chain.		This	can	also	induce	the	production	
of	 various	 cytokines,	 activation	 of	 stellate	 cells	 and	 subsequently	 progression	 to	HCC	
(Sanyal	et	al.,	2010).	
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1.2.2 Histopathology of HCCs  
	 Histological	 examination	 of	 tumor	 biopsies	 is	 one	 of	 the	 most	 important	
methods	 in	 HCC	 diagnostics.	 The	 morphological	 features	 of	 HCCs	 include	 tumor	
vascularization	 accompanied	 by	 a	 trabecular	 phenotype.	 Other	 prominent	 features	
include	acinar	patterns,	 cytologic	 atypia,	mitotic	 activity,	 active	 vascular	 invasion	and	
the	 loss	 of	 Kupffer	 cells	 and	 reticulin	 network.	 It	 has	 been	 observed	 that	 the	
morphological	 features	 of	 HCCs	 can	 differ	 significantly	 from	 one	 patient	 to	 another.	
This	 may	 be	 due	 to	 the	 different	 stages	 of	 progression	 and	 dedifferentiation	 of	 the	
tumor,	discernable	by	the	different	growth	patterns	in	the	tumor	mass.	It	had	led	to	the	
postulate	 that	 an	 initial	 well-differentiated	 small	 lesion	 undergoes	 step-wise	
dedifferentiation	into	larger	tumors	of	lower	differentiation	states,	completely	replacing	
the	 lesion	 by	 a	 nodule-like	 appearance.	 Other	 hypotheses	 postulate	 a	 multi-centric	
origin	of	HCCs,	mainly	due	to	the	advanced	HCCs	showing	morphological	features	such	
as	 encapsulation	 and	 well-established	 neovascularization	 consisting	 of	 unpaired	
arteries,	and	at	the	same	time	containing	the	other	typical	histological	patterns	of	HCC	
(Kojiro,	1998).	These	tumors	can	also	give	rise	to	satellite	nodules	in	the	vicinity	of	the	
progressed	primary	 tumor.	The	unpaired	arteries	of	 these	primary	 tumors	were	 found	
positive	 for	 smooth	muscle	actin	 (SMA)	and	CD34	 (Nakashima	et	al.,	 1995).	Based	on	
the	histological	observations,	HCCs	with	unique	features	can	be	classified	into	different	
types	 (see	below),	which	guides	 the	 choice	of	 subsequent	 therapeutic	 strategies	 to	be	
applied.		
1.2.3 HCC types  
" Fibrolamellar HCC 
	 	 Fibrolamellar	HCC	is	one	of	 the	 less	 frequent	types	of	HCC,	observed	 in	
young	patients.	 It	 is	not	 associated	with	 liver	 cirrhosis	 or	 any	other	predisposing	 risk	
factors.	The	histopathological	 features	of	 fibrolamellar	HCC	consist	of	 the	 tumor	cells	
growing	 in	 trabeculae	 and	 are	 separated	 by	 collagen	 fibers,	 visible	 by	 their	 lamellar	
pattern	(Ganeshan	et	al.,	2014).			
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" Sarcomatous HCC 
	 	 This	type	of	HCC	can	also	be	found	within	classical	HCC.	Histologically,	
sarcomatous	 HCC	 are	 recognizable	 by	 their	 spindle-shaped	 appearance	 and	 the	
presence	of	 various	anaplastic	 figures.	They	bear	 resemblance	 to	 leiomyosarcoma	and	
fibrosarcoma,	 when	 occurring	 alone,	 and	 not	 along	 with	 other	 types	 of	 HCC	
(Yamaguchi	et	al.,	1997).		
" Scirrhous HCC  
	 	 This	sub-type	of	HCC	is	characterized	by	fibrosis	occurring	in	response	to	
antitumor	 treatments	 and	 rarely	 in	 untreated	 tumors.	 Reports	 have	 shown	 that	 a	
majority	 of	 these	 tumors	 have	 observable	 CD8+	 lymphocyte	 infiltration,	 along	 with	
trabecular	atrophy	(Kojiro,	1998).	
" Clear-cell variant of HCC 
	 	 This	 variant	 of	 HCC	 was	 found	 arranged	 in	 trabecular	 pattern	 and	 the	
cells	 of	 these	 tumors	 are	 characterized	 by	 presence	 of	 fat	 vesicles	 in	 the	 cytoplasm,	
containing	glycogen.	It	is	also	found	predominant	in	males	rather	than	in	females	(Yang	
et	al.,	1996).	
" HCC with lymphoid stroma 
	 	 As	the	name	suggests,	this	sub-type	is	characterized	by	inflammatory	cells	
such	 as	 lymphocytes,	 macrophages,	 plasma	 cells,	 neutrophils	 and	 other	 giant	 cells.	
There	were	also	 found	 in	 the	 tumor	 tissues,	CD4+	T	cells	and	CD3+	T	cells	were	also	
found	(Park	et	al.,	2009).	
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1.2.4 HCC treatment modalities 
1.2.4.1 Surgical resection 
	 Removal	 of	 the	 tumor-containing	 part	 of	 the	 liver	 is	 the	 favored	 method	 of	
treatment,	 provided	 the	HCC	 is	 not	 associated	 with	 cirrhosis	 and	 the	 lesions	 are	 far	
early	in	their	stage	of	progression.	In	cirrhotic	livers,	resection	is	performed	only	if	other	
criteria,	such	as	the	tumor	size	and	bilirubin	levels	are	conducive.		Surgical	resection	is	
the	preferred	method	of	 treatment	 for	HBV-related	HCCs,	 due	 to	 these	 livers	usually	
developing	no	cirrhosis	(Llovet	et	al.,	2005).	
1.2.4.2 Liver transplantation 
	 For	 the	 patients	 who	 are	 unsuited	 to	 be	 treated	 with	 surgery,	 liver	
transplantation	 is	 the	 preferred	 therapeutic	 strategy	 (Ryder	 and	 British	 Society	 of,	
2003).	Owing	to	practical	and	technical	difficulties	associated	with	liver	transplantation,	
stringent	 rules	 and	 criteria	 have	 been	 developed,	 which	 assist	 in	 the	 selection	 of	
patients	 for	 this	 treatment.	 The	 Milan	 criteria	 have	 been	 applied	 worldwide	 to	
categorize	the	suitability	of	patients	for	this	treatment.	Additionally,	the	MELD	scores	
have	been	assigned	to	patients,	to	decide	on	the	priority	of	patients	on	the	waiting	list	
to	 receive	 donor	 organs.	When	 patients	 do	 not	meet	 the	 respective	 criteria	 for	 liver	
transplantation,	they	are	planned	for	other	forms	of	therapy.		There	have	been	different	
targeted	therapies	such	as	mTOR	inhibitors,	which	are	prescribed	to	patients	after	liver	
transplants,	 to	 prevent	 the	 recurrence	 of	 tumors,	 with	 considerable	 success	
(Cholongitas	et	al.,	2014)	
1.2.4.3 Local ablation 
	 The	patients	deemed	unsuitable	 for	 liver	 transplantation	 are	 treated	with	 local	
ablation	of	the	tumor.	This	can	be	done	by	Percutaneous	Ethanol	Injection	(PEI)	or	by	
the	more	modern	Radiofrequency	Ablation	(RFA).	The	RFA	method	has	been	shown	to	
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be	more	 successful	 in	 the	 removal	 of	 smaller	 sized	 tumors,	 compared	 to	 larger	 sized	
tumors.	Comparing	to	surgical	resection,	RFA	has	not	shown	any	significant	advantage	
in	terms	of	recurrence-free	survival	or	overall	survival	of	the	patient	(N'Kontchou	et	al.,	
2009).		
1.2.4.4 Chemoembolization  
	 This	 treatment	 method	 is	 recommended	 for	 patients	 of	 stage	 B	 classification	
according	 to	 the	 Barcelona	 clinical	 liver	 cancer	 staging	 recommendation,	 and	 to	
patients	 deemed	 unfit	 for	 other	 of	 the	 above-mentioned	 treatment	 modalities.	 It	
involves	 the	 catheterization	 of	 the	 hepatic	 artery	 to	 deliver	 chemotherapeutic	 drugs	
directly	to	the	tumors.	With	the	infusion	of	radioactive	substances,	such	as	Iodine-131,	
the	 response	 has	 been	 shown	 to	 be	 better	 (European	 Association	 for	 Study	 of	 et	 al.,	
2012).	 There	 have	 been	more	 and	more	 developments	 to	 this	method,	 to	 reduce	 side	
effects	and	improve	efficacy	(Lencioni	et	al.,	2013).		 	
1.2.4.5 Targeted therapy   
	 With	 the	 increasing	 insights	 into	 the	 different	 signaling	 pathways	 being	
activated	in	HCCs,	numerous	targeted	drugs	have	been	developed,	which	inhibit	these	
different	cellular	pathways	and	reduce	proliferation	of	the	cancer.		 	 	
Sorafenib	 is	 an	 FDA	 approved	 targeted	 therapy	 drug	 for	 HCC.	 	 Sorafenib	 has	
been	 known	 to	 inhibit	 a	 host	 of	 cellular	 receptors	 including	 the	 VEGF	 receptors	
(VEGFR-1	 ,	 VEGFR-2,	 VEGFR-3),	 PDGFRβ,	 RET,	 and	 c-KIT.	 	 Sorafenib	 is	 known	 to	
inhibit	 the	 Ras/MAPK	 pathway	 (Wilhelm	 et	 al.,	 2006).	 The	 SHARP	 clinical	 trial	 has	
shown	 an	 overall	 survival	 benefit	 of	 3	months	 for	 patients	 on	 Sorafenib	 compared	 to	
placebo	 treatment	 (Rimassa	 and	 Santoro,	 2009).	 Sorafenib	 has	 also	 been	 used	 as	
neoadjuvant,	 along	 with	 chemotherapeutic	 agents	 such	 as	 doxorubicin,	 ocreotide,	
oxaliplatin,	etc.	 	Sorafenib	has	been	administered	 in	combination	with	all	methods	of	
treatment	 for	 HCC,	 such	 as	 chemoembolization	 and	 resection,	 in	 order	 to	 improve	
therapeutic	efficiency	(Ziogas	and	Tsoulfas,	2017).	
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	 There	 have	 been	 other	 targeted	 drugs	 subjected	 to	 clinical	 trials,	 including	
Sunitinib,	 Linifanib,	 Brivanib,	 Tivantinib,	 Everolimus	 Erlotinib,	 Bevacizumab	 and	
Brivanib	 (Llovet	 et	 al.,	 2015;	 Thillai	 et	 al.,	 2016).	 In	 the	 context	 of	 the	 therapeutic	
potential	yet	 to	be	realized	by	targeted	therapies,	 it	 is	 imperative	to	study	the	various	
underlying	 mechanisms	 of	 hepatocarcinogenesis,	 in	 order	 to	 identify	 new	 molecular	
targets.		
1.2.5 Molecular mechanisms of hepato-
carcinogenesis 
	 	Different	 molecular	 mechanisms	 have	 been	 identified	 to	 be	 involved	 in	 the	
process	of	hepatocarcinogenesis.	The	most	predominant	of	those	is	the	inactivation	of	
p53	 in	 HCC	 patients	 with	 etiology	 of	 HBV/	 HCV	 infection	 or	 aflatoxin	 B1-exposure	
(Hussain	et	al.,	2007;	Tornesello	et	al.,	2013).	Further,	the	MAPK	pathway	is	activated	by	
HBV	 and	 HCV	 infections.	 The	 underlying	 mechanisms	 of	 carcinogenesis	 might	 be	
different	among	different	patients,	due	to	different	etiological	factors.	Recent	advances	
in	various	genome	analysis	 technologies	have	helped	to	obtain	significant	 insight	 into	
some	of	these	mechanisms.	
1.2.5.1 Genetic and epigenetic alterations 
	 The	constant	damage	and	regeneration	of	hepatocytes	due	to	various	etiological	
factors	provide	a	platform	for	further	genetic	and	epigenetic	alterations	to	be	acquired	
by	these	cells	that	ultimately	assists	in	the	malignant	transformation	process.	Molecular	
analysis	 of	 tumors	 from	 HCC	 patients	 has	 unraveled	 different	 genomic	 alterations	
acquired	during	the	step-wise	progression	of	HCC	from	dysplastic	nodules.		
 p53 tumor suppressor  
	 Inactivating	mutations	in	the	p53	gene	are	the	most	frequently	found	mutations	
among	HCC	patients	(Hussain	et	al.,	2007).	It	has	been	observed	in	HBx	transgenic	mice	
that	 functional	 inactivation	 of	 p53	 occurred	 in	 advanced	 tumors	 and	 not	 in	 early	
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nodules,	 thereby	 suggesting	 an	 involvement	 of	 this	mechanism	 late	 in	 the	 process	 of	
malignant	 transformation	 (Feitelson	 et	 al.,	 2002).	 This	 observation	 has	 been	
corroborated	 by	 studies	 performed	 in	 human	 tumors,	 which	 also	 showed	 p53	
inactivating	mutations	to	be	more	predominant	in	HBV,	or	HCV	infected	HCC	patients	
and	 also	 found	 more	 commonly	 in	 advanced	 tumors	 compared	 to	 recurrent	 pre-
malignant	 nodules	 (Minouchi	 et	 al.,	 2002).	 Considering	 that	most	 of	 the	 aetiological	
factors	 associated	with	HCC	 incidence	 cause	 oxidative	 stress,	 telomere	 shortening,	 or	
hepatocyte	damage,	the	additional	burden	of	p53	mutations	might	establish	a	situation	
wherein	the	cells	are	forced	into	continuous	proliferation	despite	the	presence	of	DNA	
damaging	 agents.	 This,	 along	 with	 telomere	 shortening,	 can	 lead	 to	 chromosomal	
instability	 in	the	tumors.	This	phenomenon	was	also	shown	in	p53	heterozygous	mice	
carrying	shorter	telomeres	with	chronic	liver	damage,	which	went	on	to	develop	HCCs	
(Farazi	et	al.,	2006).	
  β-Catenin activation 
	 β-Catenin	 is	 a	 downstream	 effector	 of	 the	Wnt	 signaling	 pathway.	 Activating	
mutations	 in	 the	 β-catenin	 gene	 (CTNNB1)	 is	 often	 observed	 in	 HCC	 patients	 and	
results	in	the	stabilization	of	the	protein.	The	associated	accumulation	of	the	β-catenin	
protein	 and	 its	 subsequent	 nuclear	 localization	 result	 in	 transcriptional	 activation	 of	
various	 cancer-related	genes,	 such	as	MYC,	 CCND1,	MMP7,	 etc	 (Ishizaki	 et	 al.,	 2004).	
Overexpression	 of	 the	 wild	 type	 β-catenin	 gene	 has	 also	 been	 reported	 in	 HCCs	 by	
various	 studies	 (Thorgeirsson	 and	Grisham,	 2002).	 In	 rare	 cases,	 β-catenin	mutations	
have	been	 found	 in	 conjunction	with	other	mutations,	 such	 as	 in	 the	p53	 gene,	 or	 in	
HCCs	 with	 chromosomal	 instability.	 This	 apparent	 mutual	 exclusivity	 of	 β-catenin	
activation	 with	 other	 mechanisms	 suggests	 an	 alternative	 progression	 mechanism	
involving	the	Wnt	signaling	pathway	harnessed	by	HCCs	(Calvisi	et	al.,	2004).	
 ErbB receptors overexpression 
	 The	ErbB	receptor	tyrosine	kinase	family,	comprising	the	proteins	ErbB1,	ErbB2,	
ErbB3,	 and	 ErbB4,	 has	 been	 found	 to	 be	 overexpressed	 in	 multiple	 HCC	 patients.	
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Particularly	 ErbB1	 and	 ErbB3	 overexpression	 was	 associated	 with	 more	 aggressive	
cancers	(Yamamoto	et	al.,	2001).	Inhibition	of	these	receptors	by	drugs	such	as	Gefitinib	
and	Erlotinib	showed	significant	responses	in	HCC	patients.	Also	human	cell-lines	were	
affected	by	these	drugs	in	vitro,	where	they	seemed	to	induce	apoptosis	(Hopfner	et	al.,	
2004).	Furthermore,	various	studies	 involving	one	of	 the	 ligands	of	 the	ErbB	family	of	
receptors,	demonstrated	Transforming	Growth	Factor	α	(TGFα)	to	display	a	close	 link	
between	elevated	expression	and	HCC	induction,	progression	and	poor	survival.	Lack	of	
TGFα	 in	 transgenic	mice	 reversed	 the	 pro-carcinogenic	 effects	 of	 TGFα.	 This	 empha-
sized	 the	 importance	 of	 the	 TGFα–ErbB	 receptor	 pathways	 in	 hepatocarcinogenesis	
(Jakubczak	et	al.,	1997).	
 Epigenetic regulation 
	 Epigenetic	alterations	have	been	reported	in	a	majority	of	human	HCCs,	both	in	
early	and	late	stages	of	tumor	development	(Lee	et	al.,	2003).	Hyper-methylation	of	CpG	
positions	in	selected	genes,	such	as	p16	(INK4A),	E-cadherin	(CDH1),	COX2,	apoptosis-
associated	 speck-like	 protein	 (ASC)	 and	 deleted-in-liver-cancer	 1	 (DLC1),	 have	 been	
observed.	 In	 one	 of	 the	 studies,	 treatment	 of	 tumor	 cells	 with	 demethylating	 agents	
resulted	in	over-expression	of	p16	(INK4a),	thus	implying	a	robust	epigenetic	silencing	
mechanism	 in	order	 to	 suppress	 genes	 such	as	p16	 (INK4A),	 encoding	 an	 inhibitor	of	
cellular	 proliferation	 (Maeta	 et	 al.,	 2005).	 There	 have	 also	 been	 reports	 of	 hypo-
methylation	events,	which	resulted	 in	 the	 loss	of	 imprinting	mechanisms	and	causing	
the	over-expression	of	genes	 such	as	 Insulin-like	growth	 factor	2	 (IGF2)	 that	promote	
cellular	proliferation	and	tumor	progression.	
1.2.5.2 Genomic instability 
	 Genomic	Instability	is	a	hallmark	feature	of	cancer,	including	HCC,	caused	
by	multiple	mechanistic	cues.		
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 Telomere shortening  
	 Telomere	 shortening	 has	 been	 widely	 observed	 in	 chronic	 liver	 disease.	 	 The	
various	etiological	factors	contributing	to	hepatocyte	proliferation,	coupled	to	telomere	
shortening	 associated	 with	 chronic	 liver	 disease,	 can	 ultimately	 result	 in	 genomic	
instability	in	the	cells	(Urabe	et	al.,	1996).	Genomic	instability	can	also	assist	in	tumor	
progression	 by	 causing	 alterations	 in	 the	 genome	 with	 each	 successive	 cycle	 of	 cell	
division.	 Studies	 performed	 on	 transgenic	 mice	 have	 also	 proved	 the	 link	 between	
chromosomal	 instability	 and	 telomere	 shortening	 ultimately	 resulting	 in	 tumor	
initiation	(Farazi	et	al.,	2003).	
 Telomerase overexpression  
	 Over-expression	 of	 the	 hTERT	 gene	 has	 been	 found	 in	 a	 vast	 majority	 (about	
90%)	of	human	cancers	(Zhou	et	al.,	2016).		Further	evidence	suggesting	the	important	
role	of	the	TERT	gene	came	from	the	observation	that	the	HBV	frequently	integrates	in	
the	 TERT	 locus	 of	 liver	 cells	 of	 human	 HCC	 patients	 (Ferber	 et	 al.,	 2003).	 Also,	
telomerase	 re-activation	 has	 been	 observed	 in	 recurrent	 HCCs	 after	 resection	
(Kobayashi	 et	 al.,	 2001).	 These	 findings,	 combined	 with	 the	 previous	 insights	 about	
telomere	 shortening,	 suggest	 a	 mechanism	 wherein	 telomere	 shortening	 triggers	 the	
malignant	transformation	in	liver	cells,	which	is	followed	by	telomere	reactivation	that	
assists	 in	 the	 progression	 of	 the	 tumors.	 This	was	 supported	 by	 a	 study	 on	Tert	 null	
transgenic	 mice	 where	 telomere	 dysfunction	 aided	 the	 induction	 of	 HCCs,	 whereas	
complete	lack	of	telomerase	activity	inhibited	HCC	progression	(Farazi	et	al.,	2003).	
1.2.5.3 Metabolic reprogramming 
	 Changes	 in	 the	metabolic	 preferences	 of	 cancer	 cells	 has	 been	widely	 studied,	
ever	 since	 the	 landmark	 theory	 by	 Otto	 Warburg	 in	 1924	 also	 known	 as	 aerobic	
glycolysis	or	“Warburg	effect”.	There	has	been	increasing	interest	of	late	in	this	theory,	
after	recent	findings	emphasized	the	various	metabolic	alterations	that	might	assist	the	
progression	 of	 tumors	 (Figure	 1-4).	 The	 metabolism-associated	 HIF1	 gene	 has	 been	
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found	to	assist	in	HCC	progression.	HIF1	regulation	is	known	to	be	controlled	by	other	
genes	involved	in	determining	metabolic	activity	of	a	tumor	cell	(Griffiths	et	al.,	2002).	
There	 have	 been	 additional	 reports	 identifying	 metabolic	 changes	 in	 the	 tumor	 and	
stromal	 cells,	 thereby	 directly	 affecting	 endothelial	 cells	 and	 tumor	 neo-angiogenesis	
(Fraisl	et	al.,	2008).		Recently	the	gene	PARP14	was	reported	to	be	an	important	driver	of	
the	Warburg	effect	in	HCCs	(Iansante	et	al.,	2015).	
	
Figure 1-4: Publications characterizing the Warburg effect. A strong increase in 
publications analyzing the Warburg effect is evident in the past decades. 
Picture from: (Liberti and Locasale, 2016) 
1.2.5.4 Tumor neo-angiogenesis 
	 During	the	step-wise	progression	of	HCC	in	human	patients,	it	is	noted	that	early	
dysplastic	nodules	are	difficult	to	detect	by	the	existing	methods.	Unlike	the	progressed	
HCCs,	which	can	be	visualized	using	ultrasound	imaging	due	to	the	ability	of	HCCs	to	
display	 arterial	 phase	 uptake	 upon	 contrast	 imaging.	 It	 has	 been	 postulated	 that	 the	
reason	behind	 the	 above-mentioned	observation	 rests	on	 the	 formation	of	new	blood	
vessels	 in	 the	 advanced	 HCCs.	 This	 has	 been	 considered	 a	 crucial	 milestone	 in	 the	
progression	of	HCC,	after	which	the	prognosis	to	all	types	of	treatment	modalities	turns	
significantly	 worse	 (Takayama	 et	 al.,	 1998).	 This	 crucial	 event	 has	 been	 called	 the	
“angiogenic	switch”.	This	has	been	further	substantiated	by	the	overexpression	of	VEGF	
and	 its	 regulator	HIF1	 in	many	human	 tumors.	Moreover,	 one	 of	 the	most	 successful	
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chemotherapeutic	drugs	 against	HCC,	Sorafenib,	has	been	 identified	 to	 inhibit	VEGF,	
among	 other	 molecules.	 This	 further	 underscores	 the	 importance	 of	 angiogenesis	 in	
HCC	progression.		
1.2.5.5 Epithelial-to-mesenchymal transition 
	 During	 the	 progression	 of	 HCCs,	 some	 of	 the	 tumor	 cells	 undergo	 a	
phenomenon	known	as	epithelial-to-mesenchymal	 transition	 (EMT).	 It	 is	 the	process,	
which	 brings	 about	 a	 transient	 de-differentiation	 of	 epithelial-type	 tumor	 cells	 to	 a	
mesenchymal	phenotype.	This	 is	accompanied	by	changes	in	gene	expression	patterns	
of	the	tumor	cell,	wherein	mesenchymal	marker	genes,	such	as	N-cadherin	(CDH2),	α-
smooth	muscle	actin	(αSMA)	and	fibroblast-specific	protein	(FSP-1)	are	over-expressed.	
The	 EMT	 is	 controlled	 by	 transcription	 factors	 including	 Snail	 (SNA1),	 Slug	 (SNA2),	
Twist	 and	ZEB.	Their	 expression	 levels	 are	 also	 increased	 in	 the	 context	of	EMT.	The	
EMT	 leads	 to	 elevated	motility	 of	 tumor	 cells,	 thereby	 contributing	 to	 the	metastatic	
spread	of	cancers.	The	mesenchymal	cells,	however,	can	be	reversed	to	their	epithelial	
phenotype	by	a	process	called	mesenchymal-to-epithelial	transition	(MET)	(Giannelli	et	
al.,	 2016).	 MET	 is	 frequently	 observed	 once	 tumor	 cells	 extravasate	 from	 the	 vessel	
system	and	engage	in	the	formation	of	metastatic	tumors	at	locations	distant	from	the	
primary	tumor.	
1.2.5.6 Altered regulation of gene expression 
		 Multiple	 mechanisms	 are	 involved	 in	 the	 modulation	 of	 gene	 expression	 in	
tumor	 cells.	 Below,	 some	molecular	mechanisms	 are	described,	 by	which	 cancer	 cells	
engage	in	altered	gene	expression.				
MicroRNAs 
	 MicroRNAs	 (miRNAs)	are	 short	RNA	molecules	of	 about	22	nucleotides	 length	
that	suppress	the	expression	of	their	target	genes	by	binding	to	the	3’	region	of	target	
transcripts,	subsequently	triggering	either	target	mRNA	degradation	or	 impairment	of	
INTRODUCTION	
	
	 29	
target	mRNA	translation.	This	enables	microRNAs	to	have	both	oncogenic	and	tumor	
suppressive	 function,	 depending	 on	 the	 gene	 targeted.	 In	HCC,	 several	miRNAs	have	
been	 found	 differentially	 regulated.	 Some	miRNAs,	 like	miR-221,	 miR-195,	 miR-128-2,	
miR-331-3p	and	miR-371-3	cluster,	are	found	over-expressed	in	tumors,	thus	inferring	an	
oncogenic	 function,	 whereas	 the	miRNAs	miR-100,	 let-7a-2,	miR-125b-1	 and	miR-148a	
have	 been	 found	 down-regulated	 in	 tumors	 probably	 due	 to	 their	 tumor	 suppressive	
functions	(Cairo	et	al.,	2010)	(Xu	et	al.,	2009).	In	recent	years,	our	understanding	of	the	
roles	 of	miRNAs	 in	HCC	 formation	 has	 significantly	 increased.	 Figure	 1-5	 depicts	 the	
tremendous	 increase	 in	 Pubmed	 listings	 of	 publications	 dealing	 with	 this	 area	 of	
research	.	
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Figure 1-5: Pubmed publications with keywords “miRNA, liver cancer”. The 
number of publications linking miRNAs and cancer have further increased in the 
past years. Data source: Pubmed 
	
Transcription factors 
	 Transcription	factors	are	the	special	type	of	cellular	proteins	that	mediate	extra-	
and	intra-cellular	stimuli	into	changes	in	cellular	gene	expression.	Hence	they	are	one	
of	 the	 chief	 modulators	 of	 cellular	 functions	 in	 normal	 and	 tumor	 cells.	 Numerous	
transcription	factors	have	been	found	differentially	regulated	in	human	HCCs,	such	as	
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Far	 upstream	 element	 binding	 proteins	 (FBPs),	 Yes-associated	 protein	 (YAP),	 signal	
transducer	 and	 activator	 of	 transcription	 (STAT3),	 SMADs,	Nuclear	 Factor	 of	 kappaB	
(NF-κB),	 Forkhead	 box	 M1B	 (FOXM1),	 or	 ATF5.	 However,	 the	 underlying	 role	 and	
oncogenic	 functions	 of	 many	 of	 the	 transcription	 factors	 are	 not	 been	 completely	
understood	 yet.	 	 Nevertheless,	 numerous	 studies	 on	 human	 and	mouse	 tumors	 have	
helped	 to	 unravel	 the	 specific	 functions	 of	 certain	 transcription	 factors	 in	 tumor	
progression.	
" v-myc	 avian	 myelocytomatosis	 viral	 oncogene	 homolog	 (c-
Myc)	
	 c-Myc	 is	 a	 proto-oncogene	 predicted	 to	 regulate	 genes	 involved	 in	 various	
cellular	processes	such	as	growth,	metabolism,	cell-cycle,	apoptosis,	cell	adhesion,	DNA	
repair	 and	microRNA	 regulation.	 c-Myc-dependent	 target	 gene	 expression	 signatures	
and	 c-Myc-associated	 miRNA	 signatures	 revelead	 overexpression	 in	 human	 HCCs	
(Cairo	et	al.,	2010).	The	human	genomic	 locus	8q24.21	containing	 the	c-Myc	gene	was	
found	amplified	in	60	%	of	human	HCCs,	which	could	account	for	the	over-expression	
of	the	protein	in	multiple	human	HCCs.		
" Activator	protein-1	(AP-1)	
	 The	AP-1	transcription	factor	is	a	hetero-dimer	of	different	combinations	of	the	
proteins	 Jun,	Fos	and	ATF.	They	are	activated	by	multiple	stimuli	 in	the	cell	and	they	
influence	 vital	 cellular	 processes	 such	 as	 proliferation,	 apoptosis,	 differentiation	 and	
consequently	 -	 tumorigenesis	 (Eferl	 and	Wagner,	 2003).	The	 specific	 functions	of	 this	
transcription	 factor	 complex	 depend	 largely	 upon	 the	 relative	 abundance	 and	
phosphorylation	status	of	each	of	its	sub-unit	proteins.	Altered	activity	of	the	proteins	
has	been	observed	even	in	early	stages	of	malignant	transformation	(Liu	et	al.,	2002).	
" Hypoxia-inducible	factor-1	(HIF-1)	
	 HIF-1	is	a	transcription	factor	mainly	activated	by	hypoxia,	as	the	name	suggests.	
HIF-1	 is	 a	 hetereodimeric	 protein	 comprising	 of	 the	 subunits	HIF-1α	 and	HIF-1β.	 The	
HIF-1	transcription	factor	is	known	to	activate	genes	associated	with	a	variety	of	cellular	
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functions	 such	 as	 angiogenesis,	 metabolism,	 and	 cell	 survival.	 A	 hypoxic	 tumor	
microenvironment	 is	 often	 present	 in	 advanced	 tumors	 and	 -	 due	 to	 uncontrolled	
tumor	 growth	 accompanied	 by	 high	 vascularization	 –	 these	 tumors	 are	 often	 poorly	
differentiated	and	contribute	 to	very	poor	patient	prognosis.	These	 tumors	have	been	
found	 to	 contain	 high	 amounts	 of	 HIF-1	 transcription	 factor	 and,	 interestingly,	 the	
neighboring	 non-tumorous	 liver	 tissues	 also	 expressed	 high	 amounts	 of	 HIF-1α.	 This	
implies	a	paracrine	effect	of	 the	 tumor	on	 the	 surrounding	cells	 in	 the	microenviron-
ment,	which	might	even	indirectly	assist	tumor	growth	(Simon	et	al.,	2010).	
" E2F	transcription	factors	
	 E2F	 denotes	 a	 family	 of	 transcription	 factor	 proteins,	 including	 E2F1	 through	
E2F8.	 They	 are	 regulated	 by	 the	 retinoblastoma	 tumor	 suppressor	 protein	 (Rb).	 	 Rb	
protein,	when	hypo-phosphorylated,	 binds	 and	 inactivates	 E2Fs.	 E2Fs	 are	 release	 and	
thereby	activated	upon	phosphorylation	of	Rb	and	removal	of	phosphorylated	Rb	from	
the	 chromatin.	 Other	 regulatory	 mechanisms	 acting	 on	 E2F1	 include	 miR-195-based	
mechanisms,	and	genomic	amplification	and	deletion	mutations	of	the	E2F	genes	(Choi	
et	al.,	2001).	Many	genes	belonging	to	the	E2F	family	are	 found	up-regulated	 in	HCCs	
(Zeng	et	al.,	2014).		
1.2.6 Mouse models for HCC 
	 Experimental	 animal	 models	 have	 been	 assisting	 cancer	 research	 for	 the	 past	
couple	of	decades.	Considering	 that	HCC	 is	 a	 cancer	displaying	 a	 complex	multi-step	
process	 of	 malignant	 transformation,	 the	 need	 for	 animal	 models	 to	 study	 various	
aspects	 of	HCC	 is	 apparent.	 This	 need	 has	 occasioned	 the	 development	 of	 numerous	
mouse	models	to	study	HCC.	
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Types of HCC mouse models 
	 The	mouse	models	 currently	 available,	 for	 the	 study	 of	HCCs	 can	 be	 grouped	
into	the	following	main	categories.	
! Chemically	induced	mouse	models	
! Implantation-based	models	
! Transgenic	knock-in	and	knock-out	mouse	models	
! Spontaneous	mouse	models	
1.2.6.1 Chemically Induced mouse models 
	 Several	chemical	agents	have	been	identified	that	can	cause	liver	cancer	in	mice	
when	administered	at	a	particular	dose	 for	a	particular	amount	of	 time.	The	chemical	
agents	 include	 genotoxic	 substances	 that	 can	 cause	 changes	 in	 the	DNA	composition	
and	 structure,	 as	 well	 as	 tumor	 promoting	 compounds,	 which	 by	 themselves	 do	 not	
cause	HCC	but	they	enhance	the	carcinogenic	effects	of	other	compounds.		
a. Diethylnitrosamine 
	 N-nitrosodiethylamine	(DEN)	is	one	of	the	most	widely	used	carcinogenic	agents	
to	 cause	 HCCs.	 DENs	 can	 alkylate	 chromosomal	 DNA	 within	 hepatocytes.	 The	
mechanism	of	carcinogenesis	by	DEN	administration	involves	the	oxygen-	and	NADPH-
dependent	hydroxylation	of	DEN	mediated	by	cytochrome	P450	enzyme.	This	leads	to	
the	 formation	 of	 an	 electrophilic	 ethyldiazonium	 ion	 upon	 acetaldehyde	 cleavage,	
which	causes	damage	to	the	DNA.	The	cytochrome	P450	enzyme	activity	can	also	cause	
the	release	of	ROS,	which	can	cause	oxidative	stress	in	the	cells,	which	is	also	a	major	
risk	factor	for	hepatocarcinogenesis	(Fausto	and	Campbell,	2010).	Since	DEN	works	by	
causing	DNA	 damage,	 DEN-induced	HCCs	 are	 largely	 dose-dependent.	 The	 duration	
and	extent	of	DEN	exposure	also	 influence	the	age	at	which	the	treated	mice	develop	
tumors.	 DEN-triggered	 tumours	 have	 also	 been	 shown	 to	 metastasize	 to	 the	 lungs.	
Additionally,	the	DEN	–	induced	model	can	also	be	combined	with	exposure	to	certain	
other	 tumor-promoting	compounds	 in	order	 to	enhance	 the	carcinogenic	potential	of	
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DEN.	One	 such	 compound	 is	 Phenobarbitol	 (PB)	 (Waxman	 and	Azaroff,	 1992).	 PB	 is	
often	used	in	combination	with	DEN	due	to	its	ability	to	activate	the	cytochrome	P450	
enzyme.	 PB	 treatment	 is	 also	 known	 to	 trigger	 mutations	 in	 the	 Ctnnb1	 gene.	 This	
method	of	cancer	induction	in	mice	by	DEN	is	also	affected	by	certain	hormones,	which	
results	 –	 depending	 on	 the	mouse	 strain	 -	 in	male	mice	 being	more	 prone	 to	 cancer	
than	 female	 mice.	 This	 gender	 bias	 is	 also	 observed	 during	 PB	 induced	 tumor	
promotion.	Collectively,	DEN	administration	is	a	robust	way	of	HCC	induction	in	mice,	
which	 resembles	 the	 oxidative	 stress-induced	 HCCs	 in	 humans	 (Heindryckx	 et	 al.,	
2009).	
b. Aflatoxin B1 
	 The	 hepatotoxin	 Aflatoxin	 B1	 (AFB1)	 is	 a	 known	 risk	 factor	 for	
hepatocarcinogenesis	 in	 humans.	Hence	AFB1-induced	murine	 tumors	 are	 one	 of	 the	
mouse	models	that	closely	resemble	the	human	scenario.	AFB1	is	produced	in	nature	is	
produced	 by	 the	 fungus	 Aspergillus	 flavus	 and	 is	 found	 mostly	 in	 China	 and	 West	
Africa,	 where	 there	 is	 already	 high	 prevalence	 of	 hepatitis	 virus	 infections.	 These	
etiological	factors	together	result	in	one	of	the	predominant	causes	of	HCCs	around	the	
world.	AFB1	is	converted	in	the	liver	to	an	intermediate	known	as	the	exo-8,9-epoxide,	
that	 can	bind	 to	guanine	 residues	 in	 the	DNA	and	cause	mutations.	These	mutations	
often	 trigger	 other	 genetic	 or	 chromosomal	 aberrations	 ultimately	 resulting	 in	HCCs	
(Heindryckx	et	al.,	2009)	
c. Carbon tetrachloride 
	 Carbon	tetrachloride	(CCl4)	 is	a	hepatotoxin	that	acts	similar	to	DEN,	whereby	
CCl4	metabolizes	cytochrome	P450	to	form	free	radicals	inside	the	cell.	These	radicals,	
cause	 lipid	 peroxidation	 and	 DNA	 damage.	 As	 a	 response,	 Kupffer	 cells	 induce	 an	
inflammatory	 response,	 resulting	 in	 the	 secretion	 of	 numerous	 pro-inflammatory	
agents.	These	pro-inflammatory	 factors	 also	 attract	monocytes,	neutrophils	 and	other	
immune	 cells,	 which	 can	 cause	 liver	 tissue	 damage.	 This	 repeated	 process	 of	
inflammation	and	repair	leads	to	fibrosis	and	then	to	cancer	(Heindryckx	et	al.,	2009).	
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1.2.6.2 Implantation-based mouse models 
	 Implantation	models	are	one	of	the	most	widely	used	forms	of	mouse	models	for	
HCC,	due	to	their	simple	and	cost-effective	mechanism	of	hepatocarcinogenesis.	They	
can	be	grouped	into	different	sub-groups	based	on	the	site	of	implantation	and	cellular	
origin	of	the	implant,	such	as	xenografts,	allografts,	ectopic,	and	orthotopic.		
a. Xenograft models 
	 These	are	the	most	common	of	all	types	of	mouse	model.	In	these	mouse	models,	
human	 tumor	 cells	 are	 ectopically	 or	 orthotopically	 introduced	 into	 immunodeficient	
mice.	 Due	 to	 their	 simplicity,	 these	 models	 are	 the	 preferred	 choice	 for	 testing	 of	
therapeutic	HCC	drugs	candidates	for	treatment	of	HCCs.	The	ectopic	method,	which	
involves	 the	 sub-cutanous	 injection	 of	 cancer	 cells	 in	 the	mouse,	 is	 a	 straightforward	
method	for	drug	testing	and	other	investigatinos	concerning	treatment	modalities.	The	
increase	in	number	of	human	HCC	cell-lines	and	the	advancement	in	technologies,	has	
resulted	 this	 method	 to	 be	 the	 most	 successful	 one.	 Moreover,	 the	 xenograft	 model	
enables	 the	measurement	 of	 several	 tumor	 characteristics,	 such	 as	 tumor	 length	 and	
width.(He	et	al.,	2015)	
	 The	 orthotopic	 xenograft	models	 are	 initiated	when	 tumor	 tissues	 of	 patients,	
diced	 into	a	cubic	millimeter	size,	are	 implanted	 into	 livers	of	 immune	deficient	mice	
livers.	This	approach	is	somewhat	laborious	and	complicated,	owing	to	the	implantation	
into	 the	 liver	 tissue	 of	mice.	 This	method	 does	 not	 allow	 the	 direct	measurement	 of		
parameters	like	tumor	volume,	length	and	breadth.	However,	this	method	is	preferable	
in	cases	where	the	tumor	microenvironment	represents	a	significant	aspect	of	the	study.	
Newer	technologies	have	been	developed	to	 implant	the	tumors	and	also	monitor	the	
progress	 of	 the	 tumors	 in	 the	mouse	 liver.	 Technologies	 such	 as	magnetic	 resonance	
imaging	 (MRI)	 and	positron	 emission	 tomography	 (PET)	 can	 be	 used	 in	 the	 study	 of	
these	 tumors.	 Such	 techniques	 can	 also	 aid	 in	 the	 monitoring	 of	 metastasis	 of	 the	
tumors	 into	 other	 mouse	 organs.	 There	 have	 been	 great	 advancements	 lately	 in	 the	
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orthotopic	xenograft	models,	which	includes	the	invention	of	synthetic	fibres	or	tubes	
to	assist	in	the	implantation	of	the	tissues	in	the	mouse	livers	(He	et	al.,	2015).	
b. Allograft models 
	 With	the	recent	advancements	 in	 immune	therapy	against	cancer,	 the	allograft	
models	for	HCC	have	been	developed,	in	order	to	facilitate	studies	of	the	action	of	the	
immune	 system.	 Hence	 these	 mouse	 models	 are	 predominantly	 on	 non-immune	
compromised	mice,	and	the	tumor	cells	are	also	derived	from	mice.	This	method	denies	
the	use	of	human	HCC	cell-lines	or	primary	human	cancer	cells,	due	to	the	danger	of	
immune	 reactions	 that	 are	 elicited	 upon	 exposure	 of	 mice	 to	 cells	 from	 a	 foreign	
species.	Hence	this	model	is	limited	to	murine	cancer	cells	implanted	into	other	mice.	
However,	this	method	has	resulted	in	significant	findings	regarding	the	role	of	immune	
modulation	in	cancer,	and	has	opened	up	various	avenues	of	cancer	therapy.			
 1.2.6.3 Transgenic mouse models 
	 Transgenic	mouse	models	use	genetically	engineered	mice,	used	for	assessing	the	
effects	of	specific	oncogenes	or	a	combination	of	various	oncogenes	and	other	factors	in	
hepatocarcinogenesis.	 This	 type	 of	mouse	models	 has	 an	 additional	 emphasis	 on	 the	
genetic	 alterations	 associated	 with	 carcinogenesis.	 Using	 this	 type	 of	 mouse	 model,	
genes	carrying	specific	mutations	can	also	be	 inserted	 into	 the	mouse	genome.	 In	 the	
past	 few	 decades,	 numerous	 transgenic	mouse	models	 have	 been	 developed	 for	HCC	
studies.	 Significant	 insight	 has	 also	 been	 attained	 about	 HCC	 pathophysiology	 using	
these	transgenic	mouse	models.		
a. HBV & HCV transgenic mice 
	 Given	that	the	major	cause	of	HCC	worldwide	is	HBV	infection,	transgenic	mice	
expressing	 either	 the	 whole	 genome	 or	 parts	 of	 the	 genome	 of	 HBV	 have	 been	
established.	The	HBx	gene,	is	known	to	regulate	genes	such	as	c-fos,	c-myc	and	ICAM-1	
that	 are	 associated	 with	 cell	 adhesion	 and	 proliferation.	 The	 HBx	 gene	 has	 been	
genetically	 engineered	 into	mice.	HBx	 overexpressing	 transgenic	mice	 showed	unique	
cellular	 morphologies	 such	 as	 an	 increased	 nuclear/cytoplasmic	 ratio,	 megalocytosis,	
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nuclear	 pleomorphism	and	hyperchromatism.	Tumors	were	 observable	 after	 the	mice	
were	 about	 one	 year	 old.	 Pre-natal	 complications	 and	 decreased	 birthrates	 were	
observed	 in	 these	mice.	HBx	 transgenic	mice,	 upon	 DEN	 administration,	 were	more	
prone	to	acquire	liver	tumors	compared	to	the	wild-type	mice.	Thus	the	HBx	transgenic	
mice	are	a	significant	tool	to	study	HBV-induced	human	HCC	formation	(Heindryckx	et	
al.,	2009;	Li	et	al.,	2011).	
	 Similar	to	the	HBx	transgenic	mice,	 the	HCV	transgenic	mice,	which	expressed	
the	core	protein	of	HCV	expressed	in	mice,	developed	liver	tumors.	These	mice	however	
were	less	prone	than	the	HBV	transgenic	mice.	This	might	be	due	to	influences	exerted	
by	the	genetic	background	of	the	mice	or	due	to	molecular	mechanism	under	control	of	
HCV	core	proteins	in	the	cell.		The	HBV	core	protein	activates	peroxisome	proliferators	
in	 hepatocytes,	which	 interferes	with	 lipid	metabolism	 and	 subsequently	 causes	 lipid	
accumulation	 in	 hepatocytes.	HCCs	were	 formed	 in	HCV-expressing	 transgenic	mice,	
albeit	much	 later	 than	 in	HBV	 transgenic	mice.	HCV	 transgenic	mice	 also	 showed	 a	
synergistic	effect	with	DEN	in	the	context	of	tumor	formation	(Wu	et	al.,	2009).	
b. Oncogene over-expressing transgenic mice 
	 Various	 transgenic	 mouse	 strains	 have	 been	 developed,	 which	 over-express	
certain	oncogenes	in	order	to	study	oncogene	functions	in	hepatocarcinogenesis.		
c-Myc	 is	a	transcription	factor	that	regulates	the	expression	of	numerous	genes	
by	directly	 binding	 to	 regulatory	DNA	elements.	 The	Myc	 transgenic	mice	developed	
tumors,	which	resemble	closely	those	human	HCCs	that	have	a	good	prognosis.	c-Myc	
interacts	with	multiple	other	proteins	and	influences	various	pathways	of	oncogenesis.	
It	was	also	found	that	a	small	subset	of	c-myc	transgenic	mice	displayed	overexpression	
of	β-Catenin	protein	(Heindryckx	et	al.,	2009).	
β-Catenin	transgenic	mice	are	also	available,	which	display	overexpression	of	this	
protein	or	a	mutant	form	thereof.		The	CTNNB1	gene,	along	with	TP53,	constitutes	the	
most	 frequently	 mutated	 gene	 in	 human	 HCC,	 with	 CTNNB1	 alone	 contributing	 to	
about	 30%	 of	 the	 mutations.	 Ctnnb1	 mutations	 in	 mice	 are	 not	 sufficient	 to	 induce	
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tumors	alone.	Ctnnb1	mutations	are	often	coupled	with	mutations	of	the	H-Ras	genes,	
which	rapidly	trigger	aggressive	tumors	in	mice	(Heindryckx	et	al.,	2009).	
c. Transgenic mice expressing growth factors 
	 Transforming	 growth	 factor-α	 (TGF-α)	 is	 an	 important	 molecule	 for	 the	
stimulation	of	hepatocarcinogenesis.	Liver	 tumors	occurring	 in	TGF-α	over-expressing	
mice	resemble	closely	those	human	HCCs	that	are	associated	with	very	poor	prognosis.	
These	 TGF-α	 overexpressing	 transgenic	 mice	 have	 a	 HCC	 penetrance	 of	 about	 50%.	
These	mice,	when	bred	with	c-myc	 transgenic,	developed	aggressive	 liver	 tumors	 in	a	
short	 period	 of	 time.	 This	 is	 indicative	 of	 an	 underlying	 cross-talk	 to	 exist	 between	
different	pathways	for	hepatocarcinogenesis.	 Similarly,	 Epidermal	 Growth	 Factor	
(EGF)	transgenic	mice	show	far	more	aggressive	phenotypes	when	coupled	with	other	
transgene	overexpressing	mice	(Heindryckx	et	al.,	2009).		
	 Fibroblast	 growth	 factor	 19	 (FGF19)	 transgenic	mice	were	 generated,	which	 do	
not	have	 a	 liver-specific	 expression	of	 the	 transgene.	FGF19	 expression	 in	 the	 skeletal	
muscle	cells	resulted	in	the	induction	of	tumors	in	the	liver	at	the	age	of	about	1	year.	
Interestingly,	 it	 was	 reported	 that	 the	 female	 FGF19	 transgenic	 mice	 showed	 over-
expression	 of	 β-Catenin	 while	 the	 male	 transgenic	 mice	 did	 not	 (Heindryckx	 et	 al.,	
2009).	
	 The	various	mouse	models	displaying	HCC	formation	have	helped	 improve	the	
understanding	of	HCC	pathogenesis	and	the	molecular	mechanisms	and	transcription	
factors	involved	in	malignant	transformation.		
1.3 Serum Response Factor  
	 Serum	 Response	 Factor	 (SRF)	 is	 a	 transcription	 factor	 involved	 in	 the	
transcriptional	regulation	of	numerous	target	genes,	which	include	the	Immediate	Early	
Genes	 (IEGs).	 Its	 discovery	was	 initially	 triggered	 by	 the	 observation	 that	 addition	 of	
serum	 to	 quiescent	 cells	 in	 vitro	 results	 in	 immediate	 induction	 of	 c-fos	 gene	
transcription	(Greenberg	and	Ziff,	 1984).	Further	studies	 identified	a	specific	sequence	
of	nucleotides,	located	about	300bp	upstream	of	the	transcription	start	site	(TSS)	of	the	
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c-fos	gene,	which	was	called	the	Serum	Response	Element	(SRE)	(Treisman,	1986).		The	
sequence,	 also	 known	 as	 the	 CArG	 box,	 consisted	 of	 an	 A/T	 rich	 core	 flanked	 by	 an	
inverted	repeat,	CC(A/T)6GG.	SRF	was	found	to	be	the	transcription	factor	that	bound	
to	the	CArG	box	and	controlled	the	expression	of	the	corresponding	gene.	SRF	is	known	
now	 to	 regulate	 the	 transcription	 of	 approximately	 1000	 target	 genes	 (Esnault	 et	 al.,	
2014).	
1.3.1  SRF Gene 
	 The	human	SRF	gene	sequence	 is	 10213	bp	 long	and	 is	 located	on	chromosome	
6p21.1,	 oriented	 in	 the	 plus	 strand.	 	 The	 SRF	 gene	 is	 highly	 conserved,	 and	 orthologs	
have	 been	 identified	 in	 other	 species	 such	 as	 Mus	 musculus,	 Gallus	 gallus,	 Anolis	
carolinesis,	Xenopus	laevis	and	Danio	rerio.	The	human	SRF	gene	containes	7	exons	and	
transcribes	to	a	4202	base	long	transcript	that	encodes	a	protein	of	508	amino	acids	in	
length.	The	SRF	protein	has	a	molecular	mass	of	51593	Da,	and	contains	the	following	
domains.	
" Nuclear	Localisation	Sequence	
" DNA	binding	domain	
" Transcriptional	activation	domain	
The	 DNA	 binding	 domain,	 spanning	 the	 amino	 acids	 133	 through	 222	 of	 the	
protein,	 is	 also	 responsible	 for	 dimerization	 and	 interaction	 of	 SRF	 with	 other	 co-
factors,	 essential	 for	 the	 function	 of	 the	 protein.	 This	 domain	 is	 also	 known	 as	 the	
MADS	 box,	 and	 all	 transcription	 factors	 containing	 this	 domain	 have	 been	 grouped	
together	as	the	MADS	box	family	of	transcription	factors	(Shore	and	Sharrocks,	1995).	
1.3.2  DNA binding 
	 The	SRF	protein	binds	to	the	CArG	box	DNA	sequence	in	order	to	modulate	the	
transcription	 of	 various	 target	 genes.	 The	 composition	 of	 the	 CArG	 box	 sequence	 is	
shown	in	the	Figure	1-6.	
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 Figure 1-6: The CArG box sequence. The Y-axis denotes the conservation of 
the corresponding nucleotide stacks, measured in ‘bits’. The height of each 
nucleotide at a given position represents its frequency. Picture source: (Miano, 
2010) 
	
The	 terminal	 G	 residues	 of	 the	 element	 have	 been	 shown	 to	 be	 the	 most	
significant	 nucleotides	 in	 the	 CArG	 box	 sequence,	 since	 here	 direct	 molecular	
interaction	 with	 SRF	 takes	 place.	 Mutations	 in	 these	 G	 residues	 could	 effectively	
deactivate	 the	CArG	 elements.	 Insertions	 or	 deletions	 in	 the	 inner	 (A/T)6	 core	 of	 the	
CArG	box	sequence	has	also	been	able	to	prevent	SRF	binding,	due	to	the	disruption	of	
the	 planar	 topology	 of	 the	 G	 residues,	 which	 normally	 reside	 in	 the	 major	 groove	
separated	from	each	other	by	one	helical	turn,	that	enable		the	SRF	monomer	to	be	on	
the	 same	 planar	 face	 of	 the	 DNA,	 thereby	 enabling	 efficient	 binding	 (Miano,	 2003).	
Substitutions	in	the	(A/T)6	core	also	seem	to	interrupt	SRF	binding,	due	to	the	presence	
of	 critical	 binding	 points	 in	 the	 (A/T)6	 core	 with	 the	 SRF	 protein,	 which	 are	 found	
within	 the	 narrowed	minor	 groove	 of	 DNA.	Moreover,	 an	 acute	 bend	 has	 also	 been	
observed	 in	 the	 DNA	 upon	 SRF	 binding	 (Pellegrini	 et	 al.,	 1995).	 This	 signifies	 the	
importance	 of	 the	 specific	 features	 of	 the	 CArG	 box	 in	 terms	 of	 its	 length	 and	
composition	 and	 structure,	which	 bears	 importance	 for	 the	 action	 of	 SRF	 and	 its	 co-
factors.		
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1.3.3  SRF co-factors 
	 Apart	 from	 their	 binding	 to	 DNA,	 SRF	 is	 also	 known	 to	 bind	 to	 different	 co-
factors.	Depending	upon	 the	 SRF	 co-factor	 involved,	different	 cohorts	 of	 target	 genes	
are	 regulated.	 The	 best-studied	 interaction	 partners	 of	 SRF	 are	 the	 Ternary	 Complex	
Factors	(TCFs)	and	the	Myocardin-related	transcription	factors	(MRTFs).	
The	 TCFs	 were	 the	 first	 SRF	 cofactors	 discovered	 and	 they	 support	 SRF	 to	
regulate	c-fos	 transcription	 (Shaw	et	al.,	 1989).	They	comprise	of	 the	proteins	Ets	 like	
gene	1	(Elk1),	SRF	accessory	protein	1	(SAP-1/Elk4)	and	Net	(Elk3)	(Dalton	et	al.,	1993).	
They	are	activated	by	the	MAPK	signaling	pathway.	Each	of	the	TCF	proteins	contains	
the	ETS-DNA	binding	domain	at	the	N	terminal,	close	to	the	SRF	binding	domain.		The	
highly	 conserved	ETS-DNA	binding	domain	 is	 known	 to	bind	DNA	at	 an	 ets-binding	
site	(EBS),	which	is	found	5’	to	the	CArG	box	sequence	of	the	c-fos	promoter.	The	EBS	
and	the	CArG	box	jointly	form	the	Serum	Response	Element	(SRE).		
	
Figure 1-7 : SRF-TCF binding to DNA. The TCFs bind with DNA using the ETS 
Binding domain(A), simultaneously bound to SRF using the SRF binding domain 
(B), meanwhile the Transactivation domain (C) initiates transcription. Picture 
source: (Buchwalter et al., 2004) 
	
	 The	MRTF	 protein	 family	 consists	 of	 the	 proteins	MRTF-A	 and	MRTF-B.	 The	
MRTF	proteins	contain	in	their	N-terminal	region,	a	consensus	sequence	known	as	the	
RPEL-Motiv,	which	mediates	MRTF	interaction	with	globular	actins	(G-actins).	MRTFs	
also	 contain	 an	 SRF-binding	 domain	 that	 is	 Glutamine-rich,	 and	 a	 Leucin	 Zipper	
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domain,	which	assists	in	the	homo-	or	hetero-dimerization	of	the	proteins.		The	MRTFs,	
themselves	do	not	bind	directly	to	the	DNA,	and	hence	they	do	not	contain	any	DNA	
binding	domain	of	their	own.		
	 In	 addition,	 other	 interaction	partners	 of	 SRF	have	 also	been	 identified,	which	
include	 GATA	 protein	 family	 of	 Zincfinger	 transcription	 factors,	 the	
homeodomainfactor	Nkx2.5,	the	LIM-domain-containing	Cysteine	Rich	Proteins	(CRP),	
FHL2,	 Homeobox-Protein	 (HOP),	 Sp1,	 and	 ATF6,	 among	 others.	 These	 proteins	 are	
known	to	have	either	activating	or	inhibiting	effects	on	SRF.			
1.3.4  SRF activation and regulation 
	 SRF	 has	 been	 known	 to	 be	 activated	 by	 different	 agents	 such	 as	 serum,	
lysophophatidic	 acid	 (LPA),	 anisomycin,	 mitogens,	 lipopolysaccharides,	 12-O-
tetradecanoylphorbol-13-acetate	 (TPA),	 cytokines,	 TNFα,	 Hepatitis	 B	 virus	 activator	
protein	pX,	activated	oncogenes	v-src,	v-ras,	c-raf,	and	also	anti-oxidants,	and	UV	light.	
However,	 the	 SRE	 regulating	 function	 of	 SRF	 is	 modulated	 by	 two	 major	 signaling	
pathways	as	shown	in	the	Figure	1-9.		
" MAPK	signaling	pathway	
" Rho-actin	signaling	pathway	
 1.3.4.1 MAPK signaling pathway 
	 The	TCF-dependent	transcription	regulation	by	SRF	is	mainly	activated	through	
the	 MAPK	 cascade,	 which	 involves	 various	 protein	 groups	 such	 as	 the	 extracellular	
signal	regulated	kinases	(ERK),	comprising	the	c-Jun	N-terminal	kinases	(JNK),	the	p38	
kinases,	and	the	ERK	kinases.	The	TCFs	are	needed	to	be	phosphorylated	before	binding	
to	 SRF	 and	 forming	 a	 complex,	 and	 then	 together	 they	 regulate	 the	 cohort	 of	 target	
genes,	which	have	the	SRE	sequence	5’	to	their	TSS.		The	TCFs	can	be	phosphorylated	
by	 the	 kinases	 ERK,	 JNK,	 or	 p38	 kinases	 in	 response	 to	 different	 upstream	 cues,	 as	
denoted	in	Figure	1-8.		
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Figure 1-8: Activation of SRF. The figure shows the two major signaling pathways 
that stimulate SRF via activation of SRF partner proteins. (Picture from: Prof. 
Dr. Alfred Nordheim) 
 
1.3.4.2  Rho-Actin signaling pathway 
	 The	MRTF-dependent	transcriptional	regulation	by	SRF	is	activated	through	the	
Rho-Actin	 signaling	 pathway,	 as	 shown	 in	 the	 Figure	 1-8.	 This	 pathway	 is	 largely	
modulated	 by	 the	 amount	 of	 G-actin	 present	 in	 the	 cytoplasm.	 	 G-actin	 is	 known	 to	
bind	MRTFs	 in	 the	cytoplasm.	 It	has	been	observed	 that	a	decrease	 in	 the	amount	of	
cytoplasmic	 G-actin	 in	 the	 cytoplasm,	 as	 generated	 in	 response	 to	 an	 increased	
synthesis	of	F-actin	in	the	cytoplasm,	results	in	increased	nuclear	localization	of	MRTFs	
(Miralles	 et	 al.,	 2003).	 	 This	 implies	 that	 the	 dissociation	 of	G-actin	 from	 the	MRTFs	
enables	MRTF	nuclear	localization.	Following	nuclear	localization.	MRTFs	immediately	
bind	to	SRF	and	regulate	a	specific	cohort	of	target	genes,	which	are	dependent	on	this	
pathway	for	regulation	(Olson	and	Nordheim,	2010).		
1.3.5  SRF biological function 
	 Various	genes	associated	with	proliferation	and	differentiation	are	regulated	by	
SRF.	The	role	of	SRF	in	the	transcriptional	regulation	of	the	IEGs	has	been	proven	by	a	
study	where	SRF-deficient	Embryonic	Stem	(ES)	cells	did	not	stimulate	IEG	activation	
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upon	serum	induction	(Schratt	et	al.,	2001).	However	a	similar	experiment	in	rat	smooth	
muscle	 cells	 showed	 an	 increase	 in	 proliferation	 (Kaplan-Albuquerque	 et	 al.,	 2005)In	
human	cells,	the	inhibition	of	SRF	resulted	in	reduced	proliferation	(Werth	et	al.,	2010).	
Thus,	 roles	 of	 SRF	might	 vary	 among	different	 cell	 types	 and	organisms.	Constitutive	
SRF-knockout	 showed	 that	murine	 embryos	 lacking	 SRF	 failed	 to	 develop	mesoderm	
and	hence	did	not	proceed	beyond	 the	gastrulation	 stage	 (Arsenian	et	al.,	 1998).	This	
supported	 earlier	 studies	 where	 an	 inhibition	 of	 the	 SRF	 function	 in	 vitro	 showed	 a	
complete	blockage	of	the	differentiation	of	myoblasts	to	myotubes,	which	underscored	
the	importance	of	SRF	during	differentiation,	in	a	non-cell	autonomous	manner	(Soulez	
et	 al.,	 1996).	 SRF	 knockout	 in	 ES	 cells	was	 also	 shown	 to	 affect	 ES	 cell	 adhesion	 and	
migration	 potential,	 which	 are	 dynamic	 events	 essential	 during	 gastrulation,	 which	
might	 explain	 the	 previous	 observations	 of	 embryo	 death	 at	 the	 gastrulation	 stage	
(Schratt	et	al.,	2001)	
	 SRF	 depletion	 in	 cardiomyocytes	 has	 been	 observed	 to	 have	 lethal	 effects	 on	
mice,	at	both	embryonal	and	adult	stages,	thus	signifying	the	importance	of	SRF	in	both	
heart	 development	 and	 function	 (Parlakian	 et	 al.,	 2005;	 Parlakian	 et	 al.,	
2004).Interestingly,	 an	 overexpression	 of	 SRF	 through	 specific	 cardiac	 transgenesis	
resulted	in	hypertrophc	cardiomyopathy	and	expression	of	antisense	SRF	improved	the	
mouse	cardiac	performance	(Chai	and	Tarnawski,	2002).	
	 SRF	 depletion	 in	 the	 neurons	 of	 mice	 showed	 migration	 defects	 and	 motor	
dysfunction	(Ataxie),	ultimately	resulting	in	the	death	of	the	mice	within	3	weeks	after	
birth	 (Alberti	 et	 al.,	 2005).	 Other	 studies	 have	 shown	 the	 importance	 of	 SRF	 in	 the	
development	and	function	of	mouse	retina,	smooth	muscle	cells,	skeletal	muscle	cells,	
immune	 cells,	 pancreas,	 brain	 and	 liver.	 A	 list	 of	 cell-type	 specific	 SRF	 knockout	
experiments	in	mice	and	the	corresponding	phenotypic	outcome	is	provided	in	Table	1-
1.	
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Table 1-1: Murine cell type-specific Srf knockouts and corresponding phenotypic 
effects. Table from: (Miano, 2010) 
Target cell type Phenotype 
Cardiomyocyte/SMC 
Dilated heart/reduced SMC recruitment and embryo demise 
at day e10.5 
Embryonic cells Early embryonic lethality without developing to term 
Adult 
cardiomyocytes 
Heart failure and death 10 weeks after KO 
Endothelial cell 
Aneurysm, hemorrhage, EC junctional/actin cytoskeletal 
defects, with death at day e14.5 
Skeletal muscle cell Perinatal orthopnea with thinned myofibers 
Adult skeletal muscle 
Muscle hypotrophy and poor regeneration, with 
50% mortality by 6 weeks of age 
Hepatocyte Reduced body size and chronic liver regeneration 
All pancreatic cells Pancreatitis, loss of exocrine pancreas 
Adult SMC 
Chronic intestinal pseudo-obstruction and death by 3 weeks 
after deletion of SRF 
Forebrain neurons 
Defective neuronal migration to hippocampus, impaired 
actin dynamics and axonal guidance. 
Attenuated activity-dependent immediate-early gene 
expression and long-term synaptic potentiation. 
Hippocampal 
neurons 
Defective layering of neurons and dendritic branching 
Keratinocytes 
Psoriasis-like condition with epidermal hyperproliferation, 
cytoskeletal and cell–cell contact perturbations 
Thickened epidermis, loss of barrier function and cell–cell 
contacts due to abnormal cytoskeleton 
T lymphocytes Loss in circulating T lymphocytes 
B lymphocytes Decrease in marginal zone B cells, low IgM 
Megakaryocyte Thrombocytopenia and macrothrombocytopenia 
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1.3.6  SRF and Cancer 
	 Considering	 the	 fact	 that	 SRF	 regulates	 the	 transcription	 of	 genes	 related	 to	
cellular	 proliferation	 and	 differentiation,	 the	 role	 of	 SRF	 in	 carcinogenesis	 has	 been	
studied	 with	 intense	 interest.	 Different	 studies	 reported	 increased	 levels	 of	 SRF	 in	
certain	human	cancers	(Choi	et	al.,	2009;	Park	et	al.,	2007).	However,	whether	the	SRF	
overexpression	in	human	tumors	is	a	cause	or	a	consequence	of	the	progression	of	the	
cancer,	 was	 not	 clear.	 A	 role	 of	 SRF	 in	 the	 regulation	 of	 Hippo	 signaling	 pathway,	
through	TAZ	in	breast	cancer	cells	has	been	reported	(Liu	et	al.,	2016).	There	have	been	
other	 reports	 about	 the	 role	 of	 SRF	 in	 enhancing	 the	 invasiveness	 of	 prostate	 cancer	
cells.	 Inhibition	of	 SRF	 resulted	 in	decreased	proliferation	 in	 those	 cells	 (Hermann	et	
al.,	 2016).	 Angiogenesis	 and	 increased	 cell	 migration	 during	 metastasis	 of	 certain	
cancers	have	also	been	attributed	to	SRF	(Franco	et	al.,	2013;	Kircher	et	al.,	2015).	SRF	
and	 Notch	 signaling	 pathways	 were	 found	 to	 be	 active	 in	 highly	 motile	 melanoma	
cells.(Manning	et	al.,	2015).	MRTF-depleted	and	SRF-depleted	breast	cancer	cells	were	
reported	 to	be	 less	 invasive	and	 the	xenografts	 in	mice	were	unable	 to	metastasize	 to	
the	 lung,	 thereby	 implying	 a	 fundamental	 role	 of	 SRF	 in	 cancer	 metastasis	 and	
invasiveness	(Medjkane	et	al.,	2009).	
Another	study	described	liver-specific	downregulation	of	the	microRNA	miR-122.	
The	downregulation	of	miR-122	corresponded	with	SRF	overexpression	in	these	tumors	
(Bai	et	al.,	 2009).	This	observation	was	 further	 substantiated	by	 the	 fact	 that	SRF	 is	a	
target	 of	miR-122	 and	 introduction	 of	miR-122	 in	 the	 cancer	 cells	 resulted	 in	 reduced	
tumorigenesis.	Moreover,	a	truncated	SRF	gene	lacking	the	miRNA-binding	site,	when	
introduced	in	the	miR-122-expressing	cells,	the	anti-proliferative	effect	had	disappeared.	
This	study	showed	a	clear	correlation	between	SRF	and	HCC	(Bai	et	al.,	2009).	
	 SRF	has	also	been	associated	with	induction	of	EMT	in	HCC	(Park	et	al.,	2007).	
The	 fact	 that	 the	 Hepatitis	 B	 virus	 core	 protein	 HBx	 can	 activate	 SRF	 suggests	 a	
fundamental	role	of	SRF	in	liver	carcinogenesis.		
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1.3.7  SRF-VP16 
	 SRF-VP16	is	a	fusion	protein,	where	the	transcription	activation	domain	(TAD)	of	
the	human	SRF	cDNA	,	spanning	exons	412	to	508	is	replaced	with	the	sequence	coding	
for	 the	viral	protein	VP16,	 	derived	 from	 the	Hepes	Simplex	virus.	The	 scheme	of	 the	
SRF-VP16	sequence	is	shown	in	Figure	1-9.	
Human&SRF&cDNA&sequence&
(10508)&
1" 412" 508"
Transcrip0on"ac0va0on"
domain"(TAD)"
(4129506)"
(19412)"
	
1" 412" 490"
VP16"sequence"
(4121490)"
SRF$VP16)sequence)
(1$490))
(11412)"
	
Figure 1-9: SRF-VP16 sequence. The figure shows the replacement of the terminal 
human SRF transcription activation domain (TAD) with the TAD of the VP16 
protein (Picture from: Prof. Dr. Alfred Nordheim). 
	 	
	 The	protein	SRF-VP16,	due	to	the	presence	of	the	transactivation	domain	of	the	
VP16	protein	can	perform	the	transcription	function	of	SRF	even	without	the	upstream	
cues	otherwise	necessary	to	activate	SRF.		Similarly,	SRF-VP16	function	does	not	depend	
upon	 the	 interaction	with	partner	proteins	 like	TCFs	or	MRTFs.	The	SRF-VP16	 fusion	
protein	had	been	used	widely	 in	the	study	of	the	SRF	function	(Dalton	and	Treisman,	
1992).	 The	 SRF-VP16	 protein	was	 shown	 to	 induce	morphological	 changes	 in	Srf	 (-/-)	
embryonic	stem	cells,	and	 induce	the	transcription	of	SRF	 target	genes	(Schratt	et	al.,	
2002).	 SRF-VP16	 also	 was	 shown	 to	 mimic	 SRF	 function	 in	 the	 neuronal	 cells	 by	
mediating	 their	 survival	 (Stern	 et	 al.,	 2012).	 Thus,	 SRF-VP16	 serves	 as	 a	 constitutive	
active	form	of	SRF	carrying	out	the	transcription	regulatory	function	of	SRF	in	different	
cell	types.		
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1.3.7  SRF-VP16iHep mouse model 
	 The	SRF-VP16iHep	mouse	model	was	generated	by	Dr.	Stefan	Ohrnberger	 in	 the	
group	of	Prof.	Dr.	Alfred	Nordheim,	University	of	Tuebingen.	 	The	SRF-VP16iHep	mice	
show	 mosaic	 activation	 of	 SRF-VP16	 in	 hepatocytes.	 The	 expression	 of	 SRF-VP16	
subsequently	 results	 in	 hepatocarcinogenesis	 in	 the	 livers	 of	 SRF-VP16iHep	 mice	
(Ohrnberger*,	 Thavamani*	 et	 al.,	 2015).	 The	 SRF-VP16	 triggered	 HCC	 formation	 is	
accompanied	 by	 induction	 of	 SRF	 target	 genes	 and	 hyper	 proliferation	 of	 SRF-VP16-
expressing	hepatocytes.		
1.4 Objective of this study 
	 The	 specific	 aims	 of	 the	 current	 study	 were	 to	 characterize	 the	 SRF-VP16	
triggered	murine	hepatocellular	carcinoma	(HCC)	formation,	using	a	combined	multi-
omics	 approach.	 It	 was	 thus	 the	 intention	 of	 identifying	 crucial	 events	 during	 the	
malignant	 transformation	 and	 subsequent	HCC	 tumor	 progression,	 as	 occurring	with	
100%	 penetrance	 in	 SRF-VP16iHep	 mice.	 To	 address	 this,	 the	 following	 strategy	 was	
undertaken.		
1) Identification	of	 the	 genomic	 changes	 contributing	 to	hepatocarcinogenesis	
was	attempted	by	detecting		
a. mutations	in	the	genomic	hotspot	regions	of	mutations,	using	Sanger’s	
sequencing,	and		
b. genome-wide	 nucleotide	 variations,	 using	 whole	 exome	 sequencing	
(collaboration	with	DKFZ,	Heidelberg).		
2) Charting	 alterations	 at	 the	 transcriptome	 level	 contributing	 to	 cancer	
formation	in	liver	by	using	RNAseq	technology	and	microarray	technology	(in	
collaboration	 with	 MPI,	 Tuebingen	 and	 UKT,	 University	 of	 Tuebingen	
respectively,	 bioinformatic	 support	 by	 QBiC).	 Individual	 candidate	 genes	
were	to	be	tested	using	quantitative	real	time	PCR.	
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3) Determine	 protein	 expression	 changes	 and	 posttranslational	 protein	
modifications	 (phosphorylation)	 by	 using	 LC-MS/MS	 proteomics	 (in	
collaboration	with	the	Proteome	Center	Tuebingen(PCT);	Prof.	Macek.		
4) Search	for	metabolic	alterations	by	analyzing	the	metabolome	and	lipidome	
(in	collaboration	with	MetaSysX	GmbH,	Potsdam).	
5) Comparison	of	the	obtained	data	to	each	other	and	to	human	HCCs.	
6) The	 ultimate	 goal	 being	 to	 deduce	 mechanistic	 principles	 involved	 in	
hepatocarcinogenesis	 in	 SRF-VP16iHep	 mice,	 as	 revealed	 by	 different	 omics	
technologies.	
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Figure 1-10: Objective of study described. The yellow boxes represent the 
components to be investigated. Blue boxes represent the various experimental 
techniques to be used. The green colored boxes represent the scientific insights 
aimed to be obtained from the experiments.  
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2 MATERIALS AND METHODS 
2.1 Animal Experiments 
2.1.1 Maintenance of experimental mice 
	 Mice	were	kept	 according	 to	 the	 regulations	of	 legal	 animal	protection	 laws	 in	
the	 Animal	 House	 present	 in	 the	 Interfaculty	 Institute	 for	 Cell	 Biology	 (Auf	 der	
Morgenstelle	 15,	 University	 of	 Tübingen).	 The	 recommendations	 of	 the	 “Society	 for	
Laboratory	 Animal	 Science”	 (Gesellschaft	 für	 Versuchstierkunde)	 with	 regard	 to	 the	
holding	of	 laboratory	mice	mentioned	 in	the	version-dated	20.03.2007	have	been	duly	
followed.		The	recommendations	were	based	on	the	principles	mentioned	in	Appendix	
A	of	Europarates	ETS	123,	entitled	-	“To	the	European	Convention	for	the	Protection	of	
Vertebrate	Animals	used	for	Experimental	and	other	Scientific	Purposes.	Guidelines	for	
Accommodation	and	Care	of	Animals“.		
	 The	day/night	 rhythm	followed	a	 12-hour	cycle,	which	 lasted,	 from	6:00	AM	to	
6:00	 PM	of	 ‘daytime’	with	 light	 and	 6:00	 PM	 to	 6:00	AM	of	 ‘night-time’	without	 any	
light.		The	mice	had	continuous	access	to	water	and	dried	food	pellets.	The	humidity	of	
the	rooms	was	maintained	at	55%(+	10%)	,	the	temperature	at	22	°C	(+	2	°C)	and	the	air	
flow	at	10	times	the	room-volume	per	hour.	The	animals	were	maintained	in	groups	of	
three	to	five	in	Type	II	long	cages.	Matings	were	also	set	up	in	Type	II	long	cages,	and	
were	checked	 frequently.	All	mice	were	 transferred	 to	new	cages,	once	 in	every	week.	
The	bottom	of	each	of	the	cages	was	covered	with	wooden	chips.	Additionally	the	mice	
cages	 were	 supplied	 with	 cellulose	 material	 in	 the	 form	 of	 recycled	 paper	 for	 nest	
building.	In	all	the	cages,	and	additional	play	toy,	shaped	as	a	tunnel,	made	out	of	wood	
or	plastic	was	furnished,	in	order	to	keep	the	mice	occupied.	Once	in	every	six	months,	
hygiene	control	tests	were	performed	on	randomly	chosen	mice,	where	the	presence	of	
different	mouse	pathogens	was	checked.		
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2.1.1.1 Permissions for mouse experiments 
The	mouse	experiments	carried	out	as	part	of	this	dissertation	were	duly	approved	by	
the	 corresponding	 authorities	 at	 the	 district	 administration	 (Regierungspräsidium)	 of	
Tübingen.		
I. The	 first	 part	 of	 the	 experiments	 were	 performed	 in	 accordance	 to	 the	
permission	as	stated	in	Paragraph	4	of	the	Animal	protection	laws	in	the	version	
announced	on	25th	May	1988	(BGBI.	S:	1105),	which	enables	the	sacrifice	of	mice,	
without	any	prior	experimental	treatments	for	organ	preparation	only.		
II. Upon	changes	in	the	animal	protection	laws	that	became	active	starting	from	4th	
July	 2013	 the	 newer	 version	 regarding	 usage	 of	 laboratory	 animal	 for	
experimental	purposes,	from	12th	August	2013	(BGBI.	I	S.	3125),	a	new	application	
IM	1/14	was	made	on	18.11.2014	for	“Experimental	analysis	at	the	RNA	and	protein	
levels	 in	 hepatocytes	 of	 the	 SRF-VP16iHEP	mouse	model“	 and	was	 approved	 on	
05.01.2015.		
III. Abhishek	Thavamani,	was	added	to	the	application	 for	animal	experimentation	
IM	 1/14	 as	 experimenter,	 upon	 successful	 completion	 of	 the	 Animal	 handling	
course	–	“Versuchstierkundlichen	Privatissimums”	in	the	summer	semester	2015.		
2.1.2 Mouse breeding  
	 Breeding	 of	 the	 transgenic	 mice	 was	 carried	 out	 as	 described	 below.	 SRF-
VP16(+/-):Alfp-CreERT2(-/-)	mice	were	mated	with	SRF-VP16(-/-):Alfp-CreERT2(+/-)	mice.	
The	mice	were	put	 together	 in	Type	 II	 long	cages	 for	mating.	The	mating	cages	were	
held	in	rows	separated	from	the	other	cages.	The	mating	pairs	were	at	least	6-7	weeks	of	
age.	 The	 first	morning	 after	 the	 setting	 up	 of	 the	mating,	 the	mice	were	 checked	 for	
compatibility.	In	case,	there	were	found	bloodstains	in	either	of	the	mice,	or	that	they	
were	 continually	 fighting	 with	 each	 other,	 the	 pairs	 were	 separated	 and	mated	 with	
other	mice.		
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The	 mating	 pairs	 were	 monitored	 every	 morning	 for	 the	 presence	 of	 vaginal	
plugs.	When	a	litter	was	born,	the	pups	were	monitored	each	day	for	the	first	few	days	
to	ensure	the	mothering	instincts	and	proper	nursing	of	the	pups.			
When	 the	 pups	 were	 3	 weeks	 old,	 they	 were	 weaned	 by	 transferring	 them	 into	 new	
cages,	males	and	females	separately.		
Mating	pairs	were	allowed	to	mate	for	about	5-6	months,	until	they	had	given	birth	to	
about	5-6	litters.	Subsequently,	mating	pairs	were	separated	into	different	cages,	and	a	
new	set	of	animals	was	chosen	as	mating	pairs.	After	every	third	generation	of	crossing,	
transgenic	mice	were	crossed	with	wildtype	C57BL/6	mice.	
2.1.3 Mouse ear marking  
	 When	the	pups	had	been	weaned	and	separated	into	new	cages,	the	ear	marking	
and	genotyping	was	done	to	uniquely	identify	them.		The	young	mice	were	gently	taken	
by	 their	 tails,	 and	 held	 by	 the	 skin	 behind	 their	 necks	 to	 make	 them	 motionless.		
Following	this,	a	small	hole	was	made	in	their	ear	based	on	a	pre-determined	scheme	to	
designate	the	mouse	with	a	unique	code	(Figure	2-1).	The	piece	of	skin	thereby	removed	
from	 the	 ear	 was	 immediately	 incubated	 in	 lysis	 buffer,	 and	 the	 DNA	 used	 for	
genotyping	PCR.	The	mice	were	subsequently	weighed	and	then	carefully	let	into	their	
cages	back	again.	The	unique	identification	codes	corresponding	to	the	position	of	ear	
punch	is	shown	in	Figure	2-1.	
	
Figure 2-1: Ear Marking Scheme 
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2.1.4 Genotyping  
2.1.4.1 Sample Lysis 
Materials Used  
Buffer/Instrument	 Company/	Composition	Lysis	Buffer	 10	mM				Tris-HCL,	pH	8.3	200	mM	NaCl	5mM							EDTA	0.2%							SDS	and	200	μg/mL	Proteinase	K		(freshly	added	each	time	before	use)	Heating	Block	 Eppendorf	GmbH	
The	 ear	 skin	 samples	 of	 the	 mice	 were	 incubated	 in	 100	 μL	 of	 Lysis	 Buffer	
overnight	at	55	°C.	After	that,	they	were	briefly	vortexed	and	then	heated	up	at	99	°C	for	10	minutes	to	inactivate	the	Proteinase	K	enzyme.	The	samples	were	then	centrifuged	at	high	speed	for	10	minutes.	The	DNA	released	into	the	supernatant	was	taken	as	template	for	the	genotyping	PCR	reactions.		
2.1.4.2 Genotyping PCR   
The	DNA	template	was	mixed	with	the	PCR	cocktail	and	set	up	in	the	thermocycler	for	
PCR	amplification	using	the	corresponding	primers.	The	amplified	PCR	products	were	
subsequently	analysed	using	Agarose	Gel	Electrophoresis.		
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Materials used   
Buffer/Instrument	 Company/	Composition	10x	Polymerase	Buffer	 Thermo Scientific™	Primers	 Sigma-Aldrich	DMSO	 Sigma-Aldrich	40mM	dNTPs	 Promega	GmbH	(dATP,dCTP,dGTP	and	dTTP	10mM	each)	Taq	Polymerase	(2	units)	 Thermo Scientific™	Thermocycler	 Biometra	
	 	
2.1.4.3 Genotyping of SRF-VP16 
The	presence	of	the	SRF-VP16	sequence	at	the	Rosa26	locus	in	the	genome	of	the	mice	
was	checked	using	the	following	primers	during	genotyping	PCR.	The	locations	of	the	
primers	are	shown	in	the	Figure		2-2.		
Primers 
	 A	multiplex	PCR	reaction	using	3	primers	was	used	for	genotyping	the	SRF-VP16	
transgene	insertion.	The	locations	of	the	primers	are	shown	in	Figure	2-2.	The	primers	
used	in	the	multiplex	were	as	follows.	
i. Rosa26	forward	primer	
ii. Rosa26	reverse	primer	
iii. PURO	reverse	primer	
Rosa26	forward	primer	and	the	Rosa26	reverse	primer	were	specific	to	the	wild	
type	 Rosa26	 locus	 of	 the	 mouse	 genome.	 They	 both	 combine	 to	 amplify	 a	 275	 bp	
fragment	corresponding	to	the	murine	wild	type	Rosa26	gene	locus.	The	PURO	reverse	
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primer	is	specific	to	the	Puromycin	resistance	gene	present	in	the	STOP	cassette	of	the	
inserted	 SRF-VP16	 transgene	 construct.	 The	 PURO	 reverse	 primer	 along	 with	 the	
Rosa26	forward	primer	amplify	a	fragment	of	500	bp	size,	which	occurs	only	upon	the	
presence	 of	 SRF-VP16	 transgene	 construct	 in	 the	 mouse	 genome,	 which	 implies	 a	
successful	insertion	of	the	transgene	construct	at	the	Rosa26	locus.	The	primer	mix	was	
prepared	by	mixing	5	μL	of	100M	Rosa26	forward	primer,	10	μL	of	100	μM	Rosa26	reverse	
primer	 and	 10	 μL	 of	 100	μM	PURO	 reverse	 primer.	 The	 sequences	 of	 the	 primers	 are	
given	in	section	2.10.	
4xPolyA(
STOP 
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Figure 2-2: SRF-VP16 genotyping primers. The figure shows the positions of the 
forward and reverse primers corresponding to the 2 different amplicons of the 
SRF-VP16 genotyping PCR. The genomic sequence of the SRF-VP16 transgene is 
explained in section 3.1.1.1. The primer sequences are described in section 2.10. 
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PCR reaction mix 
The	PCR	cocktail	for	each	genotyping	reaction	consisted	of	following:	
Buffer	 Concentration	 Volume	(μL)	Polymerase	Buffer	 10x 5	Primer	mix	 100x	 0.5	DMSO	 8x	 4	dNTP	mix	 40mM	 2	Taq	Polymerase	 2 units 0.5	Water	 35.5	Template	DNA	 1	Total	Volume	 50	
The	above	 cocktail	was	mixed	gently	 and	 then	placed	 in	 the	 thermocycler	 and	
the	SRF-VP16	genotyping	PCR	program	was	run.		
SRF-VP16 genotyping PCR program  
Step		 Temperature	 Time	 Repeat	Lid	pre-heating	 100	°C	 	 	Initial	denaturation	 98	°C	 3	mins	 	Denaturation	 98	°C	 30	secs	 35	times	Annealing	 62	°C	 35	secs	Extension	 72	°C	 70	secs	Final	Extension	 72	°C	 15	mins	 	Storage		 4°C	 Hold	 	
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2.1.4.4 Genotyping of Alfp-CreERT2 
The	 presence	 of	 the	Alfp-CreERT2	 sequence	 in	 the	 genome	 of	 the	mice	was	 checked	
using	 the	 following	primers	during	 genotyping	PCR.	The	 locations	of	 the	primers	 are	
shown	in	the	Figure		2-3.		
Primers 
	 A	 multiplex	 PCR	 reaction	 using	 4	 primers	 was	 used	 for	 genotyping	 the	 Alfp-
CreERT2	transgene	insertion.	The	primers	used	in	the	multiplex	were	as	follows.	
i. Alfp-CreERT2	Forward	
ii. Alfp-CreERT2	Reverse	
iii. PCR3	
iv. PCR4	
Alfp-CreERT2	forward	primer	and	the	Alfp-CreERT2	reverse	primer	were	specific	to	
the	 Alfp-CreERT2	 transgene.	 	 They	 both	 combine	 to	 amplify	 a	 200	 bp	 fragment	
corresponding	 to	 the	 Alfp-CreERT2	 transgene	 insert.	 The	 presence	 of	 the	 200	 bp	
amplicon	denoted	the	presence	of	the	Alfp-CreERT2	transgene	in	the	mouse	genome.	In	
addition	 to	 the	Alfp-CreERT2	 transgene	primers,	 the	primer	pair	PCR3/	PCR4	was	also	
taken	 in	 the	multiplex,	 which	 amplifies	 a	 random	 fragment	 located	 elsewhere	 in	 the	
mouse	 genome,	 as	 an	 internal	 control.	 The	 PCR3/PCR4	 primer	 pair	 resulted	 in	 an	
amplicon	of	 500	bp	 size.	The	presence	of	 this	 500	bp	amplicon	ensured	 that	 the	PCR	
reaction	had	been	successful.	The	primer	mix	was	prepared	by	mixing	10	μL	of	 100μM	
Alfp-CreERT2	 forward	 primer,	 10	 μL	 of	 100μM	 Alfp-CreERT2	 reverse	 primer,	 10	 μL	 of	
100μM	PCR3	primer	and	10	μL	of	100μM	PCR4	primer.	The	sequences	of	the	primers	are	
given	in	section	2.10		
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Figure 2-3: Alfp-CreERT2 genotyping primers. The figure shows the positions of 
the forward and reverse primers used in the detection of Alfp-CreERT2 genotyping 
PCR. The genomic sequence of the Alfp-CreERT2 transgene is explained in section 
3.1.1.2. The primer sequences are described in section 2.10. 
PCR reaction mix 
The	PCR	cocktail	for	each	genotyping	reaction	consisted	of	following:	
Buffer	 Amount/	
Concentration	
Volume	
(μL)	Polymerase	Buffer	 10x 5	Primer	mix	 100x	 0.5	DMSO	 5x	 2.5	dNTP	mix	 40mM	 1.5	Taq	Polymerase	 3 units 0.65	Water	 38.85	Template	DNA	 1	Total	Volume	 50	
The	cocktail	was	mixed	gently	and	then	placed	in	the	thermocycler	and	the	Alfp-
CreERT2	genotyping	PCR	program	was	run.		
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Alfp-CreERT2 genotyping PCR program  
Step		 Temperature	 Time	 Repeat	Lid	pre-heating	 100	°C	 	 	Initial	denaturation	 98	°C	 1	min	 	Denaturation	 98	°C	 10	secs	 35	times	Annealing	 55	°C	 30	secs	Extension	 72	°C	 20	secs	Final	extension		 72	°C	 10	mins	 	Storage	 4	°C	 Hold	 	
2.1.4.5 Genotyping of Srf-flex1 transgene  
The	presence	of	the	Srf-flex1	transgene,	which	contains	two	LoxP	sites	within	the	
murine	Srf	gene,	was	checked	using	the	following	primers	during	genotyping	PCR.	The	
locations	of	the	primers	are	shown	in	the	Figure	2-4.		
Primers 
	 A	multiplex	PCR	reaction	using	3	primers	was	used	 for	genotyping	the	Srf-flex1	
transgene	insertion.	The	locations	of	the	primers	are	shown	in	Figure	2-4.	The	primers	
used	in	the	multiplex	were	as	follows.	
i. Srf-KO-8	forward	primer	
ii. Srf-KO-8	reverse	primer	
iii. Lox2	primer	
Srf-KO-8	 forward	 primer	 and	 the	 Srf-KO-8	 reverse	 primer	 were	 designed	 to	
amplify	 a	 fragment	within	 the	 intron	 1	 of	Srf	 gene	 in	 the	mouse	 genome.	 In	 the	wild	
type	situation,	the	primers	combine	to	produce	an	amplicon	of	190	bp	in	length.	In	the	
Srf-flex1	 transgene,	 there	exists	a	LoxP	site	 in	 intron	1	of	Srf	gene	sequence	within	the	
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amplifying	region	of	the	Srf-KO-8	forward	and	reverse	primers.	This	results	in	a	larger	
amplicon	of	244	bp	in	length.	Hence,	during	genotyping	PCR,	the	presence	of	the	244	
bp	sized	amplicon	 implies	 the	 insertion	of	 the	Srf-flex1	 transgene.	The	third	primer	 in	
the	multiplex	the	 lox2	primer,	 is	 located	on	the	other	 loxP	site	present	 in	the	Srf-flex1	
transgene.	The	second	LoxP	site	is	present	at	the	exon	1	region	of	Srf	sequence.	In	the	
event	 of	 recombination-mediated	 deletion	 between	 the	 LoxP	 sites,	 the	 lox2	 primer	
combines	with	Srf-KO-8	reverse	primer	to	generate	an	amplicon	of	110	bp	in	length.	The	
primer	mix	was	prepared	by	mixing	15	μL	of	Srf-KO-8	forward	primer,	5	μL	of	Srf-KO-8	
reverse	 primer	 and	 10	 μL	 of	 Lox2	 primer.	 The	 sequences	 of	 the	 primers	 are	 given	
insection	2.10		.	
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Figure 2-4: Srf-flex1 transgene genotyping primers. The figure shows the 
positions of the forward and reverse primers used in the detection of Srf-flex1 
genotyping PCR. The genomic sequence of the Srf-flex1 transgene is explained in 
section 3.1.1.3. The primer sequences are described in section 2.10. 
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PCR reaction mix 
The	PCR	cocktail	for	each	genotyping	reaction	consisted	of	following:		
Buffer	 Concentration	 Volume	(μL)	Polymerase	Buffer	 10x 5	Primer	mix	 100x	 0.5	DMSO	 7x	 3.5	dNTP	mix	 40mM	 2	Taq	Polymerase	 5 units 1	Water	 37	Template	DNA	 1	Total	Volume	 50	
The	cocktail	was	mixed	gently	and	then	placed	in	the	thermocycler	and	the	Srf-
flex1	genotyping	PCR	program	was	run.		
Srf-flex1 genotyping PCR program 
Step		 Temperature	 Time	 Repeat	Lid	pre-heating	 100	°C	 	 	Initial	denaturation	 98	°C	 2	mins	 	Denaturation	 98	°C	 30	secs	 35	times	Annealing	 60	°C	 30	secs	Extension	 72	°C	 45	secs	Final	extension		 72	°C	 10	mins	 	Storage	 4	°C	 Hold	 	
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2.1.4.6     Agarose gel electrophoresis   
	 In	order	to	analyze	the	genotyping	PCR	products,	2%	agarose	gels	were	cast.	The	
agarose	 gel	 electrophoresis	 was	 performed	 as	 described	 in	 the	 Detailed	 Procedure	
section	2.8.8.	The	images	were	then	analyzed	to	determine	the	genotype	of	the	mice.		
2.1.5 Mouse health monitoring  
The	experimental	mice	of	the	desired	genotype	were	monitored	closely,	to	ensure	their	
proper	 health	 during	 the	 entire	 experimental	 period.	 Animal	 weight	 was	 measured	
every	week,	until	mice	 reached	 the	age	of	 twenty	weeks.	Thereon,	 they	were	weighed	
twice	a	week	until	the	age	of	thirty	weeks.	Thereafter,	they	were	weighed	every	day	until	
the	day	of	 sacrifice.	 	Mice	were	 also	 checked	every	day	 for	 any	abnormalities	 in	 their	
posture,	movement	or	eating	and	drinking	habits.		
2.1.6 Mouse sacrifice   
	 The	 experimental	 animals	were	 sacrificed	using	CO2	 gas.	 Efforts	were	 taken	 to	
ensure	that	the	animal	experiences	the	least	stress	during	the	entire	procedure.	Hence,	
the	 food,	 water	 and	 cage	 conditions	 of	 the	mouse	were	maintained	 as	mentioned	 in	
Section	2.1.1.		
	 The	cage	containing	 the	mouse	was	placed	 into	a	gas	chamber	and	the	 lid	was	
closed	properly.	CO2	gas	was	released	gently	 into	the	gas	chambers.	When	the	mouse	
stopped	breathing,	the	CO2	gas	input	was	maintained	for	about	1	minute,	to	ensure	that	
the	mouse	had	died.	Immediately,	the	body	was	taken	for	organ	preparation.		
2.1.6.1 Mouse liver preparation   
	 The	body	weight	of	the	mouse	was	measured	before	proceeding	with	the	organ	
preparation.	 The	 corpse	 was	 sterilized	 with	 70	 %	 Ethanol,	 following	 which	 it	 was	
carefully	dissected	and	the	liver	removed.	The	removed	liver	was	rinsed	in	PBS	and	then	
the	liver	weight	was	measured.	In	case	of	tumor-bearing	mice,	the	tumors	were	sliced	
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out	 of	 the	 liver	 and	 stored.	 The	 hyper	 proliferative	 nodule	 part	 of	 the	 liver	 was	 also	
stored.	The	liver	weight	to	body	weight	ratios	of	the	mice	was	then	calculated.		
2.1.6.2 Sample storage  
	 The	 samples	 collected	 from	 the	 harvested	 liver	 were	 stored	 appropriately	 for	
subsequent	 downstream	 analyses.	 For	 RNA	 extraction,	 the	 samples	 were	 stored	 in	
RNAlater	 and	 snapfrozen	 in	 liquid	 nitrogen.	 Samples	 required	 for	 protein	 extraction	
and	 for	 metabolomics	 analysis	 were	 placed	 in	 microcentrifuge	 tubes	 and	 snapfrozen	
immediately	in	liquid	nitrogen.	All	the	samples	were	later	transferred	to	a	-80	°C	freezer	
for	storage.		
2.2 DNA analysis   
2.2.1 DNA extraction   
	 DNA	 extraction	 from	murine	 liver	 tissue	 was	 carried	 out	 in	 conjunction	 with	
RNA	extraction.	The	Qiagen	Blood	and	Tissue	kit	was	used	 for	DNA	extraction.	From	
the	tissue	samples	being	processed	for	RNA	extraction,	the	flow-through	from	the	first	
centrifugation	 step	 of	 RNA	 extraction	 was	 used	 for	 DNA	 extraction.	 The	 detailed	
procedure	is	described	in	the	Detailed	Procedure	section	2.8.2.	
2.2.2 Mutation detection 
	 The	extracted	DNA	was	used	for	detection	of	mutations	in	the	Ctnnb1	and	Trp53	
gene.	To	 this	end,	 the	genomic	hotspot	 regions	of	mutations	 in	 the	Ctnnb1	 and	Trp53	
genes	were	amplified	first.	
Primer sequences  
	 The	 primer	 sequences	 used	 for	 the	 amplification	 of	 the	 corresponding	
amplicons	 are	 as	 follows.	 The	 primer	 sequences	 were	 obtained	 from	 Dr.	 Albert	
Braeuning.		
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Materials used   
Buffer/Instrument	 Company/	Composition	5X	Phusion	Buffer	 Thermo Scientific™	Primers	 Sigma-Aldrich	dNTPs	 Promega	GmbH	(dATP,dCTP,DGTP,dTTP)	Phusion	DNA	polymerase	 Thermo Scientific™	Thermocycler	 Biometra	
PCR reaction mix 
The	reaction	mix	for	each	PCR	reaction	consisted	of	following:		
Buffer	 Amount/	
Concentration	
Volume	
(μL)	Polymerase	Buffer	 5x 10	Forward	Primer	 0.2	μM	 2.5	Reverse	Primer	 0.2	μM	 2.5	dNTP	mix	 40mM	 1	Taq	Polymerase	 2.5 units 0.5	Water	 31	Template	DNA	 2.5	Total	Volume	 50	
The	 cocktail	 was	 mixed	 gently	 and	 then	 placed	 in	 the	 thermo	 cycler	 and	 the	
corresponding	PCR	program	was	run.	
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 Ctnnb1 and Trp53 DNA hotspot region amplification program 
Step		 Temperature	 Time	 Repeat	Lid	pre-heating	 100	°C	 	 	Initial	denaturation	 98	°C	 30	secs	 	Denaturation	 98	°C	 10	secs	
30	times	Annealing	 60	°C	for	Trp53	 20	secs	60	°C	for	Ctnnb1	Extension	 72	°C	 30	secs	Final	extension	 72	°C	 5	mins	 	Storage	 4	°C	 Hold	 	
2.2.2.1 Agarose gel electrophoresis   
	 A	part	(10	μL)	of	the	amplification	reaction	from	each	sample	was	mixed	with	6x	
(2	 μL)	 of	 loading	 dye	 and	 was	 loaded	 into	 2	 %	 agarose	 gels.	 The	 agarose	 gel	
electrophoresis	was	performed	as	described	in	detail	in	the	Detailed	Procedure	section	
2.8.8.	
2.2.2.2 PCR product purification  
	 The	PCR	amplicons	were	then	purified	using	the	GeneJET	PCR	purification	kit	by	
following	 the	 instructions	 provided	 in	 the	 kit	 handbook.	 The	 detailed	 procedure	 is	
described	in	Detailed	Procedure	section	2.8.7.	
2.2.2.3 Sanger sequencing 
	 The	purified	amplicons	were	then	sent	to	LGC	Genomics	GmbH	for	sequencing.	
150	ng	of	 the	purified	PCR	amplicons	was	 sent	 along	with	 5	pmols	 of	 the	 sequencing	
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primer	 (4	 μL).	 The	 results	 obtained	 were	 analyzed	 using	 Chromas	 Lite	 software	 to	
identify	mutations	in	the	loci.	
2.3 RNA analysis 
2.3.1 RNA extraction 
	 Tissue	 samples	 stored	 earlier	 in	 RNAlater	 were	 subjected	 to	 RNA	 extraction,	
which	was	 performed	using	 the	Qiagen	 “RNEasy	Mini”	 kit,	 as	 per	 the	manufacturer’s	
instructions.	 	 The	 detailed	 procedure	 is	 described	 in	 the	 Detailed	 Procedure	 section	
2.8.1.	Briefly,	the	tissue	samples	were	lysed	and	RNA	was	extracted	from	the	lysate	using	
the	spin	columns	provided	by	the	kit.	The	RNA	bound	to	the	columns	was	washed	and	
eluted	in	Elution	Buffer	(EB)	provided	by	the	kit.	The	concentration	of	the	eluted	RNA	
was	measured	using	the	Nanodrop	spectrophotometer	instrument.		
2.3.2 Reverse transcription 
Circular DNA synthesis 
	 1	μg	of	RNA	was	used	for	cDNA	synthesis	for	further	downstream	processes.		The	
Promega	 Reverse	 Transcription	 kit	 was	 used	 for	 cDNA	 synthesis.	 The	 procedure	 is	
described	in	the	Detailed	Procedure	section	2.8.6.	Briefly,	the	RNA	was	incubated	with	
the	 cDNA	 synthesis	 cocktail,	 consisting	 of	 random	 hexamers,	 reverse	 transcriptase	
enzyme,	 RNAse	 inhibitor,	 enzyme	 buffer,	 and	 dNTPs	 at	 optimum	 temperature	 for	 a	
specified	amount	of	time	according	to	the	protocol.		
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2.3.3 Quantitative PCR for RNA expression analysis 
        Materials used   
Buffer/Instrument	 Company/	Composition	SYBr	Green	Mastermix	 Roche	Primers	 Sigma-Aldrich	Real	Time	PCR	system	 Applied	Biosystems	
2.3.3.1 Primer design  
Expression	 analysis	 of	 candidate	 genes	 was	 performed	 using	 quantitative	 real	
time	PCR	(qPCR).	To	this	end,	primers	targeting	the	transcripts	of	each	of	the	candidate	
genes	 were	 designed	 using	 the	 PrimerBlast	 online	 tool.	 The	 default	 parameters	 of	
primer	designing,	suggested	by	the	tool	were	unchanged.	 	Primers	were	also	designed	
for	house	keeping	genes	for	normalization	of	the	qPCR	reactions	later	on.		
2.3.3.2 qPCR reaction mix 
	 The	 quantitative	 RT-PCR	was	 performed	 based	 on	 SYBR	 green	 chemistry.	 The	
reaction	mixture	consisted	of	2.5	pmols	each	of	the	forward	and	reverse	primer,	50ng	of	
cDNA	 template	 and	2x	SyBr	Green	mastermix	 (Roche).	The	qPCR	cocktail	was	mixed	
and	added	 into	96-well	plates	and	subjected	to	the	 following	program	in	an	ABI	7500	
Fast	RealTime	PCR	system.		
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qPCR program 
Step		 Temperature	 Time	 Repeat	
Lid	pre-heating	 100	°C	 	 	
Sample	pre-heating	 50	°C	 2	mins	 	
Initial	denaturation	 95	°C	 10	mins	 	
Denaturation	 95	°C	 30	secs	 40	times	Annealing	 60	°C	 15	secs	
 Data analysis 
	 The	 ABI	 7500	 Fast	 RealTime	 PCR	 system	 instrument	 measured	 fluorescence	
emitted	after	each	cycle	of	the	qPCR	program.	Based	on	the	amplification	curves	of	each	
of	 the	 sample,	 the	 cycle	 at	which	 the	 fluorescence	 emitted	by	 each	 sample	 exceeds	 a	
particular	threshold	is	computed.	This	cycle	number	was	known	as	the	Threshold	Cycle	
(Ct)	for	each	sample.	This	number	was	used	for	further	calculations	as	described	below.	
This	Ct	value	was	obtained	for	each	gene	across	all	the	different	samples.		
	 The	Ct	values	 corresponding	 to	 the	house	keeping	genes	was	 substracted	 from	
the	Ct	values	corresponding	to	the	candidate	genes,	for	each	sample.	The	ensuing	value	
was	 known	 as	 the	 ΔCt.	 The	 relative	 mRNA	 expression	 values	 for	 each	 sample	 were	calculated	using	the	following	formula.	
Relative	mRNA	level	=	2	–(ΔCt)	
	 The	Relative	mRNA	level	of	 the	tumor	and	nodular	samples	 for	each	candidate	
gene	 were	 normalized	 over	 the	 corresponding	 relative	 mRNA	 level	 of	 the	 control	
sample	for	the	same	gene.	The	ratio	obtained	herewith	was	the	fold-change	regulation	
of	 the	 candidate	 gene	 in	 the	 tumor	 and	 nodular	 samples	 compared	 to	 the	 control	
sample.		
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2.3.4 Mutation detection  
	 The	cDNA	was	also	used	for	detection	of	mutations	in	the	Ctnnb1	and	Trp53	gene	
loci,	by	amplifying	the	transcriptome	hotspot	region	of	mutations	and	sequencing	the	
amplicons.		
Materials used   
Buffer/Instrument/	Kit	 Company/	Composition	5X	Phusion	Buffer	 Thermo Scientific™	Primers	 Sigma-Aldrich	dNTPs	 Promega	GmbH	(dATP,dCTP,DGTP,	and	dTTP	10mM	each)	Phusion	DNA	Polymerase	 Thermo Scientific™	Thermocycler	 Biometra	GeneJet	purification	kit	 Thermo Scientific™	
 2.3.4.1 Primer design  
	 The	 primers	 for	 amplifying	 the	 hotspot	 of	mutations	 in	 the	Ctnnb1	 and	 Trp53	
gene	locus	had	been	designed	by	Stefan	Ohrnberger	using	the	PrimerExpress	software	
from	Applied	Biosystems.	The	parameters	considered	were	melting	temperature	(57°C	
to	63°C),	primer	 length	(18-22	bases	 long)	and	GC	content	 (45	%	–	55	%).	The	primer	
sequences	used	for	this	experiment	are	shown	in	section	2.10		
2.3.4.2 PCR reaction  
The	reaction	mix	for	each	PCR	reaction	consisted	of	following	table.	
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Buffer	 Concentration	 Volume	(μL)	Polymerase	Buffer	 5x 10	Forward	Primer	 0.2	μM	 2.5	Reverse	Primer	 0.2	μM	 2.5	dNTP	mix	 40mM	 1	Taq	Polymerase	 2.5 units 0.5	Water	 31	Template	DNA	 2.5	Total	Volume	 50	
The	 cocktail	 was	 mixed	 gently	 and	 then	 placed	 in	 the	 thermo	 cycler	 and	 the	
corresponding	PCR	program	was	run.		
 PCR program   
Step		 Temperature	 Time	 Repeat	Lid	pre-heating	 100	°C	 	 	Initial	denaturation	 98	°C	 30	secs	 	Denaturation	 98	°C	 10	secs	 30	times	Annealing	 67	°C	 20	secs	Extension	 72	°C	 30	secs	Final	extension		 72	°C	 5	mins	 	Storage	 4	°C	 Hold	 	
	 After	 the	PCR	program	had	completed,	 10	μL	of	 the	amplification	 reaction	was	
subjected	to	agarose	gel	electrophoresis,	to	check	for	proper	amplification	of	the	loci.		
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  2.3.4.3  Agarose gel electrophoresis   
	 A	part	(10	μL)	of	the	amplification	reaction	from	each	sample	was	mixed	with	6x	
(2	 μL)	 of	 loading	 dye	 and	 was	 loaded	 into	 2	 %	 agarose	 gels.	 The	 agarose	 gel	
electrophoresis	was	performed	as	described	in	detail	in	section	2.8.8.	
2.3.4.4 PCR Product purification  
	 The	 remaining	 PCR	 amplicons	 were	 then	 purified	 using	 the	 GeneJET	 PCR	
purification	kit	by	following	the	instructions	provided	in	the	kit	handbook.	The	detailed	
procedure	is	described	in	section	2.8.7	
2.3.4.5 Sanger sequencing  
	 The	purified	amplicons	were	then	sent	to	LGC	Genomics	GmbH	for	sequencing.	
150	ng	of	 the	purified	PCR	amplicons	was	 sent	 along	with	 5	pmols	 of	 the	 sequencing	
primer	 (4	 μL).	 The	 results	 obtained	 were	 analyzed	 using	 Chromas	 Lite	 software	 to	
identify	mutations	in	the	loci.		
2.3.5 Microarray analysis 
	 The	microarray	 analysis	 of	SRF-VP16iHep	mouse	 tumor	 and	nodule	 samples	was	
performed	in	collaboration	with	Dr.	Michael	Bonin,	Human	Genetics,	UKT,	University	
of	 Tuebingen.	 The	 chip	 used	 for	 the	 microarray	 gene	 expression	 profiling	 was	 the	
Mouse	Exon	 1.0	ST	kit	 from	Affymetrix.	The	coverage	of	 the	Mouse	Exon	 1.0	ST	kit	 is	
26,166	transcripts	of	the	mouse	genome	(mm9	mouse	genome	build).		
The	 procedure	 was	 as	 follows.	 The	 RNA	 of	 each	 sample	 was	 hybridized	 with	
predesigned	probes	specific	for	each	of	the	26,166	mouse	transcripts.	The	hybridization	
causes	fluorescence	to	be	emitted.	The	emitted	fluorescence	is	directly	proportional	to	
the	amount	of	transcript	bound	to	each	of	the	probes.	The	fluorescence	signal	for	each	
probe	 for	 every	 sample	 was	 measured.	 The	 intensity	 of	 signal	 is	 proportional	 to	 the	
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amount	 of	 the	 corresponding	 transcript	 present	 in	 the	 sample	 (Schinke-Braun	 and	
Couget,	2007).	The	samples	taken	for	the	study	are	shown	in	Table	2-1.	
Table 2-1: List of samples taken for microarray analysis. The litter id, sample id, 
gender, the LWBW ratio and the sample type are shown in the table. LWBW stands 
for Liver Weight to Body Weight Ratio at time of sample collection. HCCA denotes 
Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors and Nodules stand 
for pre-malignant, hyper-proliferative nodular liver tissue. Control refers to the 
samples taken from normal livers of littermate control mice,  
Litter	
Id	
Sample	
Id	
Age	
(weeks)	 Gender	
LWBWR	
(%)	
Sample	
type	15	 15-2C	 18	 M	 4.8	 Control	24	 24-2C	 30	 F	 4.4	 Control	16	 16-1C	 25	 M	 5	 Control	15	 15-1N	 18	 M	 12.4	 Nodule	17	 17-1N	 17	 F	 11.7	 Nodule	43	 43-2T	 17	 M	 10.4	 Nodule	2	 2-2T	 32	 M	 24.3	 HCC	A	25	 25-1T1	 25	 M	 41.2	 HCC	A	24	 24-1T2	 30	 F	 25.3	 HCC	B	4	 4-1T1	 32	 F	 26.3	 HCC	B	26	 26-3T1	 31	 F	 26.8	 HCC	B	25	 25-4T2	 32	 F	 30.1	 HCC	B	
2.4 Protein analysis 
2.4.1 Protein extraction  
	 The	protein	extraction	was	performed	as	described	in	Section	2.8.3.	The	murine	
liver	 tissue	preparation	was	used.	The	 flow-through	 from	 the	RNA	extraction	 column	
was	 subjected	 to	 protein	 precipitation	 using	Acetone.	 The	 precipitated	 proteins	were	
dissolved	 in	 urea	 buffer.	 The	 concentration	 of	 the	 proteins	 was	 measured	 using	
Bradford’s	reagent.	
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2.5 Combined omics analysis 
	 Tumor	 samples	harvested	 from	 the	SRF-VP16iHep	mouse	 liver	were	 subjected	 to	
the	following	high-throughput	omics	analyses.	
" Whole	Exome	Sequencing	
" Transcriptomics	analysis	-	RNAseq	
" Proteomics	analysis	using	–	LC-MS/MS	
" Phosphoproteomics	analysis	–	LC-MS/MS	
" Metabolomics	analysis	–	LC-MS/MS	
The	 results	 were	 then	 compared	 with	 the	 human	HCCs,	 in	 order	 to	 derive	 at	
meaningful	 conclusions	 about	 hepatocarcinogenesis	 using	 the	 SRF-VP16iHEP	 mouse	
model.	The	strategy	undertaken	is	summarized	in	Figure	2-5.		
SRF$VP16)expressing)liver))
Pre$malignant)Nodules) Hepatocellular))Carcinoma)
Normal)liver))
Genome) Transcriptome) Proteome)
Whole)Exome)
Sequencing) RNAseq)
Aﬀymetrix)
Array)
Proteomics)
Phospho)
Proteomics)
Comparison)with)
Human)HCC!
Metabolome)
Metabolomics)
Lipidomics)
	
Figure 2-5:Combined-omics analysis strategy showing the usage of the different 
sample groups for combined omics approach. Affymetrix array denotes the 
Microarray analysis.  
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2.5.1 Whole exome sequencing 
	 Whole	Exome	Sequencing	(WES)	was	performed	at	the	Genomics	Unit	of	DKFZ,	
Heidelberg.	44	murine	samples	coming	from	14	different	mice,	were	subjected	to	Whole	
Exome	sequencing	analysis.	The	samples	used	for	WES	analysis	are	listed	in	Table	2-2.		
Table 2-2: List of samples taken for WES analysis. The litter id, sample id, 
gender, the LWBW ratio and the sample type are shown in the table. LWBW stands 
for Liver Weight to Body Weight Ratio at time of sample collection. HCCA denotes 
Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors and Nodules stand 
for pre-malignant, hyper-proliferative nodular liver tissue. Control refers to the 
samples taken from normal livers of the littermate control mice.  
Litter	Id	 Sample	Id	 Age	(weeks)	 Gender	 LWBWR	(%)	 Sample	type	4	 4-2C	 32	 F	 4.8	 Control	25	 25-5C	 32	 F	 5.1	 Control	26	 26-4C	 31	 F	 4.2	 Control	49	 49-1C	 52	 M	 4.9	 Control	57	 57-2S	 65	 F	 NA	 Control*	60	 60-2S	 42	 F	 NA	 Control*	38	 38_1S	 68	 M	 NA	 Control*	59	 59-1S	 30	 M	 NA	 Control*	2	 2-2N	 32	 M	 24.3	 Nodule	4	 4-1N	 32	 F	 26.3	 Nodule	25	 25-4N	 32	 F	 30.1	 Nodule	26	 26-3N	 31	 F	 26.8	 Nodule	60	 60-2N	 42	 F	 29.5	 Nodule	38	 38_1N	 68	 M	 18.1	 Nodule	57	 57-2T3	 65	 F	 42.2	 HCC		57	 57-2T7	 65	 F	 42.2	 HCC		57	 57-2T9	 65	 F	 42.2	 HCC		60	 60-2T1	 42	 F	 29.5	 HCC		60	 60-2T2	 42	 F	 29.5	 HCC		60	 60-2T3	 42	 F	 29.5	 HCC		60	 60-2T4	 42	 F	 29.5	 HCC		60	 60-2T5	 42	 F	 29.5	 HCC		38	 38_1T	 68	 M	 18.1	 HCC		32	 32_1T1	 30	 F	 33.6	 HCC		47	 47_2T1	 56	 F	 36.9	 HCC		47	 47_2T2	 56	 F	 36.9	 HCC		47	 47_2T3	 56	 F	 36.9	 HCC		
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Litter	Id	 Sample	Id	 Age	(weeks)	 Gender	 LWBWR	(%)	 Sample	type	54	 54-2T2	 41	 F	 22.2	 HCC		54	 54-1T4	 62	 F	 26.7	 HCC		54	 54-1T6	 62	 F	 26.7	 HCC		54	 54-1T7	 62	 F	 26.7	 HCC		58	 58-1T1	 71	 F	 8.7	 HCC		58	 58-1T5	 71	 F	 8.7	 HCC		2	 2-2T	 32	 M	 24.3	 HCCA	4	 4-1T2	 32	 F	 26.3	 HCCA	49	 49-2T3	 52	 M	 16.4	 HCCA	59	 59-1T4	 30	 M	 23.4	 HCCA	4	 4-1T1	 32	 F	 26.3	 HCCB	24	 24-1T2	 30	 F	 25.3	 HCCB	25	 25-4T1	 32	 F	 30.1	 HCCB	26	 26-3T1	 31	 F	 26.8	 HCCB	26	 26-3T2	 31	 F	 26.8	 HCCB	59	 59-1T2	 30	 M	 23.4	 HCCB	59	 59-1T3	 30	 M	 23.4	 HCCB	
* For these control samples, the DNA was extracted from the skin of the SRF-
VP16iHep mice, which had tumor-bearing livers.  
DNA	was	extracted,	as	described	 in	section	2.2.1	and	was	sent	 to	 the	Genomics	
Unit	 of	 DKFZ,	 where	 the	 subsequent	 library	 preparation	 and	 sequencing	 was	 done.	
Briefly,	the	DNA	was	fragmented	and	then	the	exomes	were	specifically	captured	using	
specially	 synthesized	biotynilated	beads,	which	were	 specific	 for	 each	of	 the	 exons	 of	
the	 genome.	 The	 bound	 DNA	 fragments	 were	 washed	 and	 then	 eluted.	 The	 adapter	
sequences	were	fused	to	the	ends	of	the	DNA	fragments	and	then	they	were	sequenced	
(Teer	 and	 Mullikin,	 2010).	 The	 bioinformatics	 analysis	 of	 the	 sequenced	 reads	 was	
carried	out	by	Dr.	Johannes	Werner	from	the	group	of	Dr.	Mathias	Schlesner	at	DKFZ,	
Heidelberg.	
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2.5.2 Transcriptomics and proteomics 
	 Transcriptomics	 and	 proteomics	 analysis	 were	 performed	 according	 to	 the	
following	 strategy.	The	protein	 and	RNA	extraction	were	done	 concurrently	 and	 they	
were	 subjected	 to	 these	 different	 omics	 analyses	 in	 collaboration	 with	 the	 following	
institutes/	research	groups.		
" Genome	Center,	Max	Planck	Institute	(MPI),	Tuebingen	
" Dr.	Katarina	Matic,	group	of	Prof.	Dr.	B.	Macek,	PCT,	Tuebingen	
" Quantitative	Biology	Center	(QBiC),	Tuebingen	
	
SRF$VP16)expressing)mice)liver))
Pre$malignant)Nodules) Hepatocellular)Carcinoma)
HCC)A) HCC)B)
Normal)liver))
Transcriptomics) Proteomics)
#4# #4# #4# #4#
Phosphoproteomics) 	
Figure 2-6: Transcriptomic and proteomic Strategy. The numbers mentioned in 
red denote the numbers of separate murine samples that were taken from each 
category for the downstream analyses. 
	 A	total	of	16	samples,	derived	from	10	different	mice,	were	taken	and	processed	
for	RNAseq	and	mass	spectrometric	analysis.	The	samples	used	are	described	in	Table	
2-3.		
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Table 2-3: List of samples taken for transcriptomic and proteomic analysis. The 
litter id, sample id, gender, the LWBW ratio and the sample type are shown in the 
table. LWBW stands for Liver Weight to Body Weight Ratio at time of sample 
collection. HCCA denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant 
tumors and Nodules stand for pre-malignant, hyper-proliferative nodular liver 
tissue. Control refers to the samples taken from normal livers of the littermate 
mice.  
Litter	
Id	
Sample	
Id	
Age	
(weeks)	 Gender	
LWBWR	
(%)	
Sample	
type	4	 4-2C	 32	 F	 4.8	 Control	25	 25-5C	 32	 F	 5.1	 Control	26	 26-4C	 31	 F	 4.2	 Control	49	 49-1C	 52	 M	 4.9	 Control	2	 2-2N	 32	 M	 24.3	 Nodule	4	 4-1N	 32	 F	 26.3	 Nodule	25	 25-4N	 32	 F	 30.1	 Nodule	59	 59-1N*	 30	 M	 23.4	 Nodule	2	 2-2T	 32	 M	 24.3	 HCCA	4	 4-1T2	 32	 F	 26.3	 HCCA	49	 49-2T3	 52	 M	 16.4	 HCCA	59	 59-1T1*	 30	 M	 23.4	 HCCA	25	 25-4T1	 32	 F	 30.1	 HCCB	26	 26-3T2	 31	 F	 26.8	 HCCB	59	 59-1T2	 30	 M	 23.4	 HCCB	59	 59-1T3	 30	 M	 23.4	 HCCB	
• The two samples were excluded from proteomics and phosphoproteomics 
downstream analysis due to low quality.  
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2.5.3 RNAseq analysis 
	 RNAseq	 analysis	 was	 performed	 in	 collaboration	 with	 Genome	 Center,	 Max	
Planck	Institute,	Tuebingen	and	QBiC.	RNAseq	profiling	was	carried	out	on	16	different	
mouse	samples.		The	major	steps	involved	in	the	RNAseq	analysis	are	as	follows:		
" Library	preparation	
" Sequencing	
" Bioinformatic	processing	
• Data	storage	
• Data	analysis	
• Data	mining	
2.5.3.1 Library preparation 
The	 Truseq	 library	 preparation	 kit	 from	 Illumina	 Inc.	 was	 used	 for	 the	
preparation	 of	 sample	 libraries.	 The	 detailed	 procedure	 is	 described	 in	 section	 2.8.4.	
Briefly,	 the	 RNA	molecules	 were	 purified	 and	 fragmented.	 The	 RNA	 fragments	 were	
subjected	to	PCR	amplification	and	cDNA	synthesis.	The	adapter	sequences	were	then	
ligated	 to	 the	 ends	 of	 the	 fragments.	 The	 adapter-ligated	 fragments	 from	 different	
samples	were	pooled	together	before	loading	into	the	Illumina	Inc.	sequencer.		
2.5.3.2 Sequencing 
Sequencing	of	the	sample	libraries	was	performed	on	an	Illumina	Inc.	Hiseq	2000	
instrument	by	technicians	at	the	Genome	Center,	Max	Planck	Institute,	Tuebingen.		
2.5.3.3 Bioinformatics 
The	 raw	 data	 files	 containing	 the	 sequenced	 reads	 were	 transferred	 to	 the	
Quantitative	Biology	Centre	(QBiC),	Tuebingen.	Subsequent	bioinformatics	processing	
of	the	data	was	performed	by	QBiC.	The	data	was	also	stored	at	the	QBiC	facility.		
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2.5.4 LC-MS/MS analysis 
	 The	 protein	 samples	were	 analyzed	 for	 variations	 in	 their	 expression	 levels	 by	
Mass	 spectrometry	 in	 collaboration	 with	 Dr.	 Katarina	 Matic	 from	 Prof.	 Dr.	 Boris	
Macek’s	group	at	the	Proteome	Center	Tuebingen.		
Mass	spectrometric	measurement	of	the	protein	peptides	and	phospho-	enriched	
peptides	involved	the	following	steps.		
" Sample	preparation	
" Measurement	of	spectra	
" Bioinformatic	processing	
2.5.4.1 Sample preparation 
The	sample	preparation	was	performed	as	described	in	section	2.8.5.		Briefly,	the	
protein	samples	were	digested	into	peptides.	The	peptides	were	purified	using	StageTips	
(for	 proteomics)	 or	 Sep-Pak	 1cc	 C18	 Cartridges	 (for	 Phosphoproteomics).	 	 In	 case	 of	
phosphoproteomics,	the	samples	were	enriched	for	phosphopeptides	using	TiO2	beads	
and	then	purified	on	StageTips.		
2.5.4.2 LC-MS analysis 
The	 LC-MS	 Analysis	 was	 performed	 by	 Dr.	 Katarina	 Matic	 at	 the	 Proteome	
Center	 Tuebingen.	 The	 peptide	 digests	 were	 measured	 on	 EASY-nLC	 II	 nano-LCs	
(Proxeon	Biosystems)	coupled	to	an	LTQ	Orbitrap	XL	instrument	in	case	of	proteomics.	
For	 phosphoproteomic	 measurement,	 EASY-nLC	 II	 nano-LCs	 coupled	 to	 an	 LTQ	
Orbitrap	Elite	(Thermo	Fisher	Scientific)	was	used.		
2.5.4.3 Bioinformatic processing 
	 The	Bioinformatic	processing	of	the	measurements	was	done	by	Dr.	Matic	(PCT,	
University	Tuebingen)	using	the	MaxQuant	software.		
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2.6 Metabolomics analysis 
	 Metabolomics	 analysis	 was	 performed	 on	 mouse	 tumor	 liver	 tissue	 in	
collaboration	with	the	company	MetaSysX.	To	this	end,	50	mg	of	liver	tissue	was	snap	
frozen	 in	 liquid	 nitrogen	 and	 was	 stored	 in	 –	 80	 °C	 and	 later	 sent	 in	 dry	 ice	 to	 the	
MetaSysX	GmbH	laboratories	for	subsequent	processing.		
2.6.1 Samples 
	 The	following	samples	were	used	for	metabolomics	analysis.		
Table 2-4: List of samples taken for Metabolomics analysis. The litter Id, sample 
Id, gender, the LWBW ratio and the sample type are shown in the table. LWBW 
stands for Liver Weight to Body Weight Ratio at time of sample collection. HCC 
denotes the tumor samples collected from SRF-VP16iHep mice livers, while 
Nodules stand for pre-malignant, hyper-proliferative nodular liver tissue. Control 
refers to the samples taken from normal livers of the littermate mice. 
Litter	Id	 Sample	Id	 Age	(weeks)	 Gender	 LWBWR	(%)	 Sample	type	
61	 61-2C	 25	 M	 5.73	 Control	
62	 62-3C	 31	 F	 3.74	 Control	
63	 63-2C	 24	 M	 5	 Control	
64	 64-2C	 19	 M	 4.6	 Control	
61	 61-1N	 25	 M	 26.7	 Nodule	
62	 62-1N	 31	 F	 24.54	 Nodule	
62	 62-2N	 27	 F	 29.85	 Nodule	
63	 63-1N	 24	 M	 22.14	 Nodule	
64	 64-1N	 28	 M	 28.1	 Nodule	
61	 61-1T1	 25	 M	 26.7	 HCC	
61	 61-1T2	 25	 M	 26.7	 HCC	
61	 61-1T3	 25	 M	 26.7	 HCC	
62	 62-1T1	 31	 F	 24.54	 HCC	
62	 62-2T1	 27	 F	 29.85	 HCC	
62	 62-2T2	 27	 F	 29.85	 HCC	
62	 62-2T3	 27	 F	 29.85	 HCC	
62	 62-2T4	 27	 F	 29.85	 HCC	
62	 62-2T6	 27	 F	 29.85	 HCC	
62	 62-2T7	 27	 F	 29.85	 HCC	
62	 62-2T8	 27	 F	 29.85	 HCC	
64	 64-1T1	 28	 M	 28.1	 HCC	
64	 64-1T2	 28	 M	 28.1	 HCC	
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2.7 Comparison to human HCCs 
The	 high-throughput	 omics	 data,	 especially	 those	 of	 the	 transcriptome,	 were	
compared	 to	 existing	 human	 HCC	 datasets.	 The	 human	 HCC	 datasets	 used	 for	 the	
comparison	are	as	follows.	
2.7.1 Heidelberg cohort 
2.7.1.1 Patient data 
	 The	Heidelberg	Cohort	consisted	of	40	human	HCC	patients.	The	characteristic	
features	of	the	patients	are	described	in	Table	2-5.	Dr.	Thomas	Longerich	kindly	shared	
the	 Microarray	 analysis	 data	 and	 selected	 methylation	 analysis	 data	 of	 these	 tumor	
samples	
2.7.1.2 Boyault classification 
Based	on	 the	 gene	 expression	 values,	 the	 tumor	 samples	were	 classified	 into	 6	
different	groups	as	 recommended	by	Boyault	et.al,	2007	(Boyault	et	al.,	2007).	To	this	
end,	 the	 expression	 values	 of	 the	 classifier	 genes	 were	 taken	 and	 the	 values	 were	
subjected	to	the	given	formula	according	to	Boyault	et.al,	2007.	The	values	generated	by	
the	 formula	were	 then	used	 to	assign	 the	 tumors	 to	 the	 respective	 sample	group	 that	
resembled	the	sample	the	closest.	The	Boyault	classification	was	performed	in	order	to	
be	 able	 to	 better	 compare	 the	 gene	 expression	 profiling	 and	 other	 molecular	
characteristics	of	these	tumors	with	those	of	the	SRF-VP16iHep	mice.	
2.7.1.3 Unsupervised hierarchical clustering 
	 Unsupervised	 hierarchical	 clustering	 of	 the	 samples	 was	 performed	 using	 two	
different	ways.	One	was	by	using	the	software	Cluster	3.0	originally	written	by	Michael	
Eisen.	 the	version	usable	 for	Mac	was	written	by	Michiel	de	Hoon	(Eisen	et	al.,	 1998).	
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The	obtained	cluster	 files	were	visualized	using	 the	Treeview	software,	also	hosted	by	
the	same	group.		
	 The	second	method	was	by	running	a	DOS	based	script	written	mainly	for	this	
purpose	 by	 Dr.	 Michael	 Römer,	 from	 the	 group	 of	 Prof.	 Dr.	 Zell,	 University	 of	
Tuebingen.	The	 added	 advantage	of	 this	method	was	 that	 for	 each	 cluster	 generated,	
there	was	 also	 a	 Silhouette	 score	 generated,	 which	 is	 a	measure	 of	 distance	 between	
each	of	the	clusters.		
 Table 2-5: Patient information of the Heidelberg cohort consisting of 40 
human HCC patients. The etiology, age, gender of the patients and the maximum 
tumor size, tumor grade and cirrhosis status of the liver are mentioned. The 
mutation status of the patients in the context of their CTNNB1 gene locus is also 
given. HBV and HCV etiology stands for Hepatitis B Virus and Hepatitis C virus 
infection respectively. The tumor grade is mentioned in numbers, where 1 stands 
for well-differentiated HCC, 2 for moderately differentiated HCC and 3 for poorly 
differentiated HCC. There was one patient with grade 4, which denotes aggressive 
and invasive HCC at very advanced stage. The presence of cirrhosis in the liver is 
denoted by 1 and the absence by 0. In the last column, the wild type CTNNB1 
locus is denoted by WT and a mutant genotype is denoted by Mutant.  
Sample	 Etiology	 age	 sex	 max.	size	(cm)	 Grading	 cirrrhosis	
CTNNB1	
mutation	
HCC001	 HBV	 78	 m	 4.5	 2	 1	 WT	
HCC003	 HCV	 74	 f	 3.5	 2	 1	 Mutant	
HCC005	 HCV	 48	 m	 2.5	 2	 1	 WT	
HCC006	 HBV	 40	 m	 7.0	 2	 0	 WT	
HCC007	 HBV	 50	 f	 4.0	 2	 1	 WT	
HCC008	 HBV	 73	 f	 6.0	 3	 1	 WT	
HCC010	 HCV	 72	 m	 3.0	 2	 0	 WT	
HCC011	 HBV	 61	 f	 12.0	 2	 0	 WT	
HCC015	 HBV	 68	 m	 5.1	 2	 0	 WT	
HCC018	 HCV	 54	 m	 2.5	 1	 1	 WT	
HCC019	 HCV	 54	 m	 2.5	 1	 1	 WT	
HCC022	 HCV	 63	 f	 4.0	 2	 1	 WT	
HCC023	 alcohol	 70	 m	 7.0	 3	 1	 Mutant	
HCC025	 cryptogenic	 47	 m	 x	 2	 0	 WT	
HCC027	 cryptogenic	 38	 f	 29.0	 2	 0	 WT	
HCC028	 alcohol	 57	 m	 2.0	 1	 1	 WT	
HCC029	 alcohol	 57	 m	 3.0	 2	 1	 Mutant	
HCC035	 alcohol	 54	 m	 15.0	 2	 1	 Mutant	
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Sample	 Etiology	 age	 sex	 max.	size	(cm)	 Grading	 cirrrhosis	
CTNNB1	
mutation	
HCC037	 cryptogenic	 58	 m	 2.8	 2	 1	 WT	
HCC038	 alcohol	 57	 m	 3.5	 2	 1	 WT	
HCC039	 cryptogenic	 58	 m	 1.8	 1	 1	 WT	
HCC040	 HFE	 65	 m	 2.3	 2	 0	 Mutant	
HCC041	 alcohol	 52	 f	 12	 2	 1	 WT	
HCC042	 cryptogenic	 73	 m	 11.0	 2	 1	 WT	
HCC043	 HCV	 35	 m	 6.0	 2	 0	 WT	
HCC044	 cryptogenic	 16	 m	 11.5	 2	 0	 Mutant	
HCC045	 HCV	 51	 m	 2.8	 2	 1	 WT	
HCC046	 HBV	 53	 m	 5.0	 4	 1	 WT	
HCC048	 cryptogenic	 55	 m	 13.0	 2	 0	 WT	
HCC050	 cryptogenic	 54	 m	 8.0	 1	 0	 Mutant	
HCC051	 cryptogenic	 78	 m	 4.0	 2	 0	 WT	
HCC053	 HCV	 38	 f	 6.5	 2	 0	 WT	
HCC056	 	 	 m	 16.0	 2	 0	 Mutant	
HCC057	 HBV	 38	 m	 x	 3	 0	 WT	
HCC058	 HFE	 unbekannt	 f	 x	 2	 1	 WT	
HCC061	 alcohol	 55	 m	 4.0	 2	 1	 WT	
HCC063	 cryptogenic	 69	 m	 4.5	 2	 0	 WT	
HCC071	 alcohol	 68	 m	 7.0	 2	 0	 WT	
HCC072	 cryptogenic	 55	 m	 3.5	 2	 1	 Mutant	
HCC074	 cryptogenic	 69	 f	 9.0	 3	 0	 Mutant	
	
 2.7.1.4 Mainz cohort 
	 The	dataset,	which	was	based	on	RNAsq	was	shared	by	Dr.	Jens	Marquardt	from	
the	 Johannes	Gutenberg	University	 in	Mainz.	 	 The	 sample	 details	 are	 as	 described	 in	
Figure	2-7	.	
	 Briefly,	 this	 dataset	 consisted	 of	 28	 samples	 collected	 from	 8	 different	 HCC	
patients.	 From	 each	 of	 these	 patients,	 multiple	 samples	 had	 been	 collected,	
corresponding	 to	 different	 stages	 of	 tumor	 development	 such	 as	 low-grade	 dysplastic	
nodules,	high	grade	dysplastic	nodules,	early	HCC	and	progressed	HCC.	The	advantage	
of	this	approach	is	to	be	able	to	study	the	early	driver	events	that	have	occurred	during	
the	early	malignant	transformation	process	itself	(Marquardt	et	al.,	2014).				
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Figure 2-7: Patient information of the Mainz cohort of 8 human HCC patients. 
The age, gender of the patients and the tumor size, intrahepatic metastasis status 
and vascular invasion status of the livers are mentioned. The type of lesions 
derived from each sample is also denoted. LGDN stands for low-grade dysplastic 
nodule. HGDN stands for high-grade dysplastic nodule. eHCC and pHCC stand 
for early HCC and progressed HCC respectively. The expressions of marker 
proteins of the samples analysed by immunohistochemistry are also given. Neg 
denotes negative and Pos denotes a strong positive, whereas Weak denotes a 
partial positivity of the samples for the corresponding marker proteins. a This 
symbol denotes focal positivity of the samples to the corresponding genes. Source: 
(Marquardt et al., 2014) 
 2.7.1.5 TCGA dataset  
	 The	Cancer	Genome	Atlas	is	a	large-scale	collaborative	effort,	with	a	main	focus	
on	understanding	 the	basic	molecular	 features	of	different	cancers	by	using	advanced	
large-scale	genomic	sequencing	technologies.	The	 initiative	began	as	a	pilot	project	 in	
2006	by	National	Cancer	Institute	and	the	National	Human	Genome	Research	Institute.	
The	data	was	made	freely	available	to	the	public	and	now	consists	of	data	covering	more	
than	33	different	types	of	cancers.	In	the	TCGA	database,	data	is	available	for	373	liver	
cancer	 patients,	 along	 with	 51	 control	 liver	 samples.,	 which	 was	 used	 for	 clustering	
analyses	(Ho	et	al.,	2015).	
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2.8 Detailed procedures 
2.8.1 RNA extraction 
	 RNA	was	extracted	from	the	tissues	using	the	Qiagen	RNEasy	Mini	kit	based	on	
the	 instructions	 provided	 in	 the	 handbook.	 The	 procedure	 consisted	 of	 the	 following	
steps.	
 Reagents Used 
S. No. Item Supplier 
1.  70% Ethanol Sigma-Aldrich 
2.  RLT Buffer Qiagen	
3.  RW1 Buffer Qiagen	
4.  RPE Buffer Qiagen	
5.  Elution Buffer Qiagen	
	 30	mg	of	tissue	sample	was	taken	for	the	extraction.		
1. 		600	μL	of	RLT	buffer	was	added	to	the	tissue	slices	for	lysis.	
2. The	tissue	samples	were	disrupted	using	a	douncer.		
3. Tissue	samples	were	homogenized	using	needles	and	syringes.	Each	of	the	
disrupted	tissue	in	lysis	solution	was	passed	through	a	needle	for	a	couple	of	
times.		
4. Homogenized	lysate	was	centrifuged	at	14,000	rpm	for	3	minutes.		
5. The	supernatant	was	transferred	to	a	new	tube	and	to	it	was	added	1	volume	of	
70	%	Ethanol	and	mixed	gently.	
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6. The	mixture	was	added	onto	the	RNeasy	spin	columns	provided	in	the	kit.	
7. The	columns	were	then	centrifuged	at	10,000	rpm	for	1	minute.	The	flow	through	
was	collected	and	stored	for	subsequent	DNA	and	protein	synthesis.		
8. 700	μL	of	Buffer	RW1	was	added	onto	the	columns.	The	columns	were	
centrifuged	at	10,000	rpm	for	1	minute.	The	flow-throughs	were	discarded.	
9. 500	μL	of	Buffer	RPE	was	added	onto	the	columns.	The	columns	were	
centrifuged	at	10,000	rpm	for	1	minute.	The	flow-throughs	were	discarded.	
10. The	previous	step	was	repeated	once	more,	this	time	the	columns	were	
centrifuged	for	2	minutes.	
11. The	empty	columns	were	centrifuged	once	again	at	13,000	rpm	for	3	minutes	to	
remove	any	residual	ethanol	remaining	in	the	column.	
12. The	RNA	was	eluted	by	adding	50	μL	of	Elution	Buffer	to	the	columns	placed	on	
microcentrifuge	tubes	and	centrifuging	at	10,000	rpm	for	1	minute.	
13. The	RNA	concentration	was	measured	using	Qbit	or	the	Nanodrop.	
2.8.2 DNA extraction 
	 DNA	was	extracted	from	the	tissues	using	the	Qiagen	Blood	&	Tissue	kit	based	
on	the	instructions	provided	in	the	handbook.	The	procedure	consisted	of	the	following	
steps.	
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 Reagents Used 
S. No. Item Supplier 
1.  AL Buffer Qiagen 
2.  AW1 Buffer Qiagen	
3.  AW2 Buffer Qiagen	
4.  AE Buffer Qiagen	
 
1.  200	μL	of	flow-through	from	the	first	centrifugation	step	of	RNA	extraction	was	
taken	for	the	sake	of	DNA	preparation.	
2. 200	μL	of	Buffer	AL	was	added	to	the	solution	and	mixed	thoroughly.		
3. 200	μL	of	absolute	ethanol	was	added	and	the	solution	was	mixed	thoroughly	
once	again.		
4. The	mixture	was	then	loaded	immediately	into	a	DNeasy	Mini	spin	column,	and	
was	centrifuged	at	8000	rpm	for	1	minute.		
5. The	flow-through	was	saved	for	protein	extraction	later	on.		
6. 500	μL	of	Buffer	AW1	was	added	onto	the	column	and	centrifuged	at	8000	rpm	
for	1	minute.		
7. 500	μL	of	Buffer	AW2	was	added	onto	the	column	and	centrifuged	at	14,000	rpm	
for	3	minute.	
8. The	column	was	placed	in	a	microcentifuge	tube.	
9. The	DNA	was	eluted	from	the	column	by	adding	200	μL	of	buffer	AE	and	then	
centrifuged	at	8000	rpm	for	1	minute.		
10. The	concentration	of	the	eluted	DNA	was	measured	using	the	Nanodrop	
apparatus.	
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2.8.3 Protein extraction 
	 Proteins	were	extracted	from	the	tissues	using	the	Acetone	precipitation	method.	
The	procedure	involved	the	following	steps.	
 Reagents	Used	
S. No. Item Supplier/ Composition 
1.  Urea Buffer 
6M Urea,  
2M Thiourea,  
10mM Tris, pH 8  
+ 1% NOG 
2.  Acetone Sigma-Aldrich	
 
1. The entire flow-through from the first centrifugation step of DNA extraction was 
taken for the sake of protein preparation. 
2. 2.5 volumes of Acetone was added to the solution and mixed gently.  
3. The mixture was incubated at -20 °C overnight.  
4. The next day, the solution was centrifuged at 14,000 rpm for 15 minutes. 
5. The supernatant was carefully removed and discarded. 
6. The pellet was then resuspended in Urea buffer for subsequent processing.  
7. The concentration of the proteins was measured using Bradford’s reagent.  
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2.8.4 RNAseq library preparation 
 The RNAseq sample libraries were prepared using the Truseq® RNA sample 
preparation kit based on the manufacturers instructions. The protocol consists of the 
following steps. 
I. Purification and Fragmentation of mRNA 
II. First Strand cDNA synthesis 
III. Second strand cDNA synthesis 
IV. Ends Repair 
V. Adenylation of 3’ ends 
VI. Ligation of adapters 
VII. Enrichment of DNA fragments by PCR Amplification 
VIII. Validation of prepared sample libraries 
IX. Normalization and pooling of libraries 
I. Purification and fragmentation of mRNA 
 Reagents 
S. No. Item Supplier 
3.  Bead Binding Buffer Illumina Inc. 
4.  Bead Washing Buffer Illumina Inc.	
5.  Elute, Prime, Fragment Mix Illumina Inc.	
6.  Elution Buffer Illumina Inc.	
7.  Resuspension Buffer Illumina Inc.	
8.  RNA Purification Beads Illumina Inc.	
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 The above reagents were thawed at room temperature, vortexed and centrifuged 
before proceeding with the protocol.  
1. Diluted 1 μg of RNA with water to a final volume of 50 μl.  
2.  Added 50 μl RNA Purification Beads to each well of the RNA containing plate 
in order to bind the polyA RNA to the oligo-dT beads. Gently mixed the solution 
by pipetting up and down. 
3. mRNA were denatured by incubating the samples at 65 °C for 5 minutes in a 
thermal cycler apparatus.  
4. Removed the samples from the thermal cycler when it cooled down to 4 °C.   
5. Samples were incubated at room temperature for 5 minutes to  allow the binding 
of RNA to the beads.  
6. Samples were placed on a magnetic stand at room temperature for 5 minutes to 
separate the RNA bound beads from the solution. 
7. Discarded the supernatant from each well. Samples were removed from the 
magnetic stand 
8. Washed the beads by adding 200 μl of Bead Washing Buffer to each well. 
Gently mixed the solution by pipetting up and down. This removed the unbound 
RNA from the beads. 
9. Samples were placed on a magnetic stand at room temperature for 5 minutes. 
10. Discarded the supernatant mainly consisting of ribosomal and other non-
messenger RNA. Samples were removed from the magnetic stand. 
11. Added 50 μl Elution Buffer to each well and the solution was gently mixed by 
pipetting up and down.   
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12. Samples were incubated at 80 °C for 2 minutes in a thermal cycler, in order to 
elute the mRNA and the contaminant rRNA that had been bound to the beads. 
13. Samples were removed from the thermal cycler when they reached room 
temperature. 
14. Added 50 μl of Bead Binding Buffer to each well, to enable the mRNA alone to 
rebind to the beads. Gently mixed the solution by pippeting up and down.  
15. Incubated the samples at room temperature for 5 minutes. 
16. Samples were placed on the magnetic stand at room temperature for 5 minutes.  
17. Discarded the supernatant from each well and removed the samples from the 
magnetic stand.  
18. Washed the beads with 200 μl of Bead Washing Buffer and gently mixed the 
solution by pipetting up and down. 
19. Samples were placed on the magnetic stand at room temperature for 5 minutes.  
20. Discarded the supernatant containing the residual rRNA and then removed the 
samples from the magnetic stand.  
21. Added 19.5 μl of Elute, Prime, Fragment Mix (containing random hexamers) to 
the samples and mixed the solution by pipetting up and down.  
22. Incubated the samples at 94°C for 8 minutes in a thermal cycler. 
23. The samples were removed from the thermal cycler once it had cooled down to 
4°C. 
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II. Synthesis of first strand cDNA 
 Reagents 
S. No. Item Supplier 
1.  First Strand Master Mix Illumina Inc. 
The above reagent was thawed at room temperature, vortexed and centrifuged  before 
proceeding with the protocol. To the First Strand Master Mix tube was added 50 μL of 
SuperScript II and mixed thoroughly. 
1. Samples were placed on the magnetic stand at room temperature for 5 minutes.  
2.  Transferred 17 μl of the supernatant consisting of fragmented and primed mRNA 
to new wells.     
3.  Added 8 μl of pre-mixed First Strand Master Mix to each well and mixed  
4. The samples were placed in a thermal cycler and the following program was run. 
a. Lid pre-heating – 100 °C 
b. 25°C for 10 minutes   
c. 42°C for 50 minutes   
d. 70°C for 15 minutes 
e. Hold at 4 °C 
5. Samples	removed	from	thermal	cycler	once	it	had	cooled	to	4	°C.	
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III. Synthesis of second strand cDNA 
 Reagents 
S. No. Item Supplier 
1.  Second Strand Master Mix Illumina Inc. 
2.  Resuspension Buffer Illumina Inc. 
3.  AMPure XP beads Beckman Coulter GmbH 
4.  Freshly prepared 80% Ethanol Sigma-Aldrich 
The above reagents 1 & 2 were thawed at room temperature, vortexed and centrifuged 
before proceeding with the protocol. The AMPure XP beads were mixed well before 
use. 
1. Added	25	μl	of	Second	Strand	Master	Mix	to	the	samples	and	mixed	well.	
2. Samples	were	incubated	at	16°C	for	1	hour	in	a	thermal	cycler.			
3. Samples	were	removed	from	thermal	cycler	and	let	to	stand	at	the	bench	to	bring	
them	to	room	temperature.	
4. Added 90 μl of well-mixed AMPure XP beads to the samples and mixed well  	
5. Incubated the mixture at room temperature for 15 minutes.  	
6. Samples were placed on magnetic stand at room temperature for 5 minutes. 	
7. Discarded 135 μl of the supernatant from each well.	
8. Beads	were	washed	twice	with	200	μl	of	freshly	prepared	80%	ethanol	for	30	
seconds	each.		
9. The	samples	were	left	at	room	temperature	for	the	beads	to	air	dry. 
10. Samples were removed from the magnetic stand. 
11. Added 52.5 μl of Resuspension Buffer to each well and mixed thoroughly by 
pipetting up and down.  
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12. Incubated the samples at room temperature for 2 minutes. 
13. Samples were placed on magnetic stand at room temperature for 5 minutes.  
14. Transferred 50 μL of supernatant to a new well.  
IV. Ends Repair 
 Reagents 
S. No. Item Supplier 
1.  End Repair Mix Illumina Inc. 
2.  Resuspension Buffer Illumina Inc. 
3.  AMPure XP beads Beckman Coulter GmbH 
4.  Freshly prepared 80% Ethanol Sigma-Aldrich 
The above reagents 1 & 2 were thawed at room temperature, vortexed and centrifuged 
before proceeding with the protocol. The AMPure XP beads were mixed well before 
use. 
1. Added 10 μl of Resuspension Buffer to each well. 
2. Added	40	μl	of	End	Repair	Mix	to	the	samples	and	mixed	well	by	pipetting	up	
and	down.  
3. Incubated the samples at 30 °C for 30 minutes in a pre-heated thermal cycler. 
4. Removed the samples from the thermal cycler 
5. Added 160 μl of AMPure XP beads to the samples and mixed thoroughly by 
pipetting up and down. 
6. Incubated the samples at room temperature for 15 minutes. 
7. Samples were placed on magnetic stand at room temperature for 5 minutes.  
8. Discarded the supernatant. 
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9. Beads	were	washed	twice	with	200	μl	of	freshly	prepared	80%	ethanol	for	30	
seconds	each.		
10. Samples were removed from the magnetic stand.	
11. The	samples	were	left	at	room	temperature	for	the	beads	to	air	dry. 
12. Added 17.5 μl of Resuspension Buffer to the samples.	
13. Incubated	the	samples	at	room	temperature	for	2	minutes.	
14. Samples were placed on magnetic stand at room temperature for 5 minutes. 	
15. Transferred 15 μL of supernatant to a new well. 	
16. Stored	the	samples	at	-20	°C	overnight. 
V. Adenylation of 3’ ends 
 Reagents 
S. No. Item Supplier 
1.  A-Tailing mix Illumina Inc. 
2.  Resuspension Buffer Illumina Inc. 
The above reagents were thawed at room temperature, vortexed and centrifuged before 
proceeding with the protocol. 
1. The	samples	were	thawed	at	room	temperature	and	kept	on	ice.	
2. Added 2.5 μl of Resuspension Buffer to each well. 
3. Added	12.5	μl	A-Tailing mix	to	the	samples	and	mixed	well.  
4. The samples were placed in a thermal cycler and the following program was run. 
a. Lid pre-heating – 100 °C 
b. 37°C for 30 minutes   
c. 70°C for 5 minutes   
d. Hold at 4 °C 
5. Samples	removed	from	thermal	cycler	once	it	had	cooled	to	4	°C.	
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VI. Ligation of adapters 
 Reagents 
S. No. Item Supplier 
1.  Ligation Mix Illumina Inc. 
2.  Resuspension Buffer Illumina Inc. 
3.  Stop Ligation Buffer Illumina Inc. 
4.  AMPure XP beads Beckman Coulter GmbH 
5.  Freshly prepared 80% Ethanol Sigma-Aldrich 
 The above reagents 1, 2 & 3 were thawed at room temperature, vortexed and 
centrifuged before proceeding with the protocol. The AMPure XP beads were mixed 
well before use. 
1. Added	2.5	μl	of	Resuspension	Buffer	to	each	well.	
2. Added	2.5	μl	RNA	Adapter	Index	to	the	samples	and	mixed	well	by	pipetting	up	
and	down.		
3. The	samples	were	placed	in	a	pre-heated	thermal	cycler	and	incubated	at	30°C	
for	10	minutes.	
4. Samples	were	removed	from	thermal	cycler.	
5. Added	5	μL	of	Stop	Ligation	Buffer	to	the	samples	and	mixed	to	inactivate	
ligation.	
6. Added 42 μl of AMPure XP beads to the samples and mixed thoroughly by 
pipetting up and down. 
7. Incubated the samples at room temperature for 15 minutes. 
8. Samples were placed on magnetic stand at room temperature for 5 minutes.  
9. Discarded the supernatant. 
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10. Beads	were	washed	twice	with	200	μl	of	freshly	prepared	80%	ethanol	for	30	
seconds	each.	
11. The	samples	were	left	at	room	temperature	for	the	beads	to	air	dry. 
12. Samples were removed from the magnetic stand.	
13. Added 52.5 μl of Resuspension Buffer to the samples.	
14. Incubated the samples at room temperature for 2 minutes. 
15. Samples were placed on magnetic stand at room temperature for 5 minutes. 	
16. Transferred 50 μL of supernatant to a new well. 	
17. Added 50 μl of AMPure XP beads to the samples and mixed thoroughly by 
pipetting up and down. 
18. Incubated the samples at room temperature for 15 minutes. 
19. Samples were placed on magnetic stand at room temperature for 5 minutes.  
20. Discarded the supernatant. 
21. Beads	were	washed	twice	with	200	μl	of	freshly	prepared	80%	ethanol	for	30	
seconds	each.	
22. The	samples	were	left	at	room	temperature	for	the	beads	to	air	dry. 
23. Samples were removed from the magnetic stand.	
24. Added 22.5 μl of Resuspension Buffer to the samples.	
25. Incubated the samples at room temperature for 2 minutes. 
26. Samples were placed on magnetic stand at room temperature for 5 minutes. 	
27. Transferred 20 μL of supernatant to a new well. 	
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VII. Enrichment of DNA fragments 
 Reagents 
S. No. Item Supplier 
1.  PCR Master Mix Illumina Inc. 
2.  PCR Primer Cocktail Illumina Inc. 
3.  Resuspension Buffer Illumina Inc. 
4.  AMPure XP beads Beckman Coulter GmbH 
5.  Freshly prepared 80% Ethanol Sigma-Aldrich 
The above reagents 1, 2 & 3 were thawed at room temperature, vortexed and 
centrifuged before proceeding with the protocol. The AMPure XP beads were mixed 
well before use. 
1. Added 5 μl of PCR Primer Cocktail to each well. 
2. Added	25	μl	PCR Master Mix	to	the	samples	and	mixed	well. 	
3. The samples were placed in a thermal cycler and the following program was run.	
a. Lid pre-heating – 100 °C 
b. 98 °C for 30 seconds 
c. 15 cycles of   
i. 98 °C for 10 seconds 
ii. 60 °C for 30 seconds 
iii. 72 °C for 30 seconds 
d. 72 °C for 5 minutes 
e. Hold at 10 °C 
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4. Samples	removed	from	thermal	cycler	once	it	had	reached	10	°C.	
5. Added 50 μl of AMPure XP beads to the samples and mixed thoroughly by 
pipetting up and down. 
6. Incubated the samples at room temperature for 15 minutes. 
7. Samples were placed on magnetic stand at room temperature for 5 minutes.  
8. Discarded the supernatant. 
9. Beads	were	washed	twice	with	200	μl	of	freshly	prepared	80%	ethanol	for	30	
seconds	each.		
10. The	samples	were	left	at	room	temperature	for	the	beads	to	air	dry. 
11. Samples were removed from the magnetic stand.	
12. Added 32.5 μl of Resuspension Buffer to the samples.	
13. Incubated the samples at room temperature for 2 minutes. 
14. Samples were placed on magnetic stand at room temperature for 5 minutes. 	
15. Transferred 30 μL of supernatant to a new well. 	
VIII. Validation of sample libraries 
Reagents 
S. No. Item Supplier 
1.  Bioanalyzer Agilent 
2.  Agilent DNA 1000 chip Agilent 
	
1. Loaded 1 μl of sample into Agilent DNA 1000 chip and measured using the 
Agilent 2100 bioanalyzer instrument. 
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IX. Normalization and pooling 
Reagents 
S. No. Item Supplier 
1.  Tris-HCl 10mM, pH 8.5 
with 0.1 % Tween 20 
Sigma-Aldrich 
 
1. Transferred 10 μL of sample into new wells. 
2. Normalized	the	concentration	of	samples	to	10	nM	using	Tris-HCl	10mM,	pH	8.5	
with	0.1%	Tween	20.		
3. Mixed	thoroughly	the	normalized	samples	by	pipetting	up	and	down.		
4. Pooled	16	different	samples	each	containing	unique	adapter	sequences	ligated	to	
them.		
5. The	pooled	samples	were	processed	further	and	loaded	into	the	Illumina	Inc.	
Hiseq	3000	sequencer	by	technicians.	
	
	
	
	
	
	
	
	
	
	
	
	
	
MATERIALS	AND	METHODS	
	
101 
2.8.5 MS sample preparation 
 1mg of protein was taken and processed before LC-MS/MS measurement. The 
protocol consists of the following steps. 
1) Digestion of proteins 
2) Digested peptides split for proteomics and phosphoproteomics 
a. Phosphoproteomic samples 
i. Acidification of peptides for phosphoproteomic analysis 
ii. Phosphopeptide enrichment using TiO2 beads 
iii. Proceeded to purification of enriched Phosphopeptides on 
StageTips 
b. Proteomic samples 
i. Proceeded to purification of digested peptides on StageTips 
3) Purification on StageTips 
4) LC-MS/MS measurement of purified peptides. 
1. Digestion of proteins  
 Reagents 
S. No. Item Supplier 
1.  Dithiothreitol Amresco 
2.  Iodoacetamide Merck	KGaA	
3.  Endoproteinase Lys-C WAKO	
4.  Trypsin (sequence modified) Promega	GmbH	
 The above reagents were vortexed and centrifuged before proceeding with the 
protocol.  
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1. 1 mg of protein sample taken for processing.  
2.  Protein samples reduced with 1mM Dithiothreitol for 1 hour at room 
temperature. 
3. Reduced protein sample were alkylated using 5.5 mM of Iodoacetamide for 1 
hour at room temperature.  
4. Protein samples pre-digested with endoproteinase Lys-C for 3 hours at room 
temperature.   
5. Pre-digested samples diluted with 4 volumes of sterile water.  
6. Samples digested overnight with trypsin. 
7. Digested samples were split into two, for proteomics and phosphoproteomics. 
2. Phosphoproteomic samples 
   a.  Acidification of digested peptides 
 Reagents 
S. No. Item Supplier 
2.  Sep-Pak	Vac	1cc	C18		
Cartridge	columns	
Waters 
3.  Methanol Merck KGaA 
4.  Acetonitrile (ACN) Merck KGaA 
5.  Trifluoroacetic acid (TFA) Merck KGaA 
6.  Solvent A* - 2% ACN / 1% TFA self-made by PCT 
7.  Solvent A – 0.5% ACN self-made by PCT 
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1. Sep-Pak Vac 1cc C18 cartridge columns were activated using Methanol. 
2. Cartridge columns equilibrated with Solvent A*. 
3.  Digested peptides loaded onto cartridge columns. 
4.  Washed the columns with Solvent A. 
5. Eluted the peptides with 80% ACN / 6% TFA. 
b. Enrichment of phosphopeptides 
 Reagents 
S. No. Item Supplier 
5.  TiO2 beads ZirChrom 
6.  Acetonitrile (ACN) Merck KGaA 
7.  Trifluoroacetic acid (TFA) Merck KGaA 
8.  Acetic Acid (AA) Carl Roth GmbH 
9.  NH3.H2O, pH 11.0 Merck KGaA 
10.  Solvent B - 80% ACN / 0.5% AA self-made by PCT 
	
1. Eluted	peptides	were	incubated	with	twice	volume	of	TiO2	beads	for	10	mins.	
2. The	supernatant	was	transferred	to	a	new	batch	of	TiO2	beads.			
3. The	initial	batches	of	TiO2	beads	were	washed	with	Solvent	B.	
4. The enriched phosphopeptides were eluted from the TiO2 beads with 5% 
NH3.H20, pH 11.0 and then 80% ACN / 2% TFA into 20% TFA.	
5. Pooled all the eluted phosphopeptides and proceeded to purification. 
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3. Purification on StageTips 
 Reagents 
S. No. Item Supplier 
5.  C18 StageTips 
C18 discs: 3M 
(“Empore Solid Phase 
Extraction disk”), 
StageTips: self-made 
by PCT 
6.  Methanol Merck KGaA 
7.  Acetonitrile (ACN) Merck KGaA 
8.  Trifluoroacetic acid (TFA) Merck KGaA 
9.  Solvent A* - 2% ACN / 1% TFA self-made by PCT 
10.  Solvent A – 0.5% ACN self-made by PCT 
 
1. Activated C18 StageTips with of Methanol 
2. Activated C18 StageTips with of Solvent A* 
3. Peptides were loaded onto equilibrated StageTips. 
4. StageTips were washed with Solvent A. 
5. Peptides were eluted with of 80% ACN / 6% TFA. 
6. Proceeded to LC – MS/MS measurements. 
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2.8.6 Circular DNA synthesis  
 Materials Used 
S. No. Item Supplier 
1.  Reverse Transcriptase 
enzyme 
Promega GmbH 
2.  Ribolock Promega GmbH	
3.  Random Hexamers Sigma-Aldrich	
4.  dNTPs Promega GmbH	
5.  RT Enzyme Buffer Promega GmbH	
6.  Ribolock Enzyme buffer Promega GmbH	
7.  Heating Block Eppendorf GmbH 
 
1. 	1 μg of RNA was taken for cDNA synthesis.  
2. The volume of the RNA was adjusted to 8 μL by adding sterile distilled water. 
3. 5 μL of random hexamers were added to the solution to prime the cDNA 
synthesis. 
4. The mixture was incubated at 70 °C for 10 minutes. 
5. The cDNA synthesis cocktail was added to the sample mixture.  
6. They were incubated at room temperature for 10 minutes, after being mixed..  
7. The samples were immediately transferred to a different heating block and 
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incubated at 42 °C for 45 minutes.  
8. The samples were then incubated at 99 °C for 3 minutes.  
9. The samples were then transferred to ice. The concentration of the cDNA was 
adjusted by adding 30 μL of sterile water. 
2.8.7 PCR product purification  
 The amplified PCR fragments were purified, in order for them to be sequenced.  The 
GeneJET	PCR	purification	kit	was	used	for	this	purpose.	 
 Reagents Used 
S.	No.	 Buffer/	Instrument	 Company/Composition	
1.	 Binding	Buffer	 Thermo Scientific™	
2.	 Isopropanol	 Thermo Scientific™	
3.	 Wash	Buffer	 Thermo Scientific™	
4.	 Elution	Buffer	 Thermo Scientific™	
 
1.  The PCR amplicons were mixed with equal volume of Binding Buffer.  
2. When the size of the PCR amplicons was less than 500 bp, half the volume of 
isopropanol was added to the above mixture.  
3. Transferred the mixture into purification columns.  
4. The columns were centrifuged at 13,000 rpm for 1 minute. The flow-through 
was discarded. 
5. 700	μL	of	Wash	buffer	was	added	to	the	columns.	 
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6. The columns were centrifuged at 13,000 rpm for 1 minute. The flow-through 
was discarded. 
7. The	purified	amplicons	were	eluted	by	adding	30	μL	of	Elution	buffer	to	the	
purification	columns,	which	were	placed	on	microcentrifuge	tubes.	 
8. The concentration of the eluted amplicons was measured using the Nanodrop.  
2.8.8 Agarose gel electrophoresis  
 The amplified PCR fragments or the freshly extracted DNA/RNA were subjected to 
agarose gel electrophoresis to check for quality.  
 Reagents Used 
S.	No.	 Buffer/	Instrument	 Company/Composition	
1. 	 Agarose	 Geneaxxon	bioscience	
2. 	 TAE	Buffer	 242.28	g				Tris	18.61g				EDTA	60.05	g			Acetic	acid	filled	upto	1L	with	water,pH	8.5	
	 Ethidium	Bromide	 Applichem	
 
1. The required amount of agarose was weighed in glass containers and dissolved in the 
corresponding amount of TAE Buffer by boiling. The amounts of agarose required for 
different gel percentages are given below.  
 
 
 
MATERIALS	AND	METHODS	
	
108	
   Agarose amount table 
%	Gel	 Agarose	(g)	 TAE	Buffer	(mL)	 EtBr	(μL)	
2	 2.4	 120	 2.5	
1.5	 1.5	 120	 2.5	
1	 1.2	 120	 2.5	
0.8	 1	 120	 2.5	
 
2. The agarose solution dissolved in TAE buffer was allowed to cool down at RT. 
3. 2.5 μL	of	Ethidium	Bromide	was	added	to	the	solution. 
4. The solution was then poured carefully into the preset gel casting plates 
containing the gel combs. The gel casting setup was maintained at 4 °C. 
5. The	agarose	was	allowed	to	completely	solidify.	 
6. The gel combs were carefully removed.  
7. The	agarose	gels	were	transferred	to	the	gel	running	chambers	containing	TAE	
Buffer.	 
8. The	samples	premixed	with	one-fifth	the	volume	of	loading	dye	were	loaded	into	
each	of	the	wells.	DNA	ladder	was	also	loaded	into	one	of	the	wells,	to	serve	as	
size	marker.	 
9. The	samples	were	allowed	to	separate	in	the	gel	chambers	at	an	electric	field	of	
100	V for 45 minutes to 1 hour until the samples had covered more than three 
quarters of the length of the gel.  
10. Once	the	samples	had	separated,	the	images	of	the	separation	patterns	were	
captured	using	the	Gel	documentation	apparatus. 
MATERIALS	AND	METHODS	
	
109 
2.9 Softwares / online tools used 
	
	
S.No.	 Software/Tool	 Purpose/Usage	 Platform	
1.	 cBio	Portal	 Access	TCGA	and	other	human	cancer	datasets	 Online	Portal	
2.	 TCGA	Assmebler	 Download	of	TCGA	data	 R	Package	
3.	 DAVID	 Functional	analysis	of	gene	sets	 Online	Tool	
4.	 GSEA	 Gene	set	enrichment	analysis	 Software	
5.	 KEGG	Pathways	 Pathway	analysis	using	gene	candidates	 Online	tool	
6.	 ABI	7500	software	 Reatlime	PCR	analysis	 Software	
7.	 Chromas	Lite	 Sangers	sequencing	analysis	 Software	
8.	 4	Peaks	 Sangers	sequencing	analysis	 Software	
9.	 Biomart	 Conversion	of	ids	 Online	Tool	
10.	 Cluster	3.0	 Hierarchical	clustering	 Software	
11.	 Treeview	 Clustering	analysis	-	visualization	 Software	
12.	 PROVEAN/SIFT	 Amino	Acid	prediction	of	mutations	 Online	Tool	
13.	 IGV	viewer	 Visualisation	of	Reads	 Software	
14.	 Primer	BLAST	 Primer	designing	 Online	Tool	
15.	 Promotion	 CArG	box	prediction	 Online	Tool	
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2.10 Primer sequences 
Primer	 Sequence	(5’	->	3’)	 Purpose	
Genotyping	
Rosa26	forward	 CACCAGGTTAGCCTTTAAGCCTGCCC	 SRF-VP16	
genotyping	
Rosa26	reverse	 GGAGGCAGGAAGCACTTGCTCTCC	 SRF-VP16	
genotyping	
PURO	reverse	 GAACGAGATCAGCAGCCTCTGGGTCCAC	 SRF-VP16	
genotyping	
Alfp-CreERT2	forward	 GCAAACATACGCAAGGGAT	 Alfp-CreERT2	
genotyping	
Alfp-CreERT2	reverse	 CACAGTCAGCAGGTTGGAGA	 Alfp-CreERT2	
genotyping	
PCR3	 AAGAAGGGTCCGGCCCCGAAGATGCTGGGC	 Alfp-CreERT2	
genotyping	
PCR4	 CTGGATGCCCTCTCCTTCCCCGGAGCCCTG	 Alfp-CreERT2	
genotyping	
Srf-KO-8-	forward	 CCGGGGAAATATGGGGAGAGGGGAGAT	 Srf-flex1	genotyping	
Srf-KO-8-	reverse	 CTTCGCGCACACCAGGACACAGAGGAT	 Srf-flex1	genotyping	
Lox2	forward	 GCTCGCAGCGGCGGCCAGATCTATAAC	 Srf-flex1	genotyping	
(continued	…	)	
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Mutation	Detection	
Ctnnb1	forward	 GTCGTAGATGGCTTCTTCAGG	
Ctnnb1	genomic	
amplication	Ctnnb1	reverse	 TCCTTCAACCCACTTGTGC	
Trp53	forward	 GTCACCTGTAGTGAGGTAGG	 Trp53	genomic	
amplification	Trp53	reverse	 ACTCGTGGAACAGAAACAGG	
Ctnnb1_cDNA_	
forward	
GTCAGCTCGTGTCCTGTGAA	 Ctnnb1	
transcriptome	
amplication	
Ctnnb1_cDNA_	
reverse	
CAGTGTCGTGATGGCGTAGA	
Trp53_cDNA_	
forward	
GGCCCTCATCCTCCTCCTTC	 Trp53	
transcriptome	
amplification	
Trp53_cDNA_	reverse	 ACTGGCCCTTCTTGGTCTTCA	
Quantitative	PCR	
Ctnnb1_forward	 GTGCAATTCCTGAGCTGACA	 Ctnnb1	qPCR	
amplication	Ctnnb1_reverse	 CTTAAAGATGGCCAGCAAGC	
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3 Results 
3.1 The SRF-VP16iHep mouse model 
3.1.1 Genotype 
	 The	genome	of	SRF-VP16iHep	mice	consists	of	three	transgenes	inserted	into	their	
wildtype	genome.	The	transgenes	are	as	follows.	
" SRF-VP16	transgene	(referred	also	as	SRF-VP16	allele)	
" Alfp-CreERT2	transgene	(referred	also	as	Cre	allele)	
" Srf-flex1	allele,	replacing	the	endogenous	Srf	wt	allele	
3.1.1.1 SRF-VP16 transgene 
	 The	 SRF-VP16	 transgene	 comprises	 of	 the	 human	 SRF	 cDNA	 sequence,	 who’s	
transcriptional	 transactivation	 domain	 (TAD)	 has	 been	 partly	 replaced	 with	 a	
transcriptional	activator	of	the	human	Herpes	Simplex	virus	(HSV).	This	transcriptional	
activator	protein	is	called	Viral	Protein	16	(VP16).	The	cDNA	of	the	HSV	VP16	fused	to	
the	 truncated	 human	 SRF	 cDNA	 sequence	 generates	 the	 SRF-VP16	 trangene,	 which	
encodes	the	fusion	protein	SRF-VP16	(Ohrnberger	et	al.,	2015).	The	transgene	construct	
containing	the	SRF-VP16	coding	sequence	is	shown	in	Figure		3-1.		
				
4xPolyA(
STOP 
cassette 
PGK+Puro(
LoxP((
site(
LoxP((
site(
SRF+VP16(
Rosa26 
	
Figure	3-1:	The	SRF-VP16	transgene	construct.	The	SRF-VP16	transgene	construct	 is	 inserted	
in	the	Rosa26	locus	of	the	mouse	genome.	The	construct	consists	of	a	STOP	cassette	flanked	
by	LoxP	sites,	which	prevents	the	spontaneous	expression	of	SRF-VP16	transgene.	The	black	
arrows	denote	the	translational	start	sites	and	directions	of	transcription.	The	LoxP	sites	are	
represented	in	green	triangles	(Ohrnberger*,	Thavamani*	et	al.,	2015).	
RESULTS	
	
114 
3.1.1.2 Alfp-CreERT2 transgene 
The	 Alfp-CreERT2	 transgene	 is	 responsible	 for	 the	 expression	 of	 the	 Cre	
recombinase	 enzyme	 in	SRF-VP16iHep	mice.	 Expression	 and	nuclear	 localization	of	 the	
Cre	 enzyme	 is	 essential	 for	 recombination-mediated	 deletion	 between	 the	 LoxP	 sites	
flanking	 the	 STOP	 cassette	 of	 the	 SRF-VP16	 transgene	 construct.	 This	 recombination	
causes	the	deletion	of	the	STOP	cassette,	resulting	in	activation	of	SRF-VP16	transgene	
expression.	In	the	CreERT2	construct,	the	Cre	recombinase	is	fused	to	a	mutant	Estrogen	
Receptor	 protein,	 known	 as	 ERT2	,	which	 –	 upon	 tamoxifen	 application	 –	 translocates	
from	 the	 cytoplasm	 to	 the	nucleus,	 and	 thus	 completes	 the	 regulation	mechanism	of	
tamoxifen-induced	 activation	 of	 SRF-VP16	 transcription.	 However,	 the	 observed	
leakiness	 of	 Cre	 activity	 in	 hepatocytes	 of	 SRF-VP16iHep	 mice	 enables	 it	 to	 enter	 the	
nucleus	 even	 in	 the	 absence	 of	 tamoxifen,	 upon	 rare	 circumstances.	 This	 results	 in	 a	
mosaic	 activation	 of	 SRF-VP16	 expression	 in	 a	 hepatocyte-specific	 manner	 in	 SRF-
VP16iHep	mice.	The	Alfp-CreERT2	transgene	construct	contains	the	Albumin	enhancer	and	
promoter	 sequences	 that	 promote	 and	 regulate	 expression	 of	 the	 Alfp-CreERT2	
transgene	 exclusively	 in	 hepatocytes.	 The	 construct	 containing	 the	 Alfp-CreERT2	
transgene	is	represented	in	the	Figure	3-2.		
CRE$ ERT2$
hGH 
polyA 
Alpha-fetoprotein-
enhancer 
Albumin-enhancer and 
promoter 	
Figure 3-2: The Alfp-CreERT2 transgene construct (Ohrnberger*, Thavamani* et 
al, 2015). The black arrow represents the transcription start site and the direction 
of transcription. 
	 SRF-VP16iHep	mice	contain	both	the	Alfp-CreERT2	and	SRF-VP16	transgenes.	These	
animals	go	on	to	develop	HCCs	in	the	liver	after	the	age	of	about	20-25	weeks.	There	is	a	
third	transgene	present	in	the	genome	SRF-VP16iHep	mice,	namely	Srf-flex1,	representing	
a	floxed	allele	of	the	endogenous	Srf	gene.	
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3.1.1.3 Srf-flex1 allele 
	 The	wildtype	SRF	protein	can	competitively	inhibit	the	SRF-VP16	fusion	protein,	
by	 occupying	 the	 CArG-box	 binding	 sites	 of	 SRF-VP16	 on	 target	 DNA.	 The	 genomic	
replacement	 of	 the	 wildtype	 Srf	 allele	 with	 the	 Srf-flex1	 allele	 effectively	 eliminates	
wildtype	 SRF	 protein	 activity.	 The	 Srf-flex1	 allele	 consists	 of	 two	 LoxP	 sites;	 the	 first	
LoxP	 site	 is	 present	 within	 the	 5’	 untranslated	 region	 of	 the	 Srf	 gene,	 whereas	 the	
second	 LoxP	 site	 lies	 within	 the	 intron	 1	 of	 the	 Srf	 gene.	 The	 Cre-mediated	
recombination	results	in	a	deletion	of	the	complete	coding	region	of	Srf	exon	1	(Wiebel	
et	al.,	2002).	A	homozygous	deletion	effectively	nullifies	SRF	protein	activity	in	the	cells.	
Figure	2-3	describes	the	Srf-flex1	allele.	
Exon 1  
LoxP  
site 
LoxP  
site 
Exon 2  
Exon coding region 
Exon non-coding region 	
Figure 3-3: Srf-flex1 allele. The LoxP sites are represented as green triangles. 
The yellow boxes refer to the coding regions of Srf exons and the white boxes the 
non-coding regions. The first LoxP site is present within the non-coding region of 
exon 1 and the second LoxP site is present within intron 1 of the Srf gene.  
	 The	 presence	 of	 the	SRF-VP16	 and	 the	Alfp-CreERT2	transgenes	 is	 necessary	 for	
hepatocarcinogenesis	 in	SRF-VP16iHep	mice,	whereas	 the	presence	of	 the	Srf-flex1	allele	
ensures	the	minimum	interference	to	SRF-VP16	activity	by	wildtype	SRF	protein.	SRF-
VP16iHep	mice	develop	HCCs	in	their	liver	irrespective	of	the	presence	or	absence	of	the	
Srf-flex1	allele,	however	homozygous	replacement	of	wildtype	Srf	by	Srf-flex1	accelerates	
HCC	formation.		
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3.1.1.4 SRF-VP16iHep genotype 
	 The	 genotype	 of	 SRF-VP16iHep	mice	 encompasses	 the	 heterozygous	 presence	 of	
the			SRF-VP16	and	Alfp-CreERT2	transgenes,	associated	with	replacement	of	endogenous	
Srf	alleles	by	the	Srf-flex1	allele.		
In	 the	 breeding	 scheme	 used,	 the	 Srf-flex1	 allele	 could	 either	 be	 homozygous,	
heterozygous,	 or	 even	 completely	 absent	 in	 the	 SRF-VP16iHep	genome.	 Thus,	 the	 SRF-
VP16iHep	mouse	comprises	of	the	following	three	possible	genotypes.	
SRF-VP16	(+/-)	:	Alfp-CreERT2	(+/-)	:	Srf-flex1	(-/-)	
SRF-VP16	(+/-)	:	Alfp-CreERT2	(+/-)	:	Srf-flex1	(+/-)	
SRF-VP16	(+/-)	:	Alfp-CreERT2	(+/-)	:	Srf-flex1	(+/+)	
3.1.1.5 SRF-VP16iHep mating scheme 
The	 mating	 for	 the	 SRF-VP16iHep	 mice	 was	 carried	 out	 according	 t0	 the	 scheme	
described	in	Figure	3-4.		
SRF$VP16)(+/$)) Cre)(+/$))
SRF$VP16)))))))(+/$))
Alfp$CreERT2)))(+/$))
SRF$VP16))))))))($/$))
Alfp$CreERT2))))(+/$))
SRF$VP16)))))))(+/$))
Alfp$CreERT2)))($/$))
SRF$VP16)))))))($/$))
Alfp$CreERT2)))($/$))
SRF'VP16iHep))
mouse))
Li0ermate4control4mice)
	
Figure 3-4: Mating scheme of SRF-VP16iHep mice. Mice heterozygous for the SRF-
VP16 transgene were crossed with mice heterozygous for the Alfp-CreERT2 
transgene. The probability of a mouse being born as heterozygote for both of the 
transgenes is 25%.  The genotype of interest is obtained when both the SRF-VP16 
and Alfp-CreERT2 transgenes are present as heterozygous alleles in the genome. 
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The Srf-flex1 transgene genotype in the SRF-VP16iHep mice could be homozygous, 
heterozygous or null.   
	
	 SRF-VP16iHep	mice	 containing	 the	 transgenes	 SRF-VP16	 and	 Alfp-CreERT2	 were	
separated	 into	 different	 Type	 II	 long	 cages,	 along	with	 the	 corresponding	 litter-mate	
control	mice.	To	keep	the	mouse-line	replenished,	healthy	littermate	control	mice	that	
are	heterozygous	for	either	of	the	transgenes	SRF-VP16	or	Alfp-CreERT2	were	chosen	and	
bred	with	the	mice	carrying	the	complementary	genotype.		For	each	of	the	experiments	
using	 the	SRF-VP16iHep	mouse	strain,	at	 least	one	 littermate	control	mouse	was	 taken.	
Figure	3-5	describes	the	usage	of	the	mice	for	HCC	characterization.	
SRF$VP16))(+/$))
Cre$$$$$$$$$$$$$(+/$))
Nodule)
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SRF$VP16))($/$))
Cre$$$$$$$$$$$$$($/$)) Control)
sample)
SRF$VP16))($/$))
Cre$$$$$$$$$$$$$(+/$))
SRF$VP16))(+/$))
Cre$$$$$$$$$$$$$($/$))
Normal)Liver)LiDer.mate))
Control)mouse)  
Figure 3-5: Experimental Mice genotypes and their usage for sample collection. 
Mice with the genotype of interest (red) are let to grow until liver tumors are 
developed in the SRF-VP16iHep mice, at which time they are sacrificed for organ 
harvesting. The livers, containing tumors and hyper-proliferative nodular foci are 
taken for subsequent experiments. At the same time, the littermate control mice 
were also sacrificed and their livers were collected as control tissue samples.  
 3.1.2 Phenotypic observations 
	 SRF-VP16iHep	mice	 did	 not	 show	 any	 significant	 phenotypic	 abnormalities	 until	
the	age	of	about	20	to	30	weeks,	when	the	belly	started	bulging	owing	to	the	increasing	
liver	 size.	However,	 the	 general	 health	 status	 of	 the	mice	was	not	 compromised.	The	
health	of	the	mice	was	monitored	by	observing	their	body	weight,	movement	activities	
and	posture.	The	mice	were	examined	regularly	for	any	health	impairments.	The	weight	
gain	 pattern	 of	 one	 SRF-VP16iHep	mouse,	 compared	 to	 that	 of	 a	 littermate	 control,	 is	
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shown	in	figure	3-6.	The	weight	gain	pattern	of	the	control	mice	correlates	to	that	of	the	
SRF-VP16	expressing	mice	until	about	the	age	of	20-weeks.		
	
Figure 3-6: Weight gain patterns of individual mice. The weight gain patterns of 
SRF-VP16iHep and control mice show very little differences, until a time point 
starting at about 27 weeks of age. 
	
	 After	 the	 age	 of	 27	 weeks,	 depending	 upon	 the	 individual	 animal,	 increasing	
proliferation	 in	 the	 liver	 results	 in	 a	 decrease	 in	 weight	 gain,	 accompanied	 by	 other	
obvious	symptoms.	This	can	be	checked	by	observing	behavioral	features	of	the	mouse	
in	context	of	 its	movement	and	also	 its	stature	during	movement,	possibly	suggesting	
physical	 discomfort	 or	 pain.	 When	 two	 or	 more	 of	 these	 symptoms	 begin	 to	 be	
displayed	by	an	 individual	SRF-VP16iHep	 animal,	 it	 is	 ready	 to	be	 sacrificed	 in	order	 to	
prevent	further	discomfort.		
3.1.3 Liver weight to body weight ratio  
	 At	 the	 endpoint	 of	 the	 study,	 individual	SRF-VP16iHep	mice	were	 sacrificed	 and	
their	 livers	 harvested.	 Animal	 weight	 before	 dissection	 and	 liver	 weight	 immediately	
upon	harvested	were	 scored.	One	of	 the	most	 obvious	 and	 earliest	 observations	were	
the	 increased	 sizes	 of	 the	 livers	 due	 to	 SRF-VP16	 induced	 hyper-proliferation	 of	
hepatocytes.	 In	 these	 livers,	 large	 tumors	 could	 be	 seen	 and	 also	 multiple	 foci	 that	
consisted	 of	 hyper-proliferative	 cells.	 From	 such	 hyper-proliferative	 liver	 tissues	 full-
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blown	 tumors	 could	 develop.	 The	 increased	 liver	 sizes	 also	 corresponded	 to	 the	
increased	liver	weights,	which	could	be	compared	to	the	weights	of	the	individual	mice,	
in	order	to	compute	the	liver	weight	to	body	weight	(LWBW)	ratios.	Figure	3-7	shows	a	
graph	plotting	the	LWBW	ratios	of	SRF-VP16iHep	mice,	compared	to	the	LWBW	ratios	of	
corresponding	littermate	control	mice.	
	
Figure 3-7: Comparison of Liver weight to body weight (LWBW) ratios. LWBW 
ratios of mice above the age of 25 weeks and manifested HCCs in their livers are 
plotted against the LWBW ratios of normal liver sample. The graph shows the 
difference in the liver weight to body weight ratios of SRF-VP16iHep mice (right) 
in comparison control mice (left). N =42, for each genotype. 
	
3.1.3 Hepatocellular carcinomas in liver 
	 In	SRF-VP16iHep	mice	the	multiple	hyper-proliferative	foci	ultimately	result	in	the	
formation	of	 tumors	 that	 could	be	 classified	by	 liver	pathologists	 (Profs.	 Schirmacher	
and	 Longerich,	 Pathology	 University	 Clinic	 Heidelberg)	 as	 hepatocellular	 carcinoma	
(HCC).	 The	 number	 of	 tumors	 found	 in	 a	 particular	 liver	 can	 vary	with	 each	mouse,	
ranging	from	1	to	5.	The	sizes	of	these	tumors	were	also	variable	but	increased	with	age.	
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Figure 3-8: Age-dependent progression toward HCC formation. A) The continuous 
increase of the liver to body weight ratios with advancing age can be noticed from 
the graph. The green squares denote the LWBW ratios of SRF-VP16iHep mice and 
the red triangles denote the LWBW ratios of SRF-VP16iHep mice that contained 
HCCs in their livers. The blue circles denote the LWBW ratios of the littermate 
control mice. B) The images show the simultaneous increase in numbers of hyper-
proliferative pre-malignant foci, with increasing LWBW ratios. The LWBW ratios 
in percentages are displayed above each image. In the far right image, the 
ultimate development of liver tumors can be seen. The white arrows point to the 
tumors in the liver. Picture Source: Ohrnberger*, Thavamani* et al, 2015.  
	 The	 Figure	 3-8	 shows	 the	 age-dependent	 progression	 towards	 HCC	 formation	
observable	by	 the	gradually	 increasing	LWBW	ratios	due	 to	 the	 increasing	number	of	
hyper-proliferative	foci.	However,	the	littermate	control	mice	did	not	show	any	increase	
in	 their	 LWBW	 ratios,	 thus	 emphasizing	 the	 role	 of	 SRF-VP16	 in	 triggering	 this	
malignant	transformation	in	SRF-VP16iHep	livers	leading	to	HCCs.	In	Figure	3-8a	are	also	
included	the	LWBW	ratios	of	mice	that	had	been	sacrificed	by	Dr.	Stefan	Ohrnberger	
(former	postdoc,	Nordheim	Lab,	University	of	Tuebingen).	The	frequency	of	occurrence	
B	
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of	HCCs	 in	SRF-VP16iHep	mice	after	 the	age	of	25	weeks	 is	 significantly	higher	 than	at	
any	 other	 earlier	 time-point.	 This	 can	 be	 seen,	 in	 the	 Kaplan-Meier	 plot	 of	 tumor	
occurrence	 shown	 in	 Figure	 3-9.	 The	 tumors	 and	 nodules	 were	 collected	 for	 further	
downstream	experiments.			
	
Figure 3-9: HCC Penetrance in SRF-VP16iHep mice. The Kaplan Meier graph 
shows the % probability of mice to have no HCCs in its liver at the time of 
sacrifice, at increasing ages. The HCC penetrance was found to be 100 % in the 
SRF-VP16iHep mice beyond the age of about 25 weeks. Litter mate control mice did 
not show any signs of tumor formation. Picture Source: Ohrnberger*, Thavamani* 
et al, 2015.  
	
3.2 Mutation detection 
	 To	investigate	the	potential	manifestation	of	genomic	mutations	in	HCC	tumor	
tissues,	my	 initial	 investigation	 focused	 on	 the	 analysis	 of	mutations	 in	 an	 oncogene	
(Ctnnb1)	and	a	tumor	suppressor	gene	(Trp53),	known	to	be	frequently	mutated	in	the	
genomes	of	murine	and	human	liver	cancers.	
3.2.1 Frequency of mutations 
Genomic	 hotspot	 regions	 of	 mutations	 in	 the	 Ctnnb1	 and	 Trp53	 genes	 were	
amplified	and	sequenced.	Mutations	were	detected	in	both	the	gene	loci.	The	frequency	
of	mutations	in	SRF-VP16iHep	mice	is	shown	in	the	Table	3-1.		
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Table 3-1: Mutation status of tumors from SRF-VP16iHep mice at Ctnnb1 and 
Trp53 gene loci. In the table, the number of samples found to be mutant (Mt) or 
wild type (Wt) for the corresponding loci are shown. In more than 50 samples 
tested (#), Ctnnb1 mutations were found at a frequency of about 28 %. Trp53 
mutations were occurring at a frequency of 18%. 
Gene	 Ctnnb1	 Trp53	
Status	 Mt	 Wt	 Mt	 Wt	
Samples	#	 15	 39	 9	 42	
Total	#		(%)	 54		(28%)	 51		(18%)	
	
	 Mutations	 observed	 in	 the	Ctnnb1	 locus	were	more	 frequent	 than	 those	 in	 the	
Trp53	locus.	In	the	Ctnnb1	gene	locus,	different	mutations	were	detected.	The	observed	
point	 mutations	 caused	 the	 following	 coding	 changes:	 G34R,	 T41I,	 D32Y	 and	 S37F.		
These	 mutations	 can	 be	 predicted	 to	 cause	 the	 loss	 of	 β-Catenin	 protein	
phosphorylation	by	the	GSK-3β	kinase.	 	This	can	be	predicted	to	result	 in	 the	protein	
not	undergoing	degradation	via	the	ubiquitin-proteasome	pathway(Aberle	et	al.,	1997),	
leading	to	stabilization	of	the	β-Catenin	protein	within	the	cell.	Hence	these	mutations	
can	be	expected	to	serve	as	activating	mutations	of	the	β-Catenin	protein	and	hence	the	
Wnt	signaling	pathway	(de	La	Coste	et	al.,	1998).		
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Figure 3-10: Ctnnb1 and Trp53 mutations. A) The different mutations observed in 
the Ctnnb1 locus, affecting the codons 32, 34, 37 and 41. Chromatograms of the 
sequencing results show heterozygous non-synonymous mutations in the above 4 
codons. B) Insertion/deletion mutation in codon 120 of the Trp53 gene, compared 
to the wildtype sequence. The ensuing frameshift in the mutant allele results in a 
premature STOP codon at position 128. In the wildtype sequence the STOP codon 
occurs at position 382.  
	
As	 show	 in	 Figure	 3-10,	 at	 the	 Trp53	 gene	 locus,	 an	 in-frame	 deletion	 was	
detected,	which	could	result	in	a	frame	shift	during	transcription	that	can	result	in	the	
formation	of	a	premature	stop	codon.	The	ensuing	truncated	protein	might	result	in	the	
inactivation	of	the	tumor	suppressor	P53	protein.	This	can	be	expected	to	further	assist	
in	HCC	tumor	progression.			
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3.2.2 Ctnnb1 mutation associated gene 
expression changes 
	 Quantitative	 real	 time	PCR	analysis	of	 the	Ctnnb1	mutant	 and	Ctnnb1	wildtype	
tumor	samples	was	performed,	in	order	to	evaluate	mRNA	expression	levels	of	Ctnnb1	
target	genes.				
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Figure  3-11: Glul and Ctnnb1 expression levels. Plotted are the fold-change 
expression values of different tumor samples for the genes Glul and Ctnnb1, 
normalized against the control liver expression. The gene Glu1, encoding 
glutamine synthetase, was found specifically up-regulated in the Ctnnb1 mutant 
tumors. However, the Ctnnb1 expression itself was found to be variable between 
tumor samples.  
	 It	 can	 be	 deduced	 from	 Figure	 3-11	 that	 mutations	 in	 the	 Ctnnb1	 gene	 were	
paralleled	by	enhanced	expression	of	Glul.	 It	can	also	be	noted	that	in	the	Ctnnb1	wild	
type	tumors	there	was	reduced	expression	of	Glul.	This	could	be	due	to	the	changes	in	
cellular	 polarity	 and	 differentiation	 caused	 by	 Ctnnb1-stimulated	 malignant	
transformation.	 These	 observations	 warranted	 a	 genome-wide	 investigation	 of	 gene	
expression	profiles.	Henceforth,	the	Ctnnb1	mutant	tumors	were	classified	as	HCCA	and	
the	Ctnnb1	wildtype	tumors	were	classified	as	HCCB.	
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3.3 Gene expression profiling - microarray analysis  
In	 order	 to	 investigate	 at	 a	 genome-wide	 level	 the	mRNA	 expression	 levels	 of	
genes,	 microarray	 analysis	 was	 performed.	 12	 different	 samples	 (of	 different	 sample	
types)	were	analyzed	in	collaboration	with	Dr.	Michael	Bonin,	Human	Genetics,	UKT,	
University	of	Tuebingen.	The	demographics	of	the	samples	analyzed	are	given	below.	
Table 3-2: Sample Demographics - Microarray analysis. HCCA denotes Ctnnb1 wt 
tumors, while HCCB denotes Ctnnb1 mutant tumors. LWBW stands for Liver 
Weight to Body Weight Ratio at time of sample collection. Nodules stand for pre-
malignant, hyper-proliferative nodular liver tissue. 
Category	 Type	 Sample	#	 Mouse	#	
Gender	 Male	 6	 6	Female	 6	 6	
Sample	type	
Controls	 3	 3	Nodules	 3	 3	
HCCA	 3	 3	
HCCB	 3	 3	Age	 Median	Age	(weeks)	 27.5	weeks		
LWBW	ratio	 Average	LWBW	ratio	%	(Tumors	&	Nodules)	 23.2%	
For	the	downstream	analysis	of	the	microarray	expression	data,	the	p-value	cut-
off	was	set	at	0.05	and	the	fold-change	cut-off	was	set	at	2.	Hence	only	the	transcripts	
that	 displayed	 a	 difference	 in	 expression	 levels	 by	 at	 least	 2	 fold,	 compared	 to	 the	
controls,	with	a	high	significance	(p-value	<0.05),	were	considered	for	the	downstream	
analyses.	 About	 3000	 genes	were	 found	 differentially	 expressed	 (compared	 to	 control	
liver	 tissue)	 across	 all	 the	 different	 sample	 categories	 (Ohrnberger	 et	 al.,	 2015).	 The	
number	of	differentially	regulated	transcripts	and	their	overlaps	across	different	groups	
are	shown	in	Figure	3-12.		
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Figure 3-12: Dysregulated Transcripts – Microarray analysis. The overlap 
between the different sample groups is shown. HCCA denotes Ctnnb1 wt tumors, 
while HCCB denotes Ctnnb1 mutant tumors. Nodules stand for pre-malignant, 
hyper-proliferative nodular liver tissue. 
	
3.3.1 Sub-lists – microarray data 
3.3.1.1 Early driver alterations 
The	following	are	some	of	the	interesting	gene	lists	found	differentially	expressed	
in	 all	 the	 different	 sample	 groups,	 probably	 implying	 their	 involvement	 in	 tumor	
formation,	 starting	 at	 the	 early	 pre-malignant	 nodular	 stages	 of	 tumor	 development.	
There	 were	 interesting	 candidates	 in	 the	 top	 5	 list	 of	 genes	 up-regulated	 across	 all	
sample	 categories,	 including	 Igf2,	 H19,	 and	CD63	 among	others.	These	 genes	 are	 also	
known	as	the	oncofetal	liver	genes,	which	are	highly	overexpressed	in	a	specific	subset	
of	human	HCC	patients	(Ohrnberger	et	al.,	2015).		
3.3.1.2 Late driver alterations 
Another	 group	 of	 genes	 was	 noticed,	 which	 were	 highly	 deregulated	 in	 the	
tumors	tissues	but	not,	or	only	slightly,	altered	at	nodular	stages.		
RESULTS	
	
127	
Table 3-3: The 5 most dramatically up- or down-regulated genes. The highly 
deregulated samples across all groups of tissue analyzed by microarray 
expression analysis of mRNAs. HCCA denotes Ctnnb1 wt tumors, while HCCB 
denotes Ctnnb1 mutant tumors. Nodules stand for pre-malignant, hyper-
proliferative nodular liver tissue. 
Gene		
Symbol	
Nodules	vs	Control	
Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
H19	 5.1	 6.2	 6.4	
Vil1	 3.2	 4.6	 4.3	
Cd63	 4.3	 5.0	 5.1	
Igf2	 3.7	 6.7	 6.7	
Cdh1	 3.1	 3.2	 3.3	
Cyp4a14	 -4.5	 -6.6	 -4.3	
Inhbe	 -2.0	 -3.1	 -5.0	
Oat	 -2.6	 -4.5	 -3.3	
Elovl3	 -2.3	 -5.2	 -5.4	
Sucnr1	 -2.3	 -4.4	 -4.8	
Log2%Fold%Change%values%
<23%% 23%to%21% 21%to%1% 1%to%3%% >3%%  
Table 3-4:Genes dysregulated only in HCCs and not in Nodules– Microarray 
analysis. Selected genes which were up- or down-regulated in tumors, with little 
or no dysregulation during early (nodular) stages of HCC progression.are shown 
here . HCCA denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant 
tumors. The color legend is the same as that used in Table  3-3. 
Gene	Symbol	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Tspan8	 1.6	 6.0	 4.2	
A2m	 1.1	 5.2	 4.2	
Bex1	 2.1	 6.1	 6.4	
Timp1	 0.7	 5.6	 4.0	
Cpe	 0.7	 5.5	 5.7	
Mup3	 -0.2	 -3.9	 -7.3	
Es31	 0.1	 -5.5	 -6.7	
Gls2	 -0.6	 -3.4	 -5.3	
Ces1	 -0.6	 -3.1	 -4.2	
Apoa5	 -0.4	 -4.5	 -3.9	
Legend	
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The	genes	that	are	specifically	deregulated	in	the	tumor	stage	reflect	very	likely	
changes	 in	 gene	 expression	 that	 were	 acquired	 later	 during	 progression	 toward	
malignant	 transformation.	 Interestingly,	 the	 genes	Tspan8,	Timp1	 and	Cpe	 have	 been	
shown	 by	 different	 studies	 to	 be	 over-expressed	 in	 various	 cancers	 (Wei	 et	 al.,	 2015)	
(Toricelli	et	al.,	2017)	(Murthy	et	al.,	2013).	The	gene	Bex1	 is	a	member	of	the	group	of	
oncofetal	liver	genes,	which	have	been	found	overexpressed	abundantly	in	nodules	and	
tumors	of	SRF-VP16iHep	mice.	The	gene	Timp1	has	been	reported	to	be	overexpressed	in	
different	cancers,	but	has	also	been	reported	in	liver	cancers,	where	it	has	been	shown	
to	mediate	the	communication	between	tumors	and	their	respective	microenvironment,	
especially	 between	 the	 cancer	 cells	 and	 the	 hepatic	 stellate	 cells	 via	 the	 TGF-β-
dependant	FAK	signaling	pathway	(Park	et	al.,	2015).		
3.3.1.3 Genes over-expressed in pre-malignant nodular  
   tissue only 
Specific	 sets	 of	 genes	 could	 be	 identified,	 which	were	 up-regulated	 in	 nodular	
tissue	but	were	down-regulated	or	unchanged	in	the	tumor	tissues.	Listed	in	Table		3-5	
are	genes	with	such	an	expression	pattern.		
Table 3-5: Genes up-regulated in nodular tissues– Microarray analysis. 
Alterations representing early stages of HCC progression. HCCA denotes Ctnnb1 
wt tumors, while HCCB denotes Ctnnb1 mutant tumors. The color legend is the 
same as that used in Table  3-3. 
Gene	Symbol	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Moxd1	 3.3	 -0.4	 -0.4	
Slco1a1	 1.3	 -3.5	 -4.2	
Saa2	 1.7	 0.6	 -3.6	
Clec2h	 1.3	 -1.8	 -1.9	
Saa1	 1.6	 0.8	 -2.9	
C8a	 1.0	 0.2	 -2.9	
Krt23	 1.0	 0.7	 -1.2	
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These	genes	are	potential	candidate	genes	to	have	tumor	suppressive	 functions	
and	hence	they	are	down	regulated	at	the	tumor	stages.	The	genes	Slco1a1,	Clec2h	and	
Saa2	 were	 found	 differentially	 regulated	 in	 a	 HCC	 mouse	 model	 based	 on	 primary	
insulin	resistance	as	well	(Hines	et	al.,	2011).	This	implies	strong	metabolic	alterations	as	
milestone	 events	 during	 the	 switch	 from	 hyper-proliferative	 nodular	 stages	 towards	
HCCs.		
3.3.1.4 Genes over-expressed in HCCB only 
Of	further	interest,	genes	could	be	identified,	which	were	over-expressed	specifically	in	
the	Ctnnb1	mutant	HCCs.		
Table 3-6: Genes up-regulated in Ctnnb1 mutant (HCCB) tumors – Microarray 
analysis. HCCA denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant 
tumors. The color legend is the same as that used in Table  3-3. 
Gene	Symbol	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Cyp2c39	 -1.3	 -1.8	 3.1	
Pgm5	 0.0	 -1.1	 3.3	
Car4	 -0.1	 0.0	 4.9	
Sema3c	 0.2	 -0.3	 4.3	
Amy2a5	 0.0	 -0.1	 4.1	
Aldh1a2	 0.4	 0.9	 4.1	
Airn	 0.6	 0.9	 3.7	
Gpc3	 0.3	 -0.1	 3.1	
Slc1a2	 -1.2	 -3.6	 1.6	
Lgr5	 -0.7	 -1.6	 3.0	
Avpr1a	 0.2	 -1.7	 2.5	
Pdk4	 -0.8	 -1.2	 2.7	
Rcan2	 -1.7	 -0.7	 1.4	
  
	 It	 is	 interesting	 to	 note	 that,	 indeed,	 some	 of	 the	 known	 target	 genes	 of	 β-
Catenin,	 such	 as	Lgr5,	were	 found	up-regulated	 only	 in	HCCB	 tumors.	 The	 gene	Airn	
encodes	for	a	lncRNA	and	is	known	to	be	regulated	by	an	imprinting	mechanism	(Latos	
RESULTS	
	
130 
et	al.,	2012).	The	gene	Gpc3	is	a	marker	of	HCC	progression	and	is	associated	with	poor	
prognosis	in	human	HCC	patients	(Shirakawa	et	al.,	2009).	The	genes	Sema3c	has	also	
been	 shown	 to	 be	 overexpressed	 in	 various	 human	 cancers	 (Xu	 et	 al.,	 2017).	 	 The	
Cytochrome	P450	 genes	have	been	 shown	 to	have	unique	 gene	 expression	profiles	 in	
different	tumors	(Braeuning,	2008).	This	can	be	observed	in	SRF-VP16iHep	mice	as	well.	
Cyp2c39	is	found	under-expressed	in	HCCA	but	is	found	overexpressed	in	HCCB.	
3.3.1.5 Tumor heterogeneity  
	 One	of	the	interesting	aspects	of	the	tumors	of	the	SRF-VP16iHep	mice	was	their	
heterogeneity	regarding	gene	expression	profiles,	which	is	a	classical	feature	known	for	
human	HCCs.	Below	two	graphs	are	shown,	plotting	the	expression	profiles	of	specific	
gene	list	subsets	for	all	three	different	sample	groups	(nodular	tissue,	HCCA,	and	HCCB).		
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Figure 3-13: Expression profiles of specific gene sets - Microarray analysis. The 
upper panel shows the unique dysregulation pattern of HCCB for gene set 1 and 
lower panel shows the unique dysregulation pattern of HCCA for gene set 2. 
p<0.0001 
	 For	gene	set	 1,	 there	 is	a	clear	up-regulation	in	HCCB	samples,	compared	to	the	
HCCA	and	 nodular	 samples.	Whereas,	 the	 gene	 set	 2	 represents	 a	 different	 group	 of	
genes	that’s	expression	profiles	show	a	specific	up-regulation	in	HCCA	not	observed	in	
HCCB	 or	 the	 nodular	 samples.	 Such	 gene	 expression	 patterns	 hint	 toward	 the	
heterogeneity	that	exists	among	the	SRF-VP16iHep	tumors.	
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3.4 Comparison to human HCCs 
	 The	 Microarray	 data	 obtained	 our	 mouse	 model	 of	 HCC	 formation	 was	
compared	to	different	expression	profiling	datasets	from	human	HCCs.	This	was	done,	
in	 order	 to	 determine	 the	 relevance	 of	 these	 tumors	 to	 human	 HCCs,	 given	 the	
observation	 that	 the	 Ctnnb1	 gene	 mutations	 found	 in	 HCCB	 tumors	 are	 identical	 to	
mutations	found	in	a	subset	of	human	HCCs	as	well.		
3.4.1 Heidelberg cohort 
	 The	Microarray	gene	expression	data	of	40	human	HCC	patients	was	shared	by	
Dr.	Thomas	Longerich,	then	working	at	the	Department	of	Pathology,	University	Clinic	
Heidelberg.	The	sample	demographics	are	as	described	in	Table		3-7.	
3.4.1.1 Boyault classification 
	 Boyault	 classification	 is	a	method	used	 to	classify	human	 tumors	 into	different	
sub-categories,	using	 the	expression	profiles	of	a	 set	of	classifier	genes	 (Boyault	et	al.,	
2007).	The	Boyault	classification	was	made	for	the	Heidelberg	cohort,	to	determine	the	
molecular	 sub-category	 of	 each	 of	 the	 included	 human	 tumors.	 Seven	 of	 the	 tumors	
belonged	 to	 the	 G6	 sub-category	 of	 HCC,	 which	 usually	 harbors	 mutations	 in	 the	
CTNNB1	gene	locus.	Eight	of	the	human	tumors	were	classified	to	belong	to	the	G1	and	
G2	 sub-categories	 that	 are	 categorized	 by	 overexpression	 of	 oncofetal	 genes	 (among	
other	features).			
3.4.1.2 SRF expression 
	 The	 expression	of	 the	SRF	 gene	of	 the	human	 tumors	belonging	 to	 the	HD	40	
cohort	was	analyzed.	The	SRF	transcript	levels	of	the	tumors	were	compared	to	those	of	
the	 control	 human	 individuals.	 The	 expression	 levels	 of	 SRF	 in	 these	 human	 HCC	
samples	was	 correlated	with	 other	molecular	 features	 of	 the	 patient	 samples,	 such	 as	
Boyault	class,	DLC1	status,	IGF2	expression	and	CTNNB1	mutation	status,	among	others.	
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The	results	are	shown	in	Figure	3-14.	The	genomic	mutation	status	of	the	DLC1	gene	of	
the	human	patients	had	been	shared	by	Dr.	Thomas	Longerich,	Heidelberg.	The	DLC1	
protein	can	be	considered	to	be	an	upstream	inhibitor	of	SRF	(via	Rho	inhibition)	and	
its	loss	implies	an	activation	of	SRF	activity	through	stimulation	Rho/actin	signaling.	
Table 3-7: Patient demographics of Heidelberg cohort of human HCC patients. 
N	=	40	 Variables	 #	Patients	 #	SRF	Overexpressing	Patients	
Median	Age	 56	 40	 19		(48%)	
Gender	
Male	(30)	 30	 12		(40%)	
Female	(10)	 10	 7	(70%)	
Grading	
Grade	1	 5	 1	(20%)	
Grade	2	 30	 14	(47%)	
Grade	3	or	above	 5	 4		(80%)	
Cirrhosis	
Yes	 22	 8	(36%)	
No	 18	 11	(61%)	
CTNNB1	
mutation	
Yes	 10	 6	(60%)	
No	 30	 13	(43%)	
DLC1	status	
(genomic)	
Loss	 24	 14	(58%)	
Balanced	 13	 4	(31%)	
Gain	 3	 1	
The SRF expression levels of the patients were also noted.  
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Figure 3-14: SRF expression levels in Heidelberg cohort of human HCC patients. 
Features such as CTNNB1 mutation status, Boyault sub-category, and the DLC1 
mutation status are plotted. The figure indicates a clear correlation between SRF 
over-expression and loss of DLC1 in a majority of human patients (Published in 
Ohrnberger*, Thavamani* et al., 2015). 
3.4.1.3 Unsupervised hierarchical clustering 
	 The	microarray-generated	expression	profiles	of	the	human	and	the	murine	SRF-
VP16iHep	tumors	were	subjected	to	comparison	by	unsupervised	hierarchical	clustering,	
using	 the	 Cluster	 2.0	 software.	 The	 unsupervised	 hierarchical	 clustering	 analysis	
identified	a	subset	of	human	tumors,	designated	as	the	SC10,	which	show	the	maximum	
similarity	to	the	mouse	tumors.	Interestingly	they	also	show	an	enrichment	of	samples	
over-expressing	 IGF2	 and	 SRF	 and	 also	 belong	 to	 the	 G1/G2	 sub-class	 of	 Boyault	
classification,	which	holds	true	for	the	murine	HCCs	as	well	(Figure	3-15).	
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Figure 3-15: Unsupervised hierarchical clustering of mouse and human HCCs - 
SRF-VP16iHep tumors versus Heidelberg human HCC cohort. Added to the 
clustering tree are the various annotations of the human tumors regarding their 
Boyault sub-class (Blue and red arrows pointing upward), their SRF and Igf2 
expression profiles (blue triangles and yellow boxes, and their CTNNB1 mutation 
status (red triangles) (Published in Ohrnberger*, Thavamani* et al., 2015). 
3.4.2 Oncofetal liver genes 
	 The	 oncofetal	 liver	 genes	 are	 a	 set	 of	 unique	 genes,	 which	 are	 active	 in	 the	
embryonic	liver,	but	not	in	adult	liver.	In	case	of	liver	cancer,	however	they	have	been	
shown	 to	be	 frequently	overexpressed	 (Yong	et	 al.,	 2013).	Overexpression	of	oncofetal	
liver	genes	has	been	described	as	one	of	the	characteristic	feature	of	a	distinct	sub-type	
of	 human	 cancers,	 the	 G1/G2	 subtypes	 of	 human	 HCCs,	 according	 to	 the	 Boyault	
classification	(Boyault	et	al.,	2007).	Some	of	the	oncofetal	liver	genes	were	found	over-
expressed	in	the	murine	SRF-VP16iHep-derived	tumors	as	well.	
3.4.2.1 Clustering analysis based on oncofetal liver genes 
	 	 Unsupervised	hierarchical	clustering	of	the	murine	HCCs	was	performed	
not	only	comparison	to	the	Heidelberg	cohort	(HD	40),	but	also	to	two	other	datasets	
obtained	 from	 the	 Gene	 Expression	 Omnibus	 data	 portal.	 The	 clustering	 was	 done	
based	on	the	expression	profiles	of	oncofetal	liver	genes.	For	this,	11	different	oncofetal	
liver	genes	were	chosen.	The	clustering	analyses	are	summarized	below.	This	part	of	the	
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clustering	 analysis	 was	 performed	 in	 collaboration	with	Dr.	Michael	 Römer	 from	 the	
group	of	Dr.	Zell,	University	of	Tuebingen.	
Table 3-8: Oncofetal liver gene expression in SRF-VP16iHep-derived tissues. HCCA 
denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. The color 
legend is the same as used in Table  3-3. 
Gene	Symbol	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Igf2	 3.7	 6.7	 6.7	
H19	 5.1	 6.2	 6.4	
Vil1	 3.2	 4.6	 4.3	
Bex1	 2.1	 6.1	 6.4	
Psat1	 2.8	 5.3	 5.1	
Peg3	 1.2	 3.9	 2.3	
Afp	 1.0	 2.7	 2.7	
Sox9	 1.5	 2.2	 1.6	
	
Table 3-9: Summary of clustering analyses comparing oncofetal liver gene 
expression in three different data sets 
Dataset	
Id	
Source	 Total	human	
patients	in	
cohort	
Total	#	human	tumor	samples	
clustering	close	to	mouse	tumors	
(and	%)	
HD	40	 Dr.	Thomas	
Longerich	
40	 7	(17.5	%)	
ST	91	 Thorgerirsson	
et.al	
91	 9	(10%)	
NCI	247	 National	Cancer	
Institute	
247	 91	(37%)	
	 Among	 the	oncofetal	 liver	genes,	 Igf2	and	H19,	were	known	to	be	 regulated	by	
means	of	 an	 imprinting	mechanism,	which	 involves	 the	methylation	of	 genomic	CpG	
islands	present	in	the	CTGF	protein	binding	site	that	is	in	close	proximity	to	both	of	the	
genes.	 Epigenetic	 alteration	 in	 this	 locus,	 charactereized	 by	 loss	 of	 imprinting,	 is	 a	
known	 characteristic	 feature	 of	 the	 G1	 sub-type	 of	 Boyault	 classified	 human	 HCCs	
(Boyault	et	al.,	2007).		
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3.4.2.2 Genomic CpG methylation analysis 
	 Genomic	 CpG	 methylation	 data	 was	 already	 available	 for	 the	 human	 HD	 40	
cohort	 of	 HCCs,	 and	 was	 shared	 by	 Dr.	 Longerich.	 The	 methylation	 status	 of	 the	
genomic	 CpG	 sites	 located	 close	 to	 one	 of	 the	 promoters	 of	 the	 Igf2	 gene	 were	
investigated	 (in	 collaboration	 with	 Prof.	 Dr.	 C.	 Plass,	 DKFZ,	 Heidelberg).	 A	 clear	
relationship	 could	 be	 observed	 between	 hypo-methylation	 at	 3	 specific	 genomic	 CpG	
sites	close	 to	 the	P2	promoter	of	 the	human	 IGF2	 gene	and	 the	over-expression	of	 its	
transcript	levels.	
	 Interestingly,	 as	 shown	 in	 the	 Figure	 3-16,	 a	 subset	 of	 tumors	 displays	 a	 close	
correlation	 between	 genomic	 hypo-methylation	 and	 elevated	 transcript	 levels.	 A	
majority	 of	 those	 tumors	were	 also	 the	 ones	 that	 clustered	 close	 to	 the	mouse	HCCs	
during	hierarchical	clustering.	This	raised	the	hypothesis	of	a	possible	epigenetic	CpG	
methylation	 mechanism	 existing	 in	 the	 mouse	 for	 regulation	 of	 oncofetal	 liver	 gene	
expression,	similar	to	the	specific	subset	of	human	patients.	
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 Figure 3-16: Transcript expression levels vs genomic methylation patterns 
– IGF2.Transcript expression levels of IGF2, plotted against genomic methylation 
levels of 3 CpG sites close to the P2 promoter of the IGF2 gene. The bottom panel 
shows the genomic positions of the tested CpG sites within the IGF2 gene locus.  
(Published in Ohrnberger*, Thavamani* et al., 2015).  
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	 Genomic	 methylation	 analysis	 of	 the	 orthologous	 murine	 locus	 was	 done	 in	
collaboration	with	Dr.	Daniel	Lipka,	group	of	Dr.	C.	Plass,	DKFZ	Heidelberg.			
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Figure 3-16a. Genomic methylation patterns of IGF2 and H19 genes in SRF-
VP16iHep tumors (Published in Ohrnberger*, Thavamani* et al., 2015). 
	
	 There	was	significant	hypo-methylation	observed	in	the	H19	gene	locus,	but	not	
in	the	Igf2	gene	locus.	This	hypo-methylation	mig t	assume	a	significant	role	in	
determining	the	expression	level	changes	of	the	same	gene.		
Combined-omics approach 
A	combined	omics	approach	for	investigation	of	HCCs	derived	from	SRF-VP16iHep	
murine	 livers	 was	 achieved	 in	 collaboration	 with	 the	 following	 institutes/research	
groups.	
" Genome	Center,	Max	Planck	 Institute	 for	Developmental	Biology	 (MPI),	
Tuebingen	
" Dr.	Katarina	Matic,	group	of	Prof.	Dr.	B.	Macek,	PCT,		Tuebingen	
" Quantitative	Biology	Center,	Tuebingen	
" Dr.	 Johannes	 Werner,	 group	 of	 Dr.	 M.	 Schlesner,	 Computational	
Oncology	group,	DKFZ,	Heidelberg	
" High	Throughput	Sequencing	unit,	DKFZ,	Heidelberg	
" MetaSysX	GmbH,	Potsdam	
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3.5 Transcriptome and proteome analysis 
The	 combined	 transcriptomics	 and	 proteomics	 approach	 for	 RNA	 and	 protein	
analysis	were	carried	out	on	samples	collected	from	liver	tissue	samples	of	SRF-VP16iHep	
and	 littermate	control	mice.	The	demographics	of	 the	samples	are	described	below	 in	
Table	3-10.		
Table 3-10: Demographics of samples used for transcriptomic and proteomic 
analysis. HCCA denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant 
tumors. Nodules stand for pre-malignant hyper-proliferative liver tissue. LWBW 
stands for Live Weight to Body Weight Ratio.  
Category	 Type	 Sample	#	 Mouse	#	
Gender	 Male	 8	 4	Female	 8	 6	
Sample	type	
Controls	 4	 4	Nodules	 4*	 4	
HCCA	 4*	 4	
HCCB	 4	 4	Age	 Median	Age	(weeks)	 32	weeks		
LWBW	ratio	 Average	LWBW	ratio	(Tumors	&	Nodules)	 24.85%	
*During proteomic and phophoproteomic data processing, one sample from 
Nodules group and one sample from the HCCA group were excluded in 
downstream analyses owing to inadequate quality.  
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3.5.1 Transcriptomics - RNAseq 
	 The	transcriptome	profile	of	the	tumor	samples	was	analyzed	using	the	RNAseq	
method	 in	 collaboration	 with	 the	 Genome	 Center,	 Max	 Planck	 Institute	 for	
Developmental	 Biology,	 Tuebingen.	 Measurements	 were	 taken	 on	 an	 Illumina	 Inc.	
Hiseq	2000	sequencing	instrument.	The	bioinformatics	processing	of	the	obtained	data	
was	carried	out	by	QBiC,	University	of	Tuebingen.	
3.5.1.1 SRF-VP16 expression 
	 The	 SRF-VP16	 transgene	 expression	 in	 the	 nodular	 and	 tumor	 samples	 was	
measured	by	counting	the	number	of	reads	mapping	to	the	SRF-VP16	sequence	among	
all	different	 samples.	This	mapping	and	counting	of	 reads	corresponding	 to	SRF-VP16	
transgene	was	performed	by	QBiC.	The	results	are	shown	in	Figure		3-17.	
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Figure 3-17.  SRF-VP16 transgene expression. The graph showing the expression of 
SRF-VP16 sequence in the different samples, as determined by read counts. HCCA 
denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. The SRF-
VP16 reads in the four groups of samples Control Liver, pre-malignant nodular 
tissue (Nodules), HCCA and HCCB, were plotted. The SRF-VP16 reads were found 
only in the Nodular and HCC samples, but not in the control samples.  
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	 The	number	of	reads	of	SRF-VP16	sequence	was	found	at	different	 levels	 in	the	
different	samples.	The	presence	of	SRF-VP16	sequence	already	in	the	Nodular	samples	
implies	functional	expression	of	SRF-VP16	early	in	the	malignant	transformation	and	in	
tumor	progression.		
3.5.2 Principal Component Analysis (PCA) 
	 	Principle	Component	Analysis	(PCA)	of	the	different	samples	was	performed	by	
QBiC.	PCA	employs	a	mathematical	algorithm	to	convert	the	gene	expression	values	for	
all	genes,	of	the	different	sample	categories	into	two-dimensional	principal	components	
(PC)	namely	PC1	and	PC2.	Each	sample	group	is	assigned	a	pair	of	values	corresponding	
to	 each	 principal	 component	 PC1	 and	 PC2.	 The	 distance	 of	 separation	 between	 the	
sample	 groups	 in	 terms	 of	 their	 principal	 component	 values	 are	 plotted	 in	 a	 two	
dimensional	graph	to	visualize	the	magnitude	differences	in	gene	expression	patterns	of	
all	the	sample	groups.	 	The	PCA	plot	for	transcriptomics	data	(differentially	expressed	
mRNAs)	is	shown	in	Figure	3-18.		
	
Figure 3-18.  PCA plot of transcriptomics data for all samples.  The plot shows 
the relative distance between the samples in terms of their gene expression 
profiles.  Source : QBiC 
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	 The	control	samples	cluster	separately	 from	all	 the	other	samples.	The	nodular	
samples	and	the	tumor	samples	cluster	separate	from	the	control	samples.	This	implies	
a	 significant	 difference	 between	 the	 controls	 and	 the	 rest	 of	 the	 samples	 in	 terms	 of	
their	transcriptomic	profiles.	
3.5.3 Transcriptomic profile - RNAseq 
 3.5.3 .1 Number of Deregulated Transcripts 
A	 large	number	of	 transcripts	were	 found	differentially	 regulated,	 compared	 to	
control	 tissue,	 in	 the	 samples	 that	 correspond	 to	 different	 stages	 of	 malignant	
transformation	 in	 SRF-VP16iHep	 murine	 livers.	 The	 total	 numbers	 of	 deregulated	
transcripts	in	each	of	the	sample	groups	are	shown	in	Figure		3-19.		
	
Figure 3-19. # Deregulated transcripts in each sample group.  The plot shows the 
number of differentially regulated in pre-malignant nodular tissue (Nodules), 
HCCA, and HCCB, when compared to the control liver samples. HCCA denotes 
Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules denote 
premalignant hyper-proliferative liver tissues.  
	 As	 shown	 in	 Figure	 3-19,	 the	 HCCB	 sub-group	 consisting	 of	 tumors	 harboring	
mutations	 in	 the	 Ctnnb1	 gene	 showed	 the	 maximum	 number	 of	 dysregulated	
transcripts.	This	could	be	due	to	a	more	advanced	stage	of	malignant	progression	in	this	
category,	 due	 to	 the	 modulation	 of	 additional	 signaling	 pathways	 such	 as	 the	Wnt-
signaling	pathway	contributing	to	tumor	growth.	
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	 There	was	also	a	strong	overlap	observed	between	the	transcripts	deregulated	in	
the	different	sample	groups	as	shown	in	Figure	3-20.			
	
Figure 3-20: Deregulated Transcripts – RNAseq analysis. The overlap between the 
different sample groups is shown.  HCC A denotes Ctnnb1 wt tumors, while HCC 
B denotes Ctnnb1 mutant tumors, and Nodules denotes pre-malignant nodular 
tissue. 
	 In	 Figure	 3-20,	 it	 can	 be	 noted	 that,	 1859	 transcripts	 were	 found	 commonly	
deregulated	 in	 all	 the	different	 sample	 groups.	More	 than	 200	 transcripts	were	 found	
commonly	 deregulated	 in	 the	 nodular	 stage	 and	 in	 either	 of	 the	 HCC	 sub-types.	
Interestingly,	more	than	704	deregulated	transcripts	were	found,	which	were	common	
to	both	HCCA	and	HCCB.	These	might	be	genes	involved	in	critical	signaling	pathways	
responsible	for	the	progression	from	pre-malignant	nodules	to	tumors.	A	large	number	
of	transcripts	were	exclusively	deregulated	in	the	tumors	HCCA	and	HCCB,	respectively.	
These	 transcripts	 are	 likely	 those	 which	 were	 altered	 late	 during	 the	 malignant	
transformation	 process	 as	 the	 tumor	 developed	 further	 within	 the	 livers.	 This	 also	
indicates	a	step-wise	increase	comparing	the	pre-malignant	nodular	tissue,	versus	HCCA	
and	HCCB.	Shown	in	Figure	 	3-21	are	the	numbers	of	transcripts	whose	expression	are	
altered	exclusively	in	each	category	of	samples.		
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Figure 3-21: Exclusively Deregulated Transcripts – RNAseq analysis. The number 
of deregulated transcripts unique for each sub group. HCCA denotes Ctnnb1 wt 
tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules stand for pre-
malignant hyper-proliferative liver tissue.  
	
	 The	nodules	show	the	least	number	of	uniquely	deregulated	transcripts.	Among	
the	 167	 transcripts,	 the	 subgroup	 of	 upregulated	 transcripts	 likely	 encodes	 tumor	
suppressive	functions,	which	are	absent	at	later	stages	of	tumor	progression.	In	Figure		
3-21	the	step-wise	increase	of		gene-expression	changes	is	evident.	The	HCCB	shows	the	
maximum	number	of	exclusively	deregulated	transcripts.	A	majority	of	 these	could	be	
the	genes	associated	directly	or	indirectly	with	the	Wnt	signaling	pathway,	owing	to	the	
fact	that	HCCB	samples	are	those	that	harbor	gain	of	function	mutations	in	the	Ctnnb1	
gene.	
3.5.4 Comparison of RNAseq data to Microarray  
  data 
	 The	 results	 obtained	 from	 this	 RNAseq	 expression	 analysis	 complement	 the	
earlier	 microarray	 expression	 analysis.	 A	 comparison	 of	 the	 two	 datasets	 showed	 a	
significant	 overlap	 regarding	 the	 expression	 patterns	 of	 a	 majority	 of	 genes.	 Since	
different	mouse	samples	were	subjected	to	each	of	the	experimental	techniques,	a	direct	
comparison	of	both	may	not	be	prudent.	However,	 the	overlapping	expression	 trends	
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obtained	 from	 both	 technologies	 indicate	 genes	 vital	 for	 SRF-VP16-triggered	
hepatocarcinogenesis	.		
3365$ 1802$ 1032$
RNAseq' Microarray'
	
Figure 3-22: Comparison of experimental strategies – RNAseq versus Microarray. 
The numbers displayed within the circles denote the number of transcripts found 
differentially regulated in each of the analytical platforms and the number of 
transcripts commonly detected by both the technologies, as denoted in the 
intersection of the two circles (grey area). 
	
	 It	can	be	deduced	from	Figure	3-22	that	a	majority	of	the	deregulated	transcripts	
detected	by	the	microarray	experiment	were	also	detected	by	RNAseq.	In	addition,	the	
RNAseq	experiment	was	able	to	detect	50%	more	of	deregulated	transcripts.	More	than	
thousand	transcripts	(a	total	of	 1032)	detected	by	the	Microarray	were	not	detected	in	
the	RNAseq	experiment.	These	numbers	could	be	well	accounted	by	the	fact	that	both	
these	technologies	made	use	of	different	tissue	samples	(from	different	mice).	However	
to	 compare	 the	 expression	 profiles	 of	 the	 1802	 transcripts	 found	 deregulated	 in	 both	
technology	 platforms,	 the	 log2	 fold-change	 values	 compared	 to	 the	 control	 samples	
were	calculated	for	each	gene	across	the	different	sample	groups	from	both	RNAseq	and	
microarray	analysis.		
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Figure 3-23: Comparison of experiments – RNAseq and Microarray. The log2 
fold-change values of genes found deregulated in the different experiments were 
plotted against each other. HCCA denotes Ctnnb1 wt tumors, while HCCB denotes 
Ctnnb1 mutant tumors. Nodules stand for pre-malignant hyper-proliferative liver 
tissue. 
	 Gene	expression	levels	of	selected	transcripts	 from	among	the	1802	deregulated	
transcripts,	 which	 displayed	 deregulation	 in	 both	 the	 RNAseq	 and	 microarray	
platforms,	 are	 shown	 in	 Table	 3-11.	 Among	many	 other	 examples,	 the	 oncofetal	 liver	
genes	 Igf2,	 Vil1,	 H19,	 and	 Gldn	 that	were	 found	 overexpressed	 by	microarray	 analysis	
were	also	found	overexpressed	in	the	RNAseq	platform.	Direct	target	genes	of	the	SRF	
transcription	factor	were	also	among	the	1802	transcripts	to	be	commonly	dysregulated	
in	 both	 platforms.	 Interestingly,	 among	 the	 down-regulated	 transcripts,	 the	 nodular	
tissue	 samples	 from	 the	RNAseq	experiment	 showed	a	greater	 fold-change	difference,	
when	compared	to	the	nodular	tissue	sample	group	of	the	microarray	experiments.	
	
	
	
	
	
	
r	=	0.85	
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Table 3-11: Comparison of experiments – RNAseq and Microarray. The changes 
in expression levels expressed as log2 fold-change values compared to the control 
samples for each gene from the two experiments are shown. HCCA denotes Ctnnb1 
wt tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules stand for pre-
malignant hyper-proliferative liver tissue. The color legend used was the same as 
that used in Table  3-3. 
gene_id	
RNAseq	
Nodules	vs	
Control	
Log2	Fold	
Change	
RNAseq		
HCC	A	vs	
Control	
Log2	Fold	
Change	
RNAseq	
HCC	B	vs	
Control	
Log2	Fold	
Change	
Microarray	
Nodule	vs	
Control	
Log2	Fold	
change	
Microarray	
HCC	A	vs	
Control	
Log2	Fold	
change	
Microarray	
HCC	B	vs	
Control	
Log2	Fold	
change	
Cd63	 5.2	 5.7	 5.4	 4.3	 5.0	 5.1	
Cdh1	 4.4	 4.7	 4.7	 3.1	 3.2	 3.3	
Gldn	 6.3	 6.3	 6.9	 5.3	 5.4	 5.5	
Igf2	 6.3	 7.1	 6.9	 3.7	 6.7	 6.7	
Lpl	 3.8	 4.2	 4.1	 3.2	 4.1	 3.7	
Vil1	 4.8	 6.0	 6.6	 3.2	 4.6	 4.3	
H19	 4.6	 2.8	 3.9	 5.1	 6.2	 6.4	
Acss3	 -3.4	 -4.7	 -5.3	 -2.8	 -4.2	 -4.1	
Lipg	 -4.0	 -4.8	 -5.9	 -1.9	 -3.5	 -3.5	
Suox	 -3.1	 -3.8	 -3.6	 -1.6	 -3.6	 -3.6	
Inhbe	 -3.0	 -2.4	 -3.2	 -2.0	 -3.1	 -5.0	
Raet1d	 -4.1	 -2.2	 -3.1	 -1.8	 -1.6	 -4.7	
Slc15a5	 -4.3	 -4.4	 -3.7	 -1.2	 -2.3	 -2.3	
3.5.5 Comparison to human HCCs – RNAseq data 
The	RNAseq	data	of	the	mouse	samples	were	compared	with	the	RNAseq	data	of	
human	HCC	patients.		
3.5.5.1 Mainz cohort 
	 The	 RNAseq	 data	 of	 8	 HCC	 patients	 was	 obtained	 with	 thanks	 from	Dr.	 Jens	
Marquardt	 from	 the	 Johannes	 Gutenberg	 University	 in	 Mainz.	 The	 dataset	 included	
human	liver	cancer	samples	that	comprised	of	low-grade	dysplastic	nodules,	high-grade	
dysplastic	nodules,	early	HCC	and	progressed	HCC	(Table	3-12).		
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Table	3-12:	Sample	overview	–	Mainz	cohort	of	human	HCC	patient	samples.	
Liver	Cancer	stage	 #	samples	
Low-grade	dysplastic	nodule	 3	
High	grade	dysplastic	nodule	 10	
Early	HCC	 5	
Progressed	HCC	 3	
	 Unsupervised	 hierarchical	 clustering	 of	 the	 murine	 SRF-VP16iHep	 samples	 was	
performed	 along	 with	 the	 human	HCC	 samples,	 in	 order	 to	 compare	 the	 expression	
profiles	 of	 the	 two	 datasets.	 Clustering	 was	 done	 using	 the	 data	 of	 7521	 orthologous	
genes	between	21	human	samples	and	12	mouse	samples.		
Hum
an&&HCCs&
SRF$VP16
iHep-
	
Figure 3-24: Clustering analysis: SRF-VP16iHep vs Mainz cohort. The human 
samples are highlighted by the blue line and label. The SRF-VP16iHep samples are 
labeled in red. Among the 21 human HCC and dysplastic nodule samples, 5 of 
those clustered along with the SRF-VP16iHep samples. The 5 samples are 
highlighted in a red colored box. 7500 orthologous genes were taken for the 
clustering analysis.  
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Upon	clustering	analysis,	it	was	evident	that	the	3	progressed	HCC	samples	from	
3	 different	 patients	 clustered	 closer	 to	 the	murine	 samples.	Moreover,	 the	 early	HCC	
stage	sample	and	the	high-grade	dysplastic	nodular	sample	of	one	of	the	patients	also	
clustered	 closer	 to	 the	 mice	 tumors.	 This	 suggests	 that	 the	 SRF-VP16iHep	 tumors	
represent	a	subset	of	human	HCCs	that	show	aggressive	and	advanced	stage	phenotype.	
3.5.5.2 Comparison with The Cancer Genome Atlas (TCGA) 
	 The	transcriptome	data	for	HCC	patients	from	the	Cancer	Genome	Atlas,	made	
publicly	 available	 by	 the	National	Cancer	 Institute	 and	 the	National	Human	Genome	
Research	 Institute,	 was	 downloaded	 using	 the	 R	 package	 TCGA-Assembler.	 The	
downloaded	 data	 consisted	 of	 the	 read	 counts	 of	 all	 transcripts	 for	 373	 HCC	 patient	
samples	and	50	corresponding	normal	human	liver	samples.	The	average	read	count	of	
each	gene		in	the	normal	liver	sample	group	was	used	for	normalization.	The	log2	fold-
change	 values	 of	 gene	 expression	 changes	 in	 the	 HCC	 samples	 were	 calculated	 in	
comparison	to	the	average	of	the	50	normal	liver	sample	gene	expression	levels.	These	
values	were	used	for	unsupervised	hierarchical	clustering	analysis.	For	the	unsupervised	
hierarchical	clustering	analysis,	the	expression	level	changes	of	25	oncofetal	liver	genes	
from	the	human	dataset	and	the	SRF-VP16iHep	dataset	were	taken	(Figure	3-25).		
3.6  Proteomics analysis 
	 The	 proteomic	 analysis	 of	 the	 samples	was	 performed	 at	 the	 Proteome	Center	
Tuebingen.	The	data	acquisition,	 followed	by	 the	data	processing	and	 the	 subsequent	
statistical	analysis	was	done	by	Dr.	Katarina	Matic	from	Prof.	Dr.	Boris	Macek’s	group	at	
PCT,	Tuebingen.		
	 The	samples	used	for	the	proteomic	analysis	were	identical	to	those,	which	had	
been	used	for	the	RNAseq	analyses.		The	samples	have	been	described	in	Table	3-10.		
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Figure 3-25: Clustering analysis: SRF-VP16iHep vs TCGA. The human samples are 
highlighted by the blue line and label. The SRF-VP16iHep samples are labeled in 
red. Among the 373 human HCC, 115 of those clustered along with the SRF-
VP16iHep samples. The 115 samples are highlighted in a red line above. 25 
orthologous oncofetal liver genes were taken for the clustering analysis.  
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Figure 3-26: PCA plot – Proteomics. The plot shows the relative distance between 
the samples in terms of their proteomic profiles. HCCA denotes Ctnnb1 wt tumors, 
while HCCB denotes Ctnnb1 mutant tumors. Nodules stand for pre-malignant 
hyper-proliferative liver tissue. Source : Dr. Matic (PCT, University Tuebingen) 
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3.6.1  Principal Component Analysis 
	 The	Principle	Component	Analysis	(PCA)	of	the	proteome	data	was	done	by	Dr.	
Matic.		
The	 PCA	 plots	 show	 a	 clear	 segregation	 between	 the	 control	 samples	 and	 the	 other	
sample	groups	(Figure	3-26).	Notably,	 there	was	 found	one	particular	nodular	sample,	
which	showed	a	higher	proximity	to	the	control	samples	when	compared	to	the	other	
samples.	The	same	phenomenon	had	been	observed	in	the	PCA	plots	of	RNAseq	data	as	
well.	 The	nodules	 and	 tumor	 samples	 showed	higher	 overlap,	 barring	 a	 subset	 of	 the	
Ctnnb1	mutant	HCCs	
3.6.2  Altered protein levels 
	 661	 proteins	 were	 found	 in	 SRF-VP16iHep	 tissues	 that	 displayed	 a	 significant	
difference	 in	 their	 expression	 levels,	 when	 compared	 to	 control	 liver	 tissues.	 The	
analysis	 according	 to	 the	 variance	 statistical	 test	 had	 been	 applied	 to	 test	 the	
significance	of	the	protein	expression	changes.	A	cut-off	for	p-value	was	set	at	0.5,	above	
which	the	protein-level	changes	were	considered	not	significant.		
	
Figure 3-27: Total deregulated Proteins – The plot shows the number of 
differentially regulated proteins in Nodules, HCCA, and HCCB, when compared to 
the control liver samples. HCCA denotes Ctnnb1 wt tumors, while HCCB denotes 
Ctnnb1 mutant tumors. Nodules denote premalignant hyper-proliferative liver 
tissues. 
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	 At	the	nodule	stage,	303	proteins	were	found	altered	in	their	expression	levels.	In	
both	tumor	stages,	more	than	450	proteins	were	found	differentially	expressed	(Figure	
3-27).	 Unlike	 our	 deduction	 from	 RNAseq	 data,	 the	 Ctnnb1	 mutation	 status	 doesn’t	
seem	 to	 have	 a	 huge	 difference	 in	 terms	 of	 the	 number	 of	 differentially	 expressed	
proteins.	The	overlap	of	deregulated	proteins,	between	the	different	sample	groups	was	
analyzed.	The	results	are	shown	in	Figure	3-28.	
	 More	 than	 200	 proteins	were	 found,	which	were	 already	 altered	 in	 the	 nodule	
stage	 and	which	 continued	 to	be	 altered	 also	 in	 the	 tumor	 stages.	These	 are	proteins	
that	might	have	a	significant	role	in	maintaining	the	high	proliferative	potential	of	the	
tumors.	 115	 proteins	 were	 found	 altered	 only	 in	 the	 tumor	 samples	 and	 not	 in	 the	
nodular	 samples.	 They	 might	 include	 oncogenes	 and	 other	 proteins	 involved	 in	 the	
tumor	progression.	
	
Figure 3-28: Venn diagram representation of deregulated Proteins – The number 
of altered proteins across different sample groups are shown in the Venn diagram. 
HCCA denotes Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. 
Nodules denote premalignant hyper-proliferative liver tissues. 
However,	 upon	 plotting	 the	 number	 of	 proteins,	 which	 were	 found	 altered	
exclusively	in	either	of	the	sample	groups,	the	difference	between	tumors	and	nodules	
was	 much	 larger.	 The	 graph	 is	 shown	 in	 Figure	 3-29.	 The	 number	 of	 proteins	
significantly	 altered	 exclusively	 in	 the	 tumor	 stages,	 compared	 to	 that	 of	 the	 early	
RESULTS	
	
152 
nodular	 stages	 is	 about	 five-fold	higher.	 This	 gives	 a	 glimpse	 at	 the	 extent	 of	 protein	
synthetic	machinery	actively	functioning	in	the	tumors,	compared	to	the	nodules.	There	
were	 also	 a	 large	number	 of	 proteins,	which	overlapped	between	 the	 tumors	 and	 the	
nodules	in	their	expression	patterns.	
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Figure 3-29: Uniquely deregulated Proteins – The number of exclusively altered 
proteins across different sample groups are shown in the figure. HCCA denotes 
Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules denote 
premalignant hyper-proliferative liver tissues. 
3.6.3 Comparison to RNAseq 
The	proteomic	data	was	compared	to	the	RNAseq-deríved	transcriptomics	data.	
The	comparison	is	shown	in	Figure		3-30.		
4775$ 372$ 287$
RNAseq$
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Figure 3-30: Comparison of omics data – RNAseq and proteomics I. The numbers 
displayed within the circles denote the number of transcripts/proteins found 
differentially regulated in each of the omics analyses. The number of 
transcripts/proteins commonly identified by both the omics technologies, is 
denoted in the intersection of the two circles. 
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	 As	observed	in	Figure	3-30,	the	coverage	of	the	proteomics	experiment	in	terms	
of	 the	 number	 of	 peptides	 detected	 was	 lower	 than	 the	 coverage	 of	 the	 RNAseq	
experiment.	However,	a	majority	of	the	proteins	identified	to	be	differentially	regulated	
were	 also	 identified	 by	 the	 RNAseq	 experiment	 to	 be	 differentially	 expressed	 at	 the	
transcript	level.	This	implies	the	presence	of	a	robust	regulation	mechanism	at	both	the	
transcript	 and	 the	 protein	 levels,	 involved	 in	 hepatocarcinogenesis	 of	 murine	 SRF-
VP16iHep	livers.	
To	analyze	the	372	commonly	identified	transcripts	and	proteins	in	terms	of	their	
regulation	 patterns,	 their	 corresponding	 log2	 fold	 changes	 were	 compared	 to	 the	
normal	 liver	 samples,	 calculated	 from	 both	 the	 RNAseq	 and	 proteomics	 experiment,	
and	were	plotted	in	the	graph	shown	in	Figure	3-31.	The	correlation	coefficients	between	
the	two	datasets	across	the	different	sample	groups	were	above	0.86.		This	showed	that	
the	 changes	 in	 RNA	 expression	 of	 the	 genes	 were	 reflected	 in	 the	 change	 in	 protein	
levels	of	the	corresponding	proteins.	It	also	shows	that	the	results	obtained	by	either	of	
the	experiments	were	not	completely	random	events.		This	emphasizes	the	importance	
of	integrated	multi	omics	approaches	for	studying	changes	in	the	cell.		
 
Figure 3-31: Comparison of omics data – RNAseq and proteomics II. The log2 
fold-change values of genes found deregulated in the different experiments were 
plotted against each other. HCCA denotes Ctnnb1 wt tumors, while HCCB denotes 
Ctnnb1 mutant tumors. Nodules stand for pre-malignant hyper-proliferative liver 
tissue. 
	
r	=	0.86	
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3.7  Phospho-proteomics analysis 
3.7.1  Principal Component Analysis 
	 The	Principle	Component	Analysis	of	the	phospho-proteome	data	was	performed	
by	Dr.	Matic	(PCT,	Tübingen).		
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Figure 3-32: PCA plot – Phospho-proteomics. The plot shows the relative distance 
between the samples in terms of their phospho-proteomic profiles. HCCA denotes 
Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules stand for 
pre-malignant hyper-proliferative liver tissue. Source: Dr. Matic (PCT, University 
of Tuebingen). 
	
	 Similar	 to	 the	 PCA	 plot	 of	 the	 proteomics	 data,	 the	 phospho-proteomics	 data	
also	 shows	 a	 clear	 segregation	 between	 the	 control	 samples	 and	 the	 experimental	
sample	groups.	In	the	PCA	plots	of	RNAseq	and	proteomics	data,	one	nodular	sample	
was	 observed	 that	 had	 a	 very	 shorter	 distance	 from	 the	 control	 samples	 even	 in	 the	
component	 1	 segregation.	 However,	 in	 the	 phospho-proteomic	 data	 the	 separation	
between	the	control	group	and	the	nodule	group	is	even	more	pronounced,	especially	in	
the	separation	based	on	component	2	(Figure	3-32).		
	
RESULTS	
	
155	
3.7.2  Differentially phosphorylated peptides 
	 Differential	 phosphorylation	 among	 the	 peptides	 was	 calculated	 by	measuring	
the	 number	 of	 phospho-enriched	 peptides	 found	 in	 each	 sample,	 compared	 to	 the	
number	of	phospho-enriched	peptides	 found	 in	 the	 control	 sample.	The	difference	 in	
number	 of	 phospho-enriched	 peptides	 in	 each	 category	 was	 representative	 of	 the	
increased	or	decreased	phosphorylation	events	 in	 the	respective	samples	compared	 to	
the	control	sample.		
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Figure 3-33: Total number of differentially phosphorylated peptides – The plot 
shows the number of differentially phosphorylated peptides in Nodules, HCCA, and 
HCCB, compared to the control liver samples. HCCA denotes Ctnnb1 wild type 
tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules denote premalignant 
hyper-proliferative liver tissues. 
	
	 Figure	 3-33	 shows	 the	 total	 number	 of	 differential	 phosphorylation	 events	
increased	 at	 different	 stages	 of	 hepatocarcinogenic	 progression.	 	 Moreover,	 it	 was	
noticed	 that	 there	 were	 more	 dephosphorylation	 events	 when	 compared	 to	
phosphorylation	 events.	 This	 is	 evident	 by	 the	 overall	 higher	 number	 of	 phospho-
peptides	that	were	found	in	lower	amounts	compared	to	control	samples	after	phospho-
enrichment,	 thereby	 implying	 an	 increasing	 number	 of	 peptides	 being	 hypo-
phosphorylated	in	the	nodules	and	tumors	compared	to	the	controls.		
	
RESULTS	
	
156 
	 The	 types	 of	 differentially	 phosphorylated	 peptides	 were	 also	 compared.	 As	
evident	from	Figure	3-34	there	were	more	phosphorylation	events	associated	with	serine	
phosphosites	compared	to	events	associated	with	threonine	phosphorylation	events.		
	
Figure 3-34: Total number of differentially modified serine and threonine 
phosphosites – The plot shows the number of differentially phosphorylated 
peptides which had serine or threonine as kinase targets. More than 90% of the 
observed differential phosphorylation events comprised serine phosphorylation. 
	 The	 phosphopeptides	 that	 were	 found	 differentially	 modified	 in	 the	 nodules,	
HCCA	and	HCCB	were	compared	against	each	other	to	check	for	overlaps	between	the	
sample	groups.	The	comparison	is	shown	in	Figure	3-35.		
	
Figure 3-35: Differentially phosphorylated peptides –The plot shows the number 
of differentially modified phospho peptides in Nodules, HCCA, and HCCB, 
compared to the control liver samples. HCCA denotes Ctnnb1 wild type tumors, 
while HCCB denotes Ctnnb1 mutant tumors. Nodules denote premalignant hyper-
proliferative liver tissues. 
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	 Among	the	phosphopeptides	that	were	found	differentially	modified,	42	of	them	
were	observed	to	be	commonly	modified	across	all	the	sample	groups.	37	of	them	were	
found	only	in	the	tumor	samples	(HCCA	and	HCCB)	to	be	differentially	phosphorylated.	
26	phosphopeptides	were	differentially	modified	 in	 the	 early	nodular	 stage	 alone	 and	
not	in	the	tumors.	The	tumors	HCCA	and	HCCB	also	showed	unique	alterations	in	their	
posttranslational	modification	 profiles	 regarding	 phosphorylation,	 43	 phosphorylation	
events	 were	 scored	 in	 HCCA	 and	 74	 such	 events	 in	 HCCB.	 	 Some	 of	 the	 interesting	
protein	phosphorylation	events	were	as	 follows.	The	HCCB	 tumors	 showed	significant	
hypo	phosphorylation	in	a	Serine	at	position	675.	This	position	might	also	be	a	probable	
GSK-3β	kinase	site,	whose	dephosphorylation	might	be	involved	in	the	stabilization	of	
the	protein.	The	protein	encoded	by	the	gene	Acacb	was	hypo	phosphorylated	across	all	
different	sample	groups	including	the	nodules,	thereby	implying	that	it	may	be	involved	
early	on	during	the	malignant	transformation	process.		Interestingly	the	protein	Acetyl-
CoA	carboxylase	2	is	known	to	be	the	rate-limiting	step	in	fatty	acid	biosynthesis	in	the	
mitochondria.	 Decreased	 phosphorylation	 of	 this	 enzyme	 early	 on	 during	
carcinogenesis	 emphasizes	 on	 the	 role	 of	 changes	 in	 the	 fatty	 acid	 metabolism	 in	
causing	tumor	growth	and	development.	Among	the	hyper-phosphorylated	proteins	the	
Rho	GTPase	activating	protein	32	 is	a	notable	candidate	due	to	 its	 involvement	 in	the	
SRF-signallling	pathway.	
3.8  Whole exome sequencing 
	 Whole	 exome	 sequencing	 analysis	 (WES)	 was	 performed	 on	 30	 HCCs	 and	 6	
nodules	 from	SRF-VP16iHep	mice,	 along	with	8	 control	 samples.	The	WES	analysis	was	
performed	 in	 collaboration	 with	 the	 Genomics	 Unit	 of	 DKFZ,	 Heidelberg.	 The	
bioinformatics	analysis	of	sequenced	reads	was	carried	out	by	Dr.	J.	Werner	at	the	group	
of	Dr.	Mathias	Schlesner,	DKFZ	Heidelberg.	The	sample	demographics	are	described	in	
Table	3-13.	
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Table 3-13: Demographics of samples taken for WES analysis. HCCA denotes 
Ctnnb1 wt tumors, while HCCB denotes Ctnnb1 mutant tumors. Nodules stand for 
pre-malignant hyper proliferative liver tissue. HCC denote the tumors whose 
Ctnnb1 mutation status has not been determined. LWBW stands for Liver Weight 
to Body Weight Ratio. 
Category	 Type	 Sample	#	 Mouse	#	
Gender	 Male	 11	 4	Female	 33	 10	
Sample	type	
Controls	 8	 8	Nodules	 6	 6	HCC	A	 4	 4	HCC	B	 7	 4	HCC		 19	 8	Age	 Median	Age	(weeks)	 42	weeks		
LWBW	ratio	 Average	LWBW	ratio	(HCCs	&	Nodules)	 27.3%	
3.8.1 Single Nucleotide Variations 
	 The	 total	 numbers	 of	 single	 nucleotide	 variations	 (SNVs)	 detected	 specifically,	
singly	 or	 multiply,	 in	 the	 nodules	 and	 tumor	 samples	 at	 different	 locations	 of	 the	
genome	are	shown	in	Figure		3-36.	
	 The	 exonic	 variants	 form	 the	 majority	 of	 mutations	 detected	 in	 the	 samples.	
They	comprise	about	40	%	of	all	SNVs	detected.	Interestingly,	there	was	a	significantly	
high	 number	 of	 SNVs	 present	 in	 the	 intergenic	 and	 intronic	 regions	 of	 the	 genome,	
considering	 the	 fact	 that	 the	 exons	 were	 specifically	 enriched	 during	 library	
preparation,	before	sequencing.		This	could	be	due	to	incomplete	fragmentation	of	the	
genomic	 DNA,	 resulting	 in	 the	 intergenic	 and	 intronic	 regions	 to	 be	 captured	 along	
with	 the	 exons.	 For	 further	 downstream	 analyses,	 only	 the	 exonic	 mutations	 were	
considered.		
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Figure 3-36: Total single nucleotide variations detected – The location of 
different point mutations observed in the nodules and tumor samples are shown in 
the figure. 
	 Among	the	mutations	(SNVs)	detected	within	the	exonic	region	of	the	genome,	
three	types	of	alterations	were	observed,	when	considering	the	effect	of	a	mutation	on	
the	 transcriptome.	 Synonymous	 mutations	 are	 SNVs,	 which	 do	 not	 bring	 about	 a	
change	 in	 the	 amino	 acid	 sequence	 encoded	 by	 the	 transcript.	 These	 mutations	 are	
usually	at	the	third	base	of	the	codon	and	do	not	result	 in	altered	codon	information.	
The	non-synonymous	mutations	are	 the	ones	 that	bring	about	a	change	 in	 the	amino	
acid	 coding	 sequence	 and	 hence	 are	 more	 likely	 to	 have	 a	 deleterious	 effect	 on	 the	
proteins.	The	stop-gain	mutations,	as	the	name	suggests,	result	in	a	gain	of	a	stop	codon	
thereby	 causing	 termination	 of	 the	 translation	 process	 and	 resulting	 in	 truncated	 or	
stunted	 proteins,	 which	 are	 highly	 likely	 to	 be	 dysfunctional.	 Figure	 3-37	 shows	 the	
relative	number	of	mutations	of	each	sub-type	detected	in	the	samples.			
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Figure 3-37: Single nucleotide variations detected in exonic regions – The type of 
SNV detected in the exonic region of the genomes. Non-synonymous mutations 
comprise the majority of introduced SNV and synonymous mutations representing 
the second most frequent type of SNV. Also, a small number of stop-gain 
mutations were detected.  
	
3.8.1 Insertions/ Deletions 
	 Apart	from	the	SNVs,	the	exome	sequencing	analysis	also	revealed	the	presence	
of,	insertions/deletions	(indels)	in	the	tumor	samples..	Indels	are	nucleotide	variations	
that	 involve	 more	 than	 one	 single	 nucleotide	 at	 a	 given	 locus.	 They	 may	 involve	
insertions	or	deletions	of	more	than	a	single	nucleotide.	Occasionally	they	both	occur	
together	 in	 the	 genome	 as	 well.	 The	 relative	 locations	 of	 the	 indels	 in	 the	 genome,	
regarding	functional	considerations,	are	shown	in	Figure		3-38.		
	 	The	intronic	indels	represented	the	major	indels	detected	by	WES	analysis.	The	
second	most	 frequent	were	 the	 intergenic	 indels.	 Interestingly,	 the	 number	 of	 indels	
mapping	 within	 exons	 was	 not	 high	 as	 in	 the	 case	 of	 SNVs.	 However,	 only	 indels	
mapping	to	the	exonic	region	were	chosen	for	further	analyses.	
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Figure 3-38: Total insertions/Deletions – The position of various indels detected 
in the samples are shown in the figure. Exonic indels are not the majority in the 
samples.  
	 	
	 There	are	many	potential	types	of	effects	caused	by	indels	in	the	exonic	region	of	
the	genome.	The	major	effect	caused	by	indels	is	a	frameshift	in	the	coding	capacity	of	a	
gene,	resulting	in	completely	different	transcripts	and	translational	products.	This	can	
be	expected	to	lead	to	deleterious	effects	on	the	protein.	The	indels	that	do	not	cause	
frameshifts	 are	 known	 as	 non-frameshift	 indels.	 There	might	 also	 be	 stop-gains	 that	
occur	 upon	 indel	 formation.	 The	 latter	 represent	 a	 small	 proportion	 of	 the	 different	
types	of	indels.	The	different	types	of	indels	detected	in	our	WES	analysis	are	shown	in	
Figure		3-39.	
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Figure 3-39: Insertions/deletions detected in Exonic regions – The type of indels 
detected in the exonic region of the genomes. Frameshift-causing 
insertions/deletions and non-frameshift causing insertions/deletions are being 
considered. Also a small number of indels were found that resulted in gain of 
premature stop codons (stop-gain) in the corresponding genes.   
	
3.8.3 Copy number alterations 
	 Alterations	in	the	copy	number	of	a	local	DNA	segment	can	lead	to	differential	
expression	 of	 here-encoded	 genes.	 The	 copy	 number	 variations	 observed	 across	 the	
different	 samples	 are	 showed	 in	 Figure	 	 3-40.	 The	 copy	 number	 gains	 or	 losses	were	
considered	at	the	level	of	entire	chromosomes.	The	copy	number	variation	analysis	was	
done	by	Dr.	J.	Werner	(group	of	Dr.	Mathias	Schlesner,	DKFZ,	Heidelberg).	Briefly,	the	
number	of	reads	mapping	to	the	respective	chromosomes	are	considered	and	compared	
to	that	of	the	control	sample.	It	can	be	noted	that	chromosomes	15	and	18	showed	the	
highest	frequency	of	gains	in	the	mouse	genomes,	while	chromosomes	12	and	13	showed	
the	highest	frequency	of	losses.		
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Figure 3-40: Copy number alterations observed in WES analysis – A) The number 
of samples showing gain in the corresponding chromosomes are shown. B) The 
number of samples showing loss in the corresponding chromosomes are shown.   
	
3.8.4 Tumor heterogeneity 
	 The	 heterogeneity	 of	 SRF-VP16iHep	 tumors	 could	 be	 addressed	 using	 the	WES	
analysis.	The	mutation	profiles	of	individual	tumors	were	compared	against	each	other.	
In	the	cohort	of	samples	taken	for	WES	analysis,	there	were	several	tumors,	which	had	
originated	 from	 the	 same	 liver.	 The	 mutation	 profiles	 of	 these	 tumor	 samples	 were	
compared	with	each	other	 in	order	 to	determine	 the	degree	of	heterogeneity	 existing	
among	the	tumors,	despite	originating	from	the	same	liver.		
A	
B	
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	 Figure	 	 3-41	 shows	 the	mutations	 existing	 in	 each	 tumor	 belonging	 to	 a	 single	
mouse	liver.		
	
Figure 3-41: Heterogeneity among tumors – The figure shows a Venn diagram 
representation of the mutations present in each of the 5 tumors that had 
originated from the same mouse liver. It can be noted that the majority of 
mutations present in the samples are unique to them, with little or no overlap 
between the samples.  
	
	 The	mutation	 profiles	 of	 the	 samples,	 as	 highlighted	 in	 Figure	 	 3-37,	 indicates	
that	 the	 tumors	 originating	 within	 the	 same	 mouse	 liver	 could	 still	 have	 their	 own	
mutation	 profile,	 thus	 implying	 that	 the	 HCCs	 occurring	 in	 SRF-VP16iHep	 mice	 are	
heterogeneous	in	nature,	as	reflected	by	their	genomic	mutation	profiles.	
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3.9 Molecular mechanisms involved in HCC formation 
3.9.1 Wnt signaling pathway 
	 Given	that	the	gain-of-function	(i.e.	activating)	Ctnnb1	mutations	observed	in	the	
HCCB	 subset	 of	 tumors	 likely	 render	 the	 β-catenin	 protein	 to	 be	 stabilized,	 thereby	
resulting	in	the	Wnt	signaling	pathway	to	be	hyper-activated.	This	mechanism	is	indeed	
suggested	by	our	RNAseq	expression	profiling	to	be	at	work	in	the	SRF-VP16iHep	tumors	
of	HCCB	 type.	 Listed	 below	 are	 the	 expression	 profiles	 of	 some	 of	 the	 known	Ctnnb1	
target	genes.		
Table 3-14: A) Expression profiles of Ctnnb1 target genes– RNAseq data. It shows 
an upregulation of Wnt signaling target genes that are found selectively 
overexpressed in HCCB samples harboring gain-of-function mutations in the 
Ctnnb1 gene. B) Phosphorylation status of β-catenin protein. The phospho-
proteome analysis shows a decrease in phosphorylation status of the beta-Catenin 
protein that results in its stabilization. HCCA denotes Ctnnb1 wild type tumors, 
while HCCB denotes Ctnnb1 mutant tumors. Nodules denote premalignant hyper-
proliferative liver tissues. The color legend is the same as that used in Table 3-3. 
	
gene_id	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Afp	 5.11	 4.55	 5.61	
Cdh1	 4.38	 4.75	 4.72	
Igf2	 6.32	 7.11	 6.93	
Itga6	 3.35	 3.98	 3.55	
Timp1	 5.52	 6.88	 5.21	
Tspan8	 5.75	 5.88	 4.70	
Axin2	 -1.63	 -2.41	 1.16	
Dnmt1	 0.36	 0.11	 1.04	
Lgr5	 -1.46	 -2.42	 2.08	
 
	
Gene.names	 Protein.names	 Log2FC		Nodule	vs	Con	
Log2FC		
HCC_A	vs	Con	
Log2FC		
HCC_B	vs	Con	
Ctnnb1	 Catenin	beta-1	 -0.4	 -0.2	 -2.9	
Table 3-14 A) Expression profiles of Ctnnb1 target genes– RNAseq data. 
Table 3-14 B) Phosphorylation status of β-catenin protein 
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In	the	Table	3-14,	some	of	the	target	genes	are	over-expressed	only	in	the	Ctnnb1	
mutant	 tumor	 samples	 (HCCB.),	 thereby	 strongly	 inferring	 the	underlying	mechanism	
involved	in	the	cellular	proliferation	of	these	tumor	cells.	The	genes	Axin2,	Dnmt1	and	
Lgr5,	were	found	unchanged	or	under-expressed	in	the	nodules	and	in	HCCA,	but	they	
are	 found	 overexpressed	 in	 HCCB..	 The	 additional	 evidence	 from	 the	 phospho-
proteomics	analysis	showing	the	hypo-phosphorylation	of	β-catenin	protein	proves	that	
the	Wnt	signaling	pathway	is	active	in	SRF-VP16iHep	murine	tumors.	
3.9.2 SRF-target gene regulation 
	 As	expected,	a	large	number	of	known	SRF	target	genes	were	found	differentially	
regulated	in	the	tumor	and	nodular	samples,	owing	to	the	expression	of	SRF-VP16	in	the	
cells.	Shown	below	in	Table	3-15	are	the	expression	profiles	of	selected	SRF	target	genes.	
Table 3-15: Expression profiles of selected SRF target genes– RNAseq data. Up-
regulation of Srf target genes is evidenced in samples across all three categories. 
HCCA denotes Ctnnb1 wild type tumors, while HCCB denotes Ctnnb1 mutant 
tumors. Nodules stand for premalignant hyper-proliferative liver tissues. The 
color legend is the same as that used in Table 3-3. 
 
	
 
	
	
	
	
	
	
	
	
Gene	Symbol	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Ankrd1	 4.2	 3.2	 3.0	
Egr1	 5.9	 6.1	 6.2	
Egr2	 4.3	 4.0	 3.5	
Fhl3	 4.3	 4.7	 4.7	
Fos	 4.8	 3.6	 3.4	
Ier3	 4.2	 4.3	 4.6	
Tes	 4.0	 3.9	 3.5	
Thbs1	 4.1	 3.0	 5.8	
Atf3	 3.9	 3.9	 3.0	
Hk1	 2.2	 3.1	 2.4	
Acsl4	 2.1	 2.1	 2.6	
Actb	 1.3	 1.9	 1.9	
Ahnak	 2.1	 2.5	 3.0	
Bcl2	 2.9	 2.9	 2.9	
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	 The	 classical	 target	 genes	 of	SRF,	 namely	 Fos,	 Ier3,	 Thbs1,	 Egr1	 and	 Egr2,	were	
found	 highly	 up	 regulated	 in	 all	 the	 sample	 groups.	 The	 up-regulation	 of	 the	
abovementioned	genes	also	implies	cellular	hyper	proliferation	in	the	SRF-VP16iHep	liver	
tissues.	 Among	 all	 known	 SRF	 target	 genes,	 more	 than	 100	 transcripts	 were	 found	
significantly	 over-expressed	 in	 the	SRF-VP16iHep	 tissue.	 	 This	 suggests	 that	 the	 role	 of	
SRF-VP16	protein	during	malignant	transformation	is	not	limited	to	the	early	stages	of	
triggering	 hyper	 proliferation.	 The	 up-regulation	 of	 SRF	 target	 genes	 throughout	 the	
different	 stages	 of	 tumor	 progression	 emphasizes	 the	 role	 of	 SRF	 in	
hepatocarcinogenesis	of	the	SRF-VP16iHep	animal	model.	SRF	could	play	a	major	role	in	
hepatocarcinogenesis	 by	 modulating	 the	 metabolic	 pathways	 as	 well.	 The	 gene	Hk1	
encodes	 for	 the	 enzyme	 Hexokinase	 1	 which	 catalyzes	 the	 first	 step	 of	 glycolysis.	
Considering	the	general	 insight	that	cancer	cells	tend	to	feed	off	 from	glycolysis	more	
than	 normal	 cells,	 it	 may	 be	 speculated	 that	 SRF	 could	 play	 a	major	 role	 in	 various	
aspects	of	cancer	development,	including	cancer	cell	metabolism.	
3.9.3 Cell cycle regulation 
	 SRF-VP16iHep	 tumors	 and	 nodules	 show	 high	 up-regulation	 of	 genes	 associated	
with	the	cell	cycle.	Mitosis-related	genes	such	as	Aurka,	Cdk1,	Ccnb1	and	Ccnb2	are	all	
found	up	regulated	consistently	across	all	sample	groups.	The	expression	patterns	of	a	
selected	 list	 of	 mitosis–related	 genes	 observed	 in	 the	 RNAseq	 analysis	 are	 shown	 in	
Table	3-16.	The	up-regulation	of	kinases,	namely	Ttk,	Limk2,	Plk1	and	Cdk1,	 is	mirrored	
in	 multiple	 human	 tumors	 as	 well.	 The	 human	 TCGA	 data	 set	 was	 curated	 for	
expression	patterns	of	mitosis-related	genes	 in	various	human	cancers.	The	data	were	
downloaded	using	TCGA	Assembler	and	the	log	2	fold-changes	were	calculated	for	each	
dataset,	by	normalizing	against	the	control	samples.		Different	human	cancer	subtypes	
including	 breast	 adenocarcinoma,	 lung	 adenocarcinoma,	 cholangiocarcinoma,	
hepatocellular	 carcinoma	 and	 glioblastoma	 multiforme,	 showed	 over-expression	 of	
mitosis-related	 genes	 in	 a	 majority	 of	 the	 patient	 samples.	 The	 highest	 was	 in	
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cholangiocarcinoma,	 whereas	 the	 cancer	 showing	 lowest	 frequency	 of	mitosis-related	
genes	overexpression	was	prostate	adenocarcinoma.		
Table 3-16 Expression profiles of mitosis-related genes – RNAseq data. There is 
found a significant up regulation of mitosis related genes in samples across all 
groups. HCCA denotes Ctnnb1 wild type tumors, while HCCB denotes Ctnnb1 
mutant tumors. Nodules stand for premalignant hyper-proliferative liver tissues. 
The color legend is the same as that used in Table 3-3. 
gene_id	 Nodules	vs	Control	Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Cenpf	 3.25	 1.94	 3.31	
Ccnb1	 3.46	 2.59	 3.14	
Ttk	 2.99	 2.98	 3.17	
Ccna2	 2.64	 2.64	 2.48	
Limk2	 1.14	 1.20	 1.58	
Bub1	 3.13	 2.07	 2.20	
Plk1	 3.23	 2.77	 2.93	
Aurka	 1.42	 1.73	 1.37	
Cdk1	 3.34	 2.79	 3.20	
Cdkn3	 3.45	 2.92	 3.31	
Ccnb2	 4.28	 3.60	 3.91	
3.9.4 Metabolic reprogramming 
	 Alterations	in	the	regulation	of	numerous	metabolic	pathways	were	observed	in	
SRF-VP16iHep	samples.		
3.9.4.1 Glycolysis 
	 Glycolysis	 pathway	was	 one	 of	 the	 highly	 overexpressed	 pathways	 in	 the	 SRF-
VP16iHep	 samples.	Most	 of	 the	proteins	 involved	 in	 the	 glycolytic	 pathway	were	 found	
over	expressed	in	the	proteomics	data.	This	observation	was	complemented	well	by	the	
RNAseq	 data	 where	 a	 majority	 of	 the	 transcripts	 coding	 for	 enzymes	 or	 proteins	
involved	in	the	glycolysis	pathway	were	found	up	regulated.		The	Table	3-17	shows	a	list	
of	selected	genes	belonging	to	the	glycolytic	pathway	whose	protein	levels	were	found	
up	regulated.		
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Table 3-17: Glycolysis-related genes expression. Selected genes belonging to the 
glycolytic pathway found over-expressed in the SRF-VP16iHep tumors. The 
majority of entries in the table denote the protein expression levels whereas the 
entries for the genes Slc2a1 and Eno2 denote their transcript levels. HCCA 
denotes Ctnnb1 wild type tumors, while HCCB denotes Ctnnb1 mutant tumors. 
Nodules stand for premalignant hyper-proliferative liver tissues. The color legend 
is the same as that used in Table 3-3. 
Gene.names	 Nodules	vs	Control	
Log2	Fold	Change	
HCC	A	vs	Control	
Log2	Fold	Change	
HCC	B	vs	Control	
Log2	Fold	Change	
Hk1	 2.03	 2.69	 2.21	
Pfkp	 1.87	 3.12	 2.58	
Aldoa	 1.63	 1.80	 1.24	
Slc2a1*	 1.73	 2.05	 0.88	
Eno2*	 3.96	 4.41	 3.61	
Gapdh	 0.74	 1.22	 1.11	
Tpi1	 0.73	 1.42	 0.91	
Pgk1	 0.55	 0.72	 0.43	
Pgam1	 0.43	 0.26	 0.26	
Acsl4	 3.29	 3.38	 4.15	
Ldha	 1.14	 1.76	 1.52	
The	 higher	 representation	 of	 the	 glycolysis	 pathway	 members	 in	 SRF-VP16iHep	
samples	denotes	 that	 the	SRF-VP16iHep	HCCs	depend	 a	 lot	 on	 glycolysis	 for	 the	break	
down	 of	 glucose	 and	 energy	 synthesis.	 One	 of	 the	 end	 products	 of	 the	 glycolysis	
pathway	 is	 the	 metabolite	 pyruvate,	 which	 is	 either	 converted	 to	 lactate,	 or	 is	
transferred	to	the	citric	acid	cycle	
3.9.4.2 Citric acid cycle 
	 The	Citric	acid	cycle	(TCA	cycle)	is	one	of	the	major	metabolic	hubs,	functioning	
in	the	mitochondria.	It	is	the	main	acceptor	of	carbon	units	in	the	mitochondria,	and	in	
turn	 generates	 high-energy	 electrons	 (for	 ATP	 synthesis)	 and	 building	 blocks	 for	 e.g.	
fatty	 acid	 biosynthesis.	 The	 glycolysis	 pathway,	 glutaminolysis	 pathway	 and	 other	
amino	acids	catabolism	pathways,	feed	into	the	TCA	cycle	(Zong	et	al.,	2016).	The	TCA	
cycle	is	essential	for	the	mitochondrial	electron	transport	chain,	as	it	provides	electrons	
that	 facilitate	 the	 transfer	 of	 protons	 throughout	 the	 electron	 transport	 chain.	 In	 the	
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SRF-VP16iHep	mice	samples,	there	is	a	decrease	in	the	transcript	and	proteins	involved	in	
the	 TCA	 cycle.	 The	 genes	 encoding	 the	 succinate	 dehydrogenase	 enzymes,	 fumarate	
hydratase,	and	isocitrate	dehydrogenase,	were	under	expressed	at	the	transcript	level.		
	 It	 must	 be	 noted	 that,	 not	 only	 the	 TCA	 cycle,	 but	 also	 a	 majority	 of	
mitochondria-associated	components	are	also	found	down	regulated	in	the	RNAseq	and	
proteomic	 datasets.	 Gene	 set	 Enrichment	 analysis	 using	 the	 RNAseq	 and	 proteomics	
data	revealed	this	phenomenon	(Figure	3-42).	
Proteomics** RNAseq**
	
Figure 3-42: Gene set enrichment analysis (GSEA) of proteomics and RNAseq 
data – The GSEA analysis showed a significant down-regulation of transcripts 
and proteins associated with the mitochondria. 
	 The	majority	of	proteins	and	transcripts	of	the	mitochondria	are	down	regulated	
except	 the	 ones	 belonging	 to	 one	 particular	 pathway,	 the	 one-carbon	 metabolism	
pathway	 where	 the	 proteins	 and	 transcripts	 of	 the	 mitochondrial	 compartment	 are	
found	over-expressed.	
 3.9.4.3 One-carbon metabolism 
	 The	one-carbon	metabolism	(1C-metabolism)	is	an	important	metabolic	pathway	
as	it	is	involved	in	purine	and	thymidine	biosynthesis.	The	1C	metabolic	pathway	occurs	
primarily	in	the	cytoplasm.	However,	in	case	of	certain	cancers	it	has	been	noticed	that	
the	mitochondrial	components	of	the	pathway	are	highly	over-expressed	(Nilsson	et	al,	
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2014).	Serine	is	the	major	fuel	for	the	1C-metabolic	pathway,	however,	the	mitochondrial	
compartment	of	the	pathway	can	derive	1C-metabolites	from	glycine	as	well	(Locasale,	
2013).	The	mitochondrial	1C-metabolism	pathway	consists	of	4	main	proteins,	encoded	
by	the	genes	Shmt2,	Mthfd1l,	Mthfd2,	and	Aldh1l2.	They	were	all	found	up-regulated	in	
SRF-VP16iHep	samples.			
Table 3-18: Expression profiles of 1 C metabolism-related genes – RNAseq data. 
HCCA denotes Ctnnb1 wild type tumors, while HCCB denotes Ctnnb1 mutant 
tumors. Nodules stand for premalignant hyper-proliferative liver tissues. THe 
corresponding percentage of human HCC patients showing a similar pattern of 
deregulation is also shown. The color legend is the same as that used in Table 3-
3. 
Gene_Id	
Nodules	vs	
Control	
Log2	Fold	
Change	
HCC	A	vs	
Control	
Log2	Fold	
Change	
HCC	B	vs	
Control	
Log2	Fold	
Change	
Percentage	TCGA	Human		
HCCs	showing	
deregulation	%	
Mthfd1	 -1.87	 -2.39	 -2.21	 67.56	
Mthfd1l	 2.58	 3.10	 3.28	 67	
Mthfd2	 2.86	 4.44	 3.45	 17	
Shmt1	 -1.79	 -1.52	 -2.08	 70.24	
Shmt2	 -1.45	 -1.29	 -1.56	 24.66	
Aldh1l2	 2.22	 3.78	 3.07	 29	
 
3.10 Metabolomics analysis 
	 The	demographics	of	the	samples	subjected	to	metabolomics	analysis	are	given	
in	Table	3-19.	Metabolomics	analysis	was	done	 in	collaboration	with	MetaSysX	GmbH	
(Potsdam).	 Additional	 bioinformatic	 analysis	 of	 the	 metabolomics	 data	 was	 done	 by	
QBIC,	Tuebingen.		
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Table 3-19: Sample Demographics - Metabolomics analysis. 
Category	 Type	 Sample	#	 Mouse	#	
Gender	 Male	 11	 6	Female	 11	 6	
Sample	type	 Controls	 3	 4	Nodules	 3	 5	HCC	 3	 3	Age	 Median	Age	(weeks)	 27	weeks		
LWBW	ratio	 Average	LWBW	ratio	(HCCs	&	Nodules)	 27.84%	
	 Various	metabolites	and	lipids	were	found	differentially	expressed	in	the	tumors	
and	 nodules	when	 compared	 to	 the	 control	 liver	 samples.	 A	 list	 of	 up-regulated	 and	
down-regulated	metabolites	 in	 the	 nodules	 and/or	 the	 tumor	 samples	 is	 displayed	 in	
Table	3-20.		
The	metabolite	S-Adenosyl-L-homocysteine	(SAH)	was	found	down	regulated	in	
the	SRF-VP16iHep	samples.	In	certain	liver	cancer	mouse	models,	SAH	was	found	highly	
over-expressed.	The	ratio	between	SAH	and	S-	Adenosyl-Methionine	(SAM)	is	a	known	
marker	 for	 methylation	 profile	 changes	 associated	 with	 various	 diseases,	 including	
cancer	and	cardiovascular	diseases	(Caudill	et	al.,	2001;	Zhang	et	al.,	2016b).		The	under-
expression	of	glutamine	is	also	interesting,	given	the	context	of	glutaminolysis	feeding	
into	the	TCA	cycle,	which	is	found	down-regulated	in	SRF-VP16iHep	samples.	
	 Functional	 classification	 and	 further	 scrutiny	 of	 the	metabolites	 is	 required	 to	
reveal	 potentially	 interesting	 insights	 into	 metabolic	 changes	 associated	 with	
hepatocarcinogenesis	in	SRF-VP16iHep	mice.		
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Table 3-20: Up-regulated and down-regulated metabolites. Metabolomics 
analysis. Indicated are metabolites that were found differentially displayed in the 
nodules and/or tumors.  
 
Up	regulated	Metabolites	 Down	regulated	Metabolites	
Fructose	 Adenosine	5prime-phosphate	
Xanthine	 N-Acetylglutamic	acid	
Pantothenic	acid	(Vitamine	B5)	 Xanthosine	
L-Tyrosine	 Uridine	5prime-monophosphate	
Adenosine-5-monophosphate	 Uric	acid	
O-Acetyl-L-carnitine	 L-Glutamine	
Citric	acid	 Glycerophosphate	
Cytidine	 Xanthine	
Idose	 Cysteine	
Indole-3-lactic	acid	 Cystine	
Cytidine	3prime-phosphate	
Pyridoxal-5prime-
monophosphate	
4-Guanidinobutyric	acid	 S-Adenosyl-L-homocysteine	
O-Acetyl-L-homoserine	 Deoxyguanosine		diphosphate	
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4 DISCUSSION 
	 The	 SRF-VP16iHep	mouse	 strain	 proved	 a	 highly	 useful	 model	 for	 the	 study	 of	
hepatocellular	 carcinoma.	 In	 the	 present	 study,	 the	 HCCs	 occurring	 in	 SRF-VP16iHep	
mice	 have	 been	 characterized,	 along	 with	 premalignant	 hyper-proliferative	 nodular	
tissues.	To	this	end,	a	combined	multi-omics	approach	has	been	undertaken,	in	order	to	
study	 the	 various	 molecular	 events,	 as	 detected	 by	 different	 omics	 technology	
platforms,	collectively	involved	in	hepatocarcinogenesis	in	SRF-VP16iHep	murine	livers.		
4.1 Insights obtained from the present study 
4.1.1  Mosaic hepatocyte expression of SRF-VP16 establishes 
a cellular platform for initiation and progression of HCC 
formation in mice 
	 SRF-VP16iHep	 mice	 carry	 the	 SRF-VP16	 and	 Alfp-CreERT2	 transgenes	 in	 their	
genome,	along	with	the	Srf-flex1	 transgene.	Activation	of	the	Cre	recombinase	induces	
SRF-VP16	 transgene	 expression	 upon	 recombination-mediated	 deletion	 of	 a	 STOP	
cassette	flanked	by	LoxP	sites.		The	presence	of	the	STOP	cassette	prevents	spontaneous	
expression	 of	SRF-VP16	 transgene	 in	 the	 absence	 of	 active	Cre.	However,	 as	 reported	
earlier	 (Ohrnberger*,	 Thavamani*,	 et	 al.,	 2015),	 leakiness	 of	 Cre	 recombinase	 activity	
results	in	sporadic	SRF-VP16	activation	in	a	small	number	of	hepatocytes	in	the	absence	
of	 the	 inducer	 tamoxifen.	 This	 triggers	 a	 cascade	 of	 events,	 including	 hyper-
proliferation	 of	 SRF-VP16-expressing	 hepatocytes.	 This	 ultimately	 leads	 to	 HCC	
formation	 in	 the	 livers	 of	 SRF-VP16iHep	 mice.	 It	 must	 be	 noted	 that	 SRF	 was	 first	
identified	as	a	transcription	factor	that	regulates	the	expression	of	various	proliferation-
associated	genes,	 including	the	family	of	 immediate	early	response	genes	(IEGs)	(Chai	
and	Tarnawski,	2002).		Thus,	it	can	be	concluded	that	–	at	least	in	hepatocytes	-	SRF	has	
a	vital	proliferative	function.	The	knockout	of	Srf	in	early	embryonic	stages	was	shown	
to	 hinder	 developmental	 processes	 (Schratt	 et	 al.,	 2001).	 In	 contrast,	 upon	 SRF-VP16	
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expression,	 numerous	 genes	 associated	 with	 cell	 proliferation	 were	 found	 activated.	
These	 include	the	Egr1,	Egr2	and	c-fos	genes.	Activation	of	 these	genes	 likely	causes	a	
continuous	 proliferative	 stimulus	 to	 be	 exerted,	 resulting	 in	 hepatocyte	 hyper-
proliferation.	 Proliferative	 stress	 can	 result	 in	 the	 accumulation	 of	 replication	 errors,	
DNA	damage,	and	genomic	instability.	Furthermore,	hyper-proliferation	of	SRF-VP16iHep	
hepatocytes	 resulted	 in	 changes	 in	 the	 expression	 levels	 of	 genes	 regulating	 the	 cell	
cycle.	This	situation	can	additionally	 favor	the	occurrence	of	mutations	 in	the	cellular	
genome.	The	 observed	 alterations	 in	 gene	 expression	profiles,	 in	 association	with	 the	
multitude	of	mutations	identified	in	our	WES	analysis,	are	best	explained	by	a	cancer-
promoting	 scenario	 that	 is	 based	 on	 hepatocyte	 hyper-proliferation.	We	 also	 found	 a	
significant	overexpression	of	SRF	target	genes,	even	 in	the	early	nodular	samples.	The	
expression	levels	of	the	SRF	target	genes	continued	to	remain	high	even	at	the	terminal	
tumor	 stages	 (HCCA	 and	 HCCB).	 This	 indicated	 the	 importance	 SRF-VP16	
transcriptional	 activity	 throughout	 the	 hepatocarcinogenesis	 process,	 in	 order	 to	
provide	 a	 platform	 for	 cancer	 development	 via	 accumulating	 additional	 pro-
carcinogenic	mechanisms.		
	 It	 must	 be	 noted	 that	 similar	 scenarios	 of	 transcription	 factor-driven	
carcinogenesis	 have	 been	 reported	 previously.	 A	 transgenic	 mouse	 was	 reported,	 in	
which	 expression	 of	 the	Myc	 gene	 gave	 rise	 to	 HCCs	 (Murakami	 et	 al.,	 1993).	 The	
heterozygous	Myc	 transgenic	 mice	 were	 crossed	 with	 homozygous	 TGFα	 transgenic	
mice,	the	TGFα	transgene	being	driven	by	the	metallothionein	promoter.	These	double	
transgenic	mice	were	found	to	develop	HCCs	at	a	penetrance	of	20%	at	5	months	of	age	
and	a	penetrance	of	100	%	at	8	to	10	months	of	age	(Fausto	and	Campbell,	2010).	
Transcription	 factor-induced	 liver	 carcinogenesis	 has	 been	 reported	 before	
(Heindryckx	 et	 al.,	 2009).	 However,	 SRF-VP16iHep	mice	 are	 unique	 in	 their	 ability	 to	
cause	tumors	with	a	100%	penetrance.	This	strongly	suggests	a	more	general	role	of	SRF	
and	SRF-directed	target	genes	in	cancer	formation.		
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4.1.2  The step-wise progression of HCCs starting from early 
stages can be studied in detail using SRF-VP16iHep mice. 
	 The	chosen	multi-omic	approach	to	study	the	SRF-VP16iHep	mice	has	enabled	the	
investigation	of	early,	pre-malignant	stages	of	HCC	development.	The	nodular	samples	
present	a	unique	sample	set	that	enables	the	study	of	the	early	events	occurring	during	
liver	 carcinogenesis.	 In	 the	 current	 study,	 numerous	 events	 were	 identified	 at	 the	
genomic,	transcriptomic	and	proteomic	levels	that	were	exclusive	to	the	early	nodular	
stages.	The	number	of	deregulation	events	exclusively	observed	in	the	nodular	stage	was	
far	lower	than	those	observed	in	the	tumors.		This	indicated	a	principle	of	accumulation	
of	 transformation-inducing	 events	 at	 successive	 stages	 of	 tumor	 progression.	
Dysregulation	of	 certain	genes,	 e.g.	Moxd1,	 Slco1a1,	 Saa1,	 Saa2,	 Clec2h,	 C8a	 and	 Krt23,	
was	 observed	 at	 the	 nodular	 stage	 only.	 Subsequently,	 these	 genes	 were	 not	
differentially	expressed	in	the	tumors;	in	some	cases	they	were	even	down-regulated	in	
the	 tumors,	as	was	 the	case	 for	Slco1a1.	The	Slco1a1	gene	belongs	 to	 the	Solute	carrier	
organic	 anion	 transporter	 family.	 It	 has	 been	 shown	 to	 be	 over-expressed	 in	 certain	
disease	 conditions	 in	 the	 liver.	 It	 has	 been	 associated	 with	 acute	 liver	 congestion	
(Shimizu	et	al.,	2015).		
	 Other	 genes	 showed	 similar	 deregulated	 expression	 patterns	 at	 early	 stages	 of	
hyper-proliferation,	which	might	have	tumor	suppressive	functions	in	the	SRF-VP16iHep	
liver.	The	SRF-VP16iHep	mice	provide	a	tool	for	studying	these	early	stage	events	of	HCC	
progression.	 The	 value	 of	 such	 premalignant	 nodular	 samples	 for	 studying	 the	
pathogenesis	 of	 the	 liver	 cancer	 has	 been	 realized	 by	 others.	 In	 one	 such	 example,	 8	
human	HCC	 patients	 from	Mainz	 (Germany)	were	 characterized	 by	 the	 group	 of	Dr.	
Jens	Marquardt	(Fausto	and	Campbell,	2010;	Marquardt	et	al.,	2014).	The	data	generated	
in	this	study	was	compared	with	the	SRF-VP16iHep	data.	The	advanced	stage	tumors	from	
3	patients	clusters	closer	to	the	mHCCs.	Interestingly	the	nodule	samples	of	the	mouse	
clustered	close	to	the	advanced	HCC	samples	of	human	patients.	This	implies	that	the	
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nodule	stages	of	SRF-VP16iHep	mice	already	show	features	similar	to	those	of	advanced	
stages	in	humans.	The	presence	of	samples	from	early	malignancy	stages	could	result	in	
the	identification	of	biomarkers	that	might	be	used	for	early	detection	of	liver	cancer	in	
human	patients.	Moreover,	 the	 premalignant	 samples	 provide	 a	 tool	 for	 the	 develop-
ment	of	therapeutic	modalities	at	early	stages	of	the	disease	when	it	 is	more	tractable	
compared	to	the	later	stages.	Thus,	the	pre-malignant	nodular	samples	can	serve	as	an	
experimental	tool	for	studies	regarding	detection	of	early	biomarkers	and	also	regarding	
development	of	therapeutic	modalities	for	early-detected	cancer	patients.	
4.1.3  Multiple mechanisms are involved in the progression of 
HCCs in SRF-VP16iHep murine livers 
	 The	 step-wise	 progression	 of	HCCs	 in	 the	SRF-VP16iHep	 livers	was	 paralleled	 by	
cumulative	activation	of	molecular	mechanisms	supporting	tumor	growth.	A	synergism	
of	 various	 mechanisms	 appears	 to	 be	 involved	 in	 the	 progression	 of	 SRF-VP16iHep	
tumors.	Some	of	the	different	mechanisms	suggested	by	the	present	study	are	discussed	
in	the	following.		
 4.1.3.1 Mitosis 
	 Genes	and	proteins	associated	with	cell	 cycle	 control	 and	 regulation	of	mitosis	
were	 found	 to	 be	 up-regulated	 in	 the	 samples	 obtained	 from	 SRF-VP16iHep	 livers.	 The	
mitosis-associated	genes	were	also	found	up-regulated	in	various	human	cancers	(TCGA	
data),	 such	 as	 lung	 adenocarcinoma,	 breast	 adenocarcinoma,	 brain	 cancer	 and	 liver	
cancers.	 	The	mitosis-associated	genes	that	are	found	up-regulated	in	the	SRF-VP16iHep	
HCCs	include	Cenpf,	Ccnb1,	Ccnb2,	Ttk,	Limk2,	Bub1,	Plk1,	Aurka	and	Cdk1	among	others.	
Interestingly,	a	few	of	the	genes	are	considered	direct	target	genes	of	SRF.		
 4.1.3.2 Wnt signaling pathway 
	 The	Wnt	signaling	pathway	is	also	found	activated	in	some	SRF-VP16iHep	tumors.		
β-Catenin	 is	 one	 of	 the	 downstream	 effector	 proteins	 of	Wnt	 signaling	 pathway.	 The	
gene	coding	for	the	β-Catenin	protein,	the	Ctnnb1	gene,	is	found	mutated	in	a	subset	of	
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SRF-VP16iHep	tumors;	such	tumors	were	 labeled	HCCB.	The	observed	mutations	can	be	
considered	activating	(gain-of-function)	mutations,	resulting	in	the	stabilization	of	the	
β-Catenin	 protein.	 This	 subsequently	 results	 in	 the	 Wnt	 signaling	 pathway	 being	
consistently	active.	RNAseq	analysis	on	the	SRF-VP16iHep	tumors	revealed	that,	in	HCCB	
tumors,	 indeed	 numerous	 target	 genes	 of	 the	 Wnt	 signaling	 pathway	 were	 over-
expressed.	Thus,	the	Wnt	signaling	pathway	is	found	to	be	actively	contributing	to	the	
tumor	growth	in	a	subset	of	SRF-VP16iHep	tumors.	
 4.1.3.3 Hippo signaling pathway 
	 The	Hippo	signaling	pathway	is	a	major	regulator	of	vital	cellular	functions	such	
as	 proliferation,	 differentiation,	 growth	 and	 cell	 death.	 The	 pathway	 is	 basically	 a	
cascade	of	kinase	activities	resulting	ultimately	in	the	transcription	regulation	of	target	
genes,	 via	 activation	 of	 the	 transcription	 factors	 TEAD1	 to	 TEAD4,	 as	 well	 as	 their	
partner	 proteins	 YAP/TAZ.	 In	 the	 SRF-VP16iHep	 tumors,	 a	 large	 proportion	 of	 Hippo	
signaling	 pathway	 target	 genes	 were	 found	 over-expressed,	 including	 such	 as	 Loxl4,	
Ccnb2,	Foxm1,	Psat1,	Dusp9,	and	Tmem171,	among	others.	The	over-expression	was	also	
observed	 at	 the	 proteomics	 level,	 with	 a	 significant	 number	 of	 proteins,	 encoded	 by	
Hippo	target	genes,	being	overexpressed	such	as	the	proteins	encoded	by	Myh10,	Myh9,	
Aldoa,	Bub3,	Fus,	Ranbp1,	Rangap1,	Ywhaz	and	Crip1	among	others.	Interestingly,	it	has	
been	 speculated	 that	 the	 proteins	 YAP/TAZ,	 which	 are	 the	major	 modulators	 of	 the	
Hippo	 signaling	 pathway,	 can	 also	 interact	 with	 SRF	 to	 regulate	 the	 transcription	 of	
various	 target	genes	 (Liu	et	al.,	2016).	The	results	 from	our	current	study	also	suggest	
that	some	of	the	target	genes	of	Hippo	signaling	may	indeed	be	regulated	by	SRF.		
 4.1.3.4 MAPK signaling pathway 
	 The	 MAPK	 signaling	 pathway	 is	 an	 activator	 of	 SRF-mediated	 transcriptional	
activation.	 The	 MAPK	 signaling	 pathway	 is	 activated	 in	 a	 variety	 of	 tumors.	 The	
constitutively	active	SRF-VP16	protein	can	regulate	 target	genes	of	MAPK	signaling	 in	
the	absence	of	partner	protein	activation.	Thus,	 the	expression	profile	of	SRF-VP16iHep	
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tumors	 has	 shown	 considerable	 overlap	 with	 the	 gene	 expression	 profiles	 of	 ras-
mediated	tumors.			
 4.1.3.5 Nanog signaling pathway 
	 Nanog	is	a	transcription	factor,	which	is	known	to	be	associated	with	stem	cell	
features	 in	 cells.	Nanog	 itself	 is	 known	 to	 be	 a	 stem	 cell	marker	 protein	 (Jeter	 et	 al.,	
2015).	Our	RNAseq	analysis	 revealed	 that	 a	 large	number	of	Nanog	 target	 genes	were	
found	over-expressed	 in	 the	SRF-VP16iHep	tumors.	Examples	 include	Acsl4,	 Foxj1,	 Cdh1,	
Rab15,	 Anxa1,	 Alcam,	 Nfe2l3	 and	 Bcas1	 among	 others.	However,	 Nanog	 itself	 was	 not	
differentially	 regulated.	 This	 suggests	 the	 presence	 of	 alternative	 regulatory	
mechanisms	 for	 Nanog	 target	 genes	 in	 SRF-VP16iHep	 tumors.	 It	 is	 known	 that	 Nanog	
expression	 generally	 is	 inversely	 proportional	 to	 the	 β-Catenin	 expression,	 wherein	
Nanog	 is	 known	 to	 stimulate	 β-Catenin	 phosphorylation	 and	 subsequent	 ubiquitin-
mediated	 proteasomal	 degradation	 (Cheng	 et	 al.,	 2015).	 In	 SRF-VP16iHep	 tumors,	 both	
these	signaling	pathways	seem	to	be	active.	This	highlights	the	inherent	heterogeneity	
of	SRF-VP16iHep-derived	tumors.	
4.1.4  SRF-VP16iHep HCCs show heterogeneous molecular 
features 
	 The	 heterogeneity	 of	 liver	 tumors,	 especially	 HCCs,	 continues	 to	 be	 a	 major	
challenge	 for	 determining	 treatment	 modalities	 specifically	 suited	 for	 an	 individual	
patient.	SRF-VP16iHep	tumors	also	show	a	high	degree	of	heterogeneity.	WES	analysis	of	
different	SRF-VP16iHep	tumors,	occurring	in	the	same	liver	tissue,	showed	highly	varying	
mutation	 profiles.	 Significant	 molecular	 differences	 were	 displayed	 by	 the	 different	
tumors,	although	they	arose	within	the	same	liver.	This	indicates	that	each	tumor	may	
have	had	its	unique	path	towards	malignant	transformation	during	tumor	progression.	
This	 observation	 also	 indicates	 that,	 at	 the	 genomic	 level,	 the	 various	 alterations	
observed	were	 not	 directly	 caused	 by	 SRF-VP16	 expression.	 The	 heterogeneity	 of	 the	
HCCs	 characterized	 reflects	 the	 characteristic	 feature	of	human	HCCs	 also	displaying	
high	molecular	heterogeneity.	Due	to	their	heterogeneity,	human	HCCs	were	classified	
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into	sub-categories	(Boyault	et	al.,	2007)	in	order	to	achieve	a	better	understanding	of	
the	etiologies	and	therapeutic	responses	of	individual	HCCs.		
 4.1.4.1 Classification of human HCCs 
		 There	have	been	significant	efforts	to	classify	human	HCCs.	One	such	attempt	to	
classify	 human	HCCs	was	 put	 forth	 by	 Boyault	 et	 al.	 in	 2007.	 This	 classification	was	
based	on	gene	expression	profiles	of	the	tumor	samples.	The	classification	consisted	of	6	
different	 sub-categories	 namely	 G1	 –	 G6.	 In	 this	 study,	 the	 SRF-VP16iHep	 tumors	 were	
subjected	to	this	classification	and	were	found	to	overlap	most	closely	with	the	G1/G2	
sub-class	of	human	HCC.	The	CTNNB1	mutant	human	tumors	were	classified	under	the	
G6	category.	In	the	SRF-VP16iHep	tumors,	we	found	molecular	features	corresponding	to	
both	G1/G2	and	G6.	This	indicates	molecular	heterogeneity	of	the	SRF-VP16iHep	tumors.	
Recent	advances	in	genome-wide	technologies	can	be	expected	in	the	future	to	assist	a	
more	 refined	 characterization	 of	 human	 HCCs.	 Our	 multi-omic	 analysis	 of	 the	 SRF-
VP16iHep	mouse	model	might	 support	 the	 efforts	 currently	 being	 taken	 in	 the	 human	
cancer	 clinic.	 	 Comprehensive	 datasets,	 such	 as	 the	 human	 cancer	 genome	 atlas	
(TCGA),	which	contain	information	at	multiple	omics	levels,	will	aid	the	formulation	of	
the	best	possible	tumor	classification	strategy.	Mouse	models,	such	as	the	SRF-VP16iHep	
line,	can	also	be	expected	to	support	these	efforts.			
4.1.5  SRF-VP16iHep tumors closely resemble a subset of human 
HCCs 
	 Comparative,	 unsupervised	 hierarchical	 clustering	 of	 SRF-VP16iHep	 mouse	 and	
human	 tumor	 was	 performed.	 This	 revealed	 that	 the	 SRF-VP16iHep	 samples	 clustered	
closely	to	a	subset	of	human	HCCs.	For	example,	in	the	dataset	from	the	HD-40	cohort	
of	human	patients,	a	subset	of	 10	HCCs	clustered	closely	with	our	mouse	samples	(SC	
10).	These	10	HCCs	were	further	characterized	and	similarities	were	observed	in	terms	of	
the	molecular	characteristics	of	both	human	and	murine	tumors.	For	example,	most	of	
the	 SC	 10	 tumors	were	 over-expressing	 the	 IGF2	 gene.	 The	murine	 ortholog	 Igf2	was	
found	highly	over-expressed	in	SRF-VP16iHep	tumors	as	well.	Further	clustering	analyses	
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with	 multiple	 other	 datasets	 also	 showed	 the	 presence	 of	 specific	 subsets	 of	 human	
HCCs	that	bore	striking	molecular	similarities	to	the	SRF-VP16iHep	tumors.		
4.1.6  Key metabolic pathways are altered in SRF-VP16iHep 
HCCs 
	 Numerous	metabolic	 pathways	were	 found	 altered	 in	 the	SRF-VP16iHep	 tumors.	
One	 example	 is	 the	 glycolysis	 pathway.	Genes	 and	proteins	 of	 the	 glycolysis	 pathway	
were	found	highly	overexpressed	in	the	SRF-VP16iHep	 tumors.	The	initiating	enzyme	of	
the	pathway	Hexokinase	1	is	encoded	by	the	gene	Hk1,	which	is	an	SRF	target	gene.	The	
enzymes	 involved	 in	 subsequent	 steps	 of	 glycolysis	were	 all	 found	 up-regulated.	 This	
indicates	aerobic	glycolysis	to	be	at	work	in	SRF-VP16iHep	tumors,	a	phenomenon	called	
“Warburg	 effect”.	 Glycolysis	 generates	 pyruvate,	 which	 feeds	 the	 mitochondrial	 TCA	
cycle.	However	 in	the	SRF-VP16iHep	 tumors,	 the	TCA	cycle	enzymes	were	found	highly	
down-regulated.	This	is	in	line	with	pyruvate	being	converted	into	lactate,	as	is	the	case	
in	 aerobic	 glycolysis.	 Many	 other	 mitochondrial	 enzymes	 were	 also	 found	 down	
regulated	 at	 the	mRNA	or	 protein	 levels.	As	 a	notable	 exception,	 the	 genes	 encoding	
mitochondrial	 enzymes	 of	 the	 one-carbon	 metabolism	 (1C-metabolism)	 were	 found	
over-expressed,	at	the	expense	of	their	cytoplasmic	counterparts.	This	seems	to	indicate	
that	 the	 SRF-VP16iHep	 tumors	 efficiently	 engage	 in	 mitochondrial	 1C-metabolism.	 In	
support,	 given	 that	 serine	 is	 required	 for	 the	 1C-metabolic	 pathway,	 the	 enzymes	
involved	 in	 the	 serine	 synthesis	 pathway	 are	 also	 found	 up-regulated	 (at	 both	 the	
transcriptomic	and	proteomic	 levels).	Thus,	 considerable	metabolic	 reprogramming	 is	
occurring	in	SRF-VP16iHep	HCCs.	
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4.2 Future Perspectives 
4.2.1 Usage of SRF-VP16iHep mouse line 
	 The	SRF-VP16iHep	mouse	model	promises	to	represent	an	apt	tumor	model	for	the	
study	 of	 human	HCC.	This	may	 be	 particularly	 true	 for	 the	G1/G2	 subtype	 of	 human	
HCC.	 	 The	 SRF-VP16iHep	 mouse	 line	 can	 be	 used	 for	 the	 study	 of	 other	 molecular	
features	 of	 liver	 tumors,	 such	 as	 cellular	 interactions	 within	 the	 tumor	
microenvironment,	 epigenetic	 regulation	 of	 cancer	 formation,	 metabolic	
reprogramming,	 and	 others.	 The	mouse	 line	 could	 be	 used	 for	 the	 testing	 of	 various	
drugs	 targeting	 specific	 pathways	 that	 are	 highly	 dysregulated	 in	 liver	 cancer,	
specifically	HCC.				
4.2.2 Drug development for HCC treatment 
	 There	is	an	urgent	need	for	new	drugs	in	targeted	therapy	of	human	HCC.	The	
use	of	mouse	models	such	as	SRF-VP16iHep	promise	to	suit	such	needs.	The	multi-omics	
characterization	of	the	SRF-VP16iHep	mouse	tumors	has	revealed	significant	insights	into	
molecular	 mechanisms	 involved	 in	 hepatocarcinogenesis	 at	 various	 stages	 of	 tumor	
progression.	 These	 insights	 will	 support	 the	 identification	 of	 new	 therapeutic	 targets	
and	of	drugs	affecting	such	target	activities.	
4.2.3 Effect of SRF-VP16 activation in other cell types and 
organs. 
	 Having	 observed	 the	 effect	 upon	 expression	 of	 SRF-VP16	 in	 hepatocytes	 has	
given	rise	to	a	new	scope	of	developing	mouse	models	 for	various	cancers	 in	different	
cell	types.	By	following	approaches	comparable	to	SRF-VP16iHep	 tumor	formation,	SRF-
VP16iPan	mice	could	be	generated,	which	express	the	SRF-VP16	transgene	in	fibroblasts	of	
the	pancreas.	This	could	help	unravel	the	role	of	SRF	in	carcinogenesis	of	other	tumor	
entities.		
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μL	 Microliters	
A2m	 alpha-2-macroglobulin		
Acsl4	 acyl-CoA	synthetase	long-chain	family	member	4		
Acss3	 acyl-CoA	synthetase	short-chain	family	member	3		
Actb	 actin,	beta		
Afp	 alpha	fetoprotein		
Ahnak	 AHNAK	nucleoprotein	(desmoyokin)		
Aldh1a2	 aldehyde	dehydrogenase	family	1,	subfamily	A2		
Aldh1l2	 aldehyde	dehydrogenase	1	family,	member	L2		
Alfp	 Alpha	fetoprotein	
Ankrd1	 ankyrin	repeat	domain	1	(cardiac	muscle)		
Ap	1	 Activator	protein	-1	
ASC	 apoptosis	associated	speck	like	protein	
Atf3	 activating	transcription	factor	3		
ATF5.	 Activating	Transcription	Factor	5	
ATP	 Adenosine	Tri	phospate	
Aurka	 aurora	kinase	A		
Axin2	 axin2		
BAC		 Bacterial	Artificial	Chromosomes		
Bcl2	 B	cell	leukemia/lymphoma	2		
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Bex1	 brain	expressed	gene	1		
bp	 base	pairs	
Bub1	 budding	uninhibited	by	benzimidazoles	1	homolog	(S.	cerevisiae)		
c-fos	 FBJ	murine	osteosarcoma	
CCl4		 Carbon	tetrachloride		
Ccna2	 cyclin	A2		
Ccnb1	 cyclin	B1		
Ccnb2	 cyclin	B2		
CCND1			 Cyclin	D1	
Cd63	 CD63	antigen		
cdh1	 E-cadherin	
Cdh2	 N-cadherin		
Cdk1	 cyclin-dependent	kinase	1		
Cdkn3	 cyclin-dependent	kinase	inhibitor	3		
cDNA	 circular	DNA	
Cenpf	 centromere	protein	F		
cox2	 Cytochrome	c	oxidase	2	
Cpe	 carboxypeptidase	E		
DEN		 N-nitrosodiethylamine		
DLC1	 deleted	in	liver	cancer	1		
DMSO	 Dimethyl	sulfoxide	
DNA	 Deoxyribonucleic	acid	
Dnmt1	 DNA	methyltransferase	(cytosine-5)	1		
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dNTPs	 Nucleoside	tri	phosphates	
EDTA	 Ethylendiaminetetraacetate	
Egr1	 early	growth	response	1		
Egr2	 early	growth	response	2		
Elk-1	 Ets	like	gene	1	
EMT	 Epithelial-to-mesenchymal	transition	
Eno2	 enolase	2,	gamma	neuronal		
ER	 Estrogen	Receptor	
FBPs				 Far	upstream	element	binding	proteins		
fgf19	 fibroblast	growth	factor	19	
Fhl3	 four	and	a	half	LIM	domains	3		
flex1	 floxed	exon	1	
Fos	 FBJ	osteosarcoma	oncogene		
FOXM1			 Forkhead	box	M1B		
FSP	 fibroblast	specific	protein		
Gldn	 gliomedin		
Gls2	 glutaminase	2	(liver,	mitochondrial)		
H19	 NA	
HBV	 Hepatitis	B	virus	
HCC	 Hepatocellular	carcinoma		
HCl	 Hydrochloric	acid	
HCV	 Hepatitis	C	virus	
HIF1	 Hypoxia-inducible	factor	1	
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Hk1	 hexokinase	1		
HOP	 Homeobox	Protein		
IARC		 International	Agency	on	Cancer		
ICC	 Intrahepatic	cholangiocarcinoma		
IEGs	 Immediate	early	genes	
Ier3	 immediate	early	response	3		
IFN	γ	 Interferon	γ	
IFNα	 interferon	α		
Igf2	 insulin-like	growth	factor	2		
IMAC			 immobilized	metal	ion	chromatography		
Inhbe	 inhibin	beta	E		
IR	 insulin	resistance	
Itga6	 integrin	alpha	6		
LC	 Liquid	Chromatography	
Lgr5	 leucine	rich	repeat	containing	G	protein	coupled	receptor	5		
Limk2	 LIM	motif-containing	protein	kinase	2		
Lipg	 lipase,	endothelial		
LoxP	 Locus	of	X-over	P1	
Lpl	 lipoprotein	lipase		
LWBW	 Liver	Weight	to	Body	Weight	ratio	
MAPK	 Mitogen	activated	protein	kinase	
MET	 Mesenchymal-to-epithelial	transition	
miRNA	 MicroRNA	
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Mt	 Mutant	
Mthfd1	
methylenetetrahydrofolate	 dehydrogenase	 (NADP+	 dependent),	
methenyltetrahydrofolate	cyclohydrolase,	formyltetrahydrofolate	synthase		
Mthfd1l	 methylenetetrahydrofolate	dehydrogenase	(NADP+	dependent)	1-like		
Mthfd2	
methylenetetrahydrofolate	 dehydrogenase	 (NAD+	 dependent),	
methenyltetrahydrofolate	cyclohydrolase		
Mup3	 major	urinary	protein	3		
Peg3	 paternally	expressed	3		
Pfkp	 phosphofructokinase,	platelet		
Plk1	 polo-like	kinase	1		
Psat1	 phosphoserine	aminotransferase	1		
Raet1d	 retinoic	acid	early	transcript	delta		
Shmt1	 serine	hydroxymethyltransferase	1	(soluble)		
Shmt2	 serine	hydroxymethyltransferase	2	(mitochondrial)		
Slc15a5	 solute	carrier	family	15,	member	5		
Slc2a1	 solute	carrier	family	2	(facilitated	glucose	transporter),	member	1		
SNA1	 Snail	
SNA2	 Slug	
Sox9	 SRY	(sex	determining	region	Y)-box	9		
Suox	 sulfite	oxidase		
Tes	 testis	derived	transcript		
TGFβ	 transforming	growth	factor	β	
Thbs1	 thrombospondin	1		
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Timp1	 tissue	inhibitor	of	metalloproteinase	1		
Tspan8	 tetraspanin	8		
Ttk	 Ttk	protein	kinase		
Vil1	 villin	1		
Wt		 Wild	type	
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Murine Hepatocellular Carcinoma (HCC) triggered by dysregulated Serum 
Response Factor (SRF)  
Abhishek Thavamani, Stefan Ohrnberger, Alfred Nordheim* 
Interfaculty Institute for Cell Biology 
*alfred.nordheim@uni-tuebingen.de 
Gene Ontology Clustering Analysis: - 
•  Activations of SRF or other  downstream transcription factors  
could be the initiation driver event in tumors  could explain drug  
resistance and tumor recurrence too. 
•  Mutations and other genomic alterations could be progressive  
driver events acquired later on to assist  in proliferation.  
•  Considering the presence of SRF binding sequence in genes like  
Igf2, Ins2, and Igf2als, SRF could have implications in diabetes and  
a wide range of other diseases as well. 
•  Results could infer a much greater role of metabolism  in cancer 
development and progression.  
•  The SRF-VP16iHep mouse line could serve as a platform  to study 
the mechanism behind the various characteresics of tumours 
 - Both Igf2 and H19 are highly up-regulated in our dataset and also      
have SRF-binding sites close to their promoters. 
-  Both genes are regulated inversely to each other due to the 
presence of an imprinting loci in between. Methylation at this site 
switches gene regulation.  
-  Igf2 and H19 have a canonical and non-canonical SRF-binding  
sequence near to their promoters respectively. 
Abstract 
Serum Response Factor (SRF)  
 Hepatocellular carcinoma (HCC) is the one of the most 
lethal types of human carcinoma. One of the remarkable 
features of HCC progression is the accumulation of 
numerous genomic alterations, owing to various 
mutagenic insults leading to HCC (e.g. viral infection, liver 
cirrhosis and chemical exposure). However, the initiating 
driver events that instigate malignant transformation and 
the subsequent tumor progression driver events are not 
well-defined as yet. Here, I propose to track the initiation 
and progression of HCC using the SRF-VP16iHep mouse 
line, which displays controlled expression of a constitutive 
active version of the transcription factor Serum Response 
Factor (SRF-VP16). SRF-VP16 expression in murine 
hepatocytes causes HCC formation. This mouse cancer 
model allows the identification of genomic alterations 
associated with oncogenic transformation and progression 
to malignant liver cancer.  
Introduction 
(Schratt et.al, 2002) 
412 492 
VP16-
-TAD 
SRF-VP16iHep mouse line 
CRE ERT2 
albumin – 
enhancer and 
promoter 
hGH  
polyA 
alpha-fetoprotein 
enhancer 
Previous Work 
Results 
Mutation Analysis 
Gene CTNNB1 TP53 
Status Mt Wt Mt Wt 
Samples 10 8 0 18 
Total 18 18 
T41I S37F G34R D32Y 
 - CTNNB1 gene mutations detected in 55% of tumours upon 
sequencing by Sanger’s method 
 - No mutations detected in TP53 gene 
 - All detected mutations – comparable to human HCC 
Expression Analysis 
Fo
ld
 C
ha
ng
e 
- Glutamine Synthetase gene  specifically up-regulated in CTNNB1 
mutant HCCs 
Category Control Nodular HCC A 
(CTNNB1 wt) 
HCC B 
(CTNNB1 mt) 
Number of 
Samples 
 
3 
 
3 
 
3 
 
3 
Relative 
Profile  
Nodular vs 
Control 
HCC_A vs 
Control 
HCC_B vs 
Control 
 
No. of genes 
 
3719 
Min. Fold change > 1.5 
Mouse  Gene  1.0 ST 
Array 
Ctrl Nodular HCC
A 
HCC
B 
Relative 
Profile 
Number 
of Genes 
Total 
No. of 
Genes 
0 N up 644 1032 
0 N down 388 
0 HCC A up 1400 2539 
0 HCC A down 1139 
0 HCC B up 1458 2654 
0 HCC B down 1196 
0 HCC A and B up 314  
807 0 HCC A and B 
down 
493 
Rank Molecular Function Cellular Component 
1 Protein binding Membranous 
2 Metal-ion binding Integral  to membrane 
3 Catalytic activity Cytoplasm 
4 Transferase activity Nucleus 
5 Hydrolase activity Plasma membrane 
 - Comparison with human HCC data revealed high degree of 
correlation 
Gene 
Symbol 
Fold-Change 
(Nodular vs. 
Control) 
Fold-Change 
(HCC_A vs. 
Control) 
Fold-Change 
(HCC_B vs. 
Control) 
Igf2 13.1 106.2 104.2 
Bex1 4.1 70.4 83.8 
H19 35.4 72.7 82.7 
Tspan8 3.1 62.8 18.6 
Klrb1a 11.0 52.6 19.5 
Top 5 genes  highly up-regulated in the HCCs 
Insulin-like growth factor 2  
(Bergman et.al, 2012) 
Future Plans 
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Expression 
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RNASeq 
Affymetrix 
array 
Methylation 
Analysis Proteomics and/
or Phospho 
proteomics 
Functional 
analysis 
 (shRNA 
screens) 
In vivo 
In vitro 
qRT-
PCR 
Comparison with 
Human HCC 
Results 
Awaited 
To be 
Carried out 
Complete Ongoing 
Chromatin 
Immuno 
Precipitation 
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Implications 
SRF is a transcription factor, 
which is activated by different 
stimuli including two major 
signalling pathways – the 
MAPK pathway and the Rho-
dependant actin dynamics 
pathway. SRF subsequently  
binds with other partner 
proteins such as Ternary 
Complex factors(TCFs) or the 
M y o c a r d i n - r e l a t e d 
transcription factors (MRTFs) 
and regulates cytoskeletal  
genes and also the Immediate 
early genes (IEGs).  
 - Active SRF-VP16 in hepatocytes 
results in the regulation of the 
corresponding SRF target genes  in 
the liver. 
 - Hyperproliferation in the liver as 
observed by the increase in 
its size. 
 - Hyperproliferation leads to 
malignant transformation and finally 
aggressive Hepatocellular Carcinoma 
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7.	 Reverse	transcription	&	cDNA	synthesis	 2.3.2	
8.	 Quantitative	real	time	PCR	 2.3.3	
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Lanz,	MPI	Tuebingen)	
2.8.4	
10.	 MS	 sample	 preparation	 (supervised	 by	 Dr.	 Katarina	
Matic,	PCT	Tuebingen)	
2.8.5	
11.	 Data	Mining	–	RNAseq	/	Microarray	 3.3	&	3.5.1	
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14.	 Unsupervised	Hierarchical	clustering	 3.4	
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